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Abstract 
The composition of vaginal microbiota in pregnancy is important as it may influence 
susceptibility to adverse pregnancy outcomes. Dysbiosis of the vaginal microbiota 
caused by the replacement of protective resident microorganisms such as Lactobacillus 
spp. by anaerobic bacteria is known as bacterial vaginosis (BV). BV is prevalent in 
women of African descent and may be a cause of higher rates of adverse birth outcomes 
in these women. Adverse birth outcomes have been reported to be higher in HIV-
infected women both on treatment or treatment naïve compared to HIV-uninfected 
women. The relationship between the vaginal microbiome, HIV and pregnancy 
outcomes has not yet been established in Zimbabwean women, nor reported in sub 
Saharan Africa, where the burden of disease is high. Identification of specific organisms 
and immune factors associated with adverse pregnancy outcomes could lead to 
interventions or diagnostic algorithms to prevent and predict these outcomes in this 
population. 
 
We recruited 420 pregnant Zimbabwean women [48 (11.4%) HIV infected, 372 
(88.6%) HIV uninfected], between 13-35 weeks of gestation with a median gestational 
age of 30 weeks. Vaginal swabs were collected at enrollment and women were followed 
until pregnancy outcome was determined. Bacterial DNA was extracted from the 
vaginal swabs using an optimized Phenol chloroform extraction method with an 
addition of an enzymatic cocktail step. Library preparation was done using the 
Universal primers (515F/806R) for the hypervariable V4 region of the 16S rRNA gene. 
For the first PCR KAPA Hotstart + primers (Roche Lifescience, UK), were used for 
amplification. After amplification AMPure XP beads (Beckman Coulter, Brea, CA, 
USA) were used for cleaning of the PCR products at all stages. For the second PCR 
Nextera XT, Index Kit (Illumina) was used adding unique sequencing adapters to the 
amplicons.  Quantitative PCR was used for library quantification and pooled libraries 
were the sequenced using Illumina MiSeq.  Upstream analysis of sequencing data was 
done using QIIME and UPARSE and downstream analysis using custom R scripts on 
samples with good quality reads (>5000). Concentrations of 27 cytokines were 
measured in vaginal swab samples using a Bio-Plex Pro Human Cytokine 27-
plex Assay (Bio-Rad Laboratories Inc., USA). Assay plates were read using a Bio-Plex 
Suspension Array Reader (Bio-Rad Laboratories Inc., USA). Data were analyzed using 
Bio-Plex manager software (version 4). Cytokine levels that were below the lower limit 
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of detection of the assay were reported as the mid-point between zero and the lowest 
detectable level measured for that given cytokine. 
 
Pregnant women in this cohort had vaginal microbiota that clustered into 3 main 
community state types (CST): 109/356 (31%) CST1 - Lactobacillus iners dominant, 
102/356 (29%) CST2 - Lactobacillus crispatus dominant and 145/356 (41%) CST3 -
Gardnerella vaginalis dominant. There was a high prevalence of dysbiotic vaginal 
communities and L. iners was the predominant taxa found in > 90% of the women. 
When exploring whether the vaginal microbiota is associated with pregnancy 
outcomes, L. iners was highly associated low birth weight (LBW) and small for 
gestational age deliveries (SGA) while in contrast G. vaginalis was associated with 
normal birth outcome. There were no strong relationships identified between preterm 
birth (PTB) and vaginal microbiota. There was a strong correlation between vaginal 
microbiota and proinflammatory and adaptive cytokines. BV associated organisms 
(Gardnerella, Aerococcus, Prevotella Coriobacteriaceae and Dialister) were highly 
inflammatory while Lactobacillus spp were associated with low inflammation. Low 
levels of IL-13 and PDGF-BB cytokines were associated with LBW and PTB. We 
found that HIV status was highly associated with high vaginal microbial diversity. HIV-
infected women had significantly higher alpha diversity in their vaginal microbiota, and 
they were more likely to have CST3. Surprisingly,  having a diverse community type 
was not associated with high levels of vaginal inflammation. However low levels of IL-
13 and IL-I7 while high levels of TNF-α were associated with HIV status. 
 
In conclusion this study found that a highly dysbiotic vaginal environment is 
characteristics of Zimbabwean pregnant women and that vaginal microbiota is weakly 
associated with some poor pregnancy outcomes. The high prevalence of L. iners and 
its association with poor pregnancy outcomes suggests that vaginal microbiota may 
partly explain the high incidence of adverse pregnancy outcomes in African women. 
Low level of Th2 cytokines and growth factors may lead to adverse birth outcomes. 
Longitudinal studies of vaginal microbiota and soluble factors are needed in African 
women.  
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Chapter 1: Introduction  
1.1 Study Overview  
Globally, the main direct causes of neonatal death are estimated to be preterm birth 
(PTB; 28%), severe infections (26%), and asphyxia (23%) [1]. Neonatal mortality 
accounts for 45% of under-five deaths in sub-Saharan Africa, and has not declined 
despite much effort the past decade [2]. Preterm delivery (PTD), intrauterine growth 
restriction (IUGR), and neonatal sepsis are responsible for approximately 99% of 
neonatal deaths that occur in low- and middle-income countries [3]. In Zimbabwe, 
preterm birth complications, birth asphyxia and neonatal sepsis account for 29% of 
under-five mortality [4]. Furthermore, HIV infection is the leading cause of childhood 
death in Zimbabwe contributing 22% of childhood mortality [4]. Among other factors 
that may influence infant mortality, the gut microbiota has been extensively studied and 
proven to be important in determining health. Likewise for the past decade the vaginal 
microbiota have been studied in different ethnic origins and geographical locations [5-
9]. However, the bacterial diversity of the maternal vagina in health and disease has 
underexplored in African pregnant women. 
 
The composition of vaginal microbiota in pregnancy is important as it may influence 
susceptibility to adverse pregnancy outcomes  [10]. The shift of the vaginal microbiota 
caused by the replacement of protective resident microorganisms such as Lactobacillus 
spp. by anaerobic bacteria is termed bacterial vaginosis (BV)  [11]. BV is an extremely 
common reproductive tract condition worldwide, with a reported prevalence of between 
10 and 50% among pregnant women[12]. A high prevalence has been reported among 
African populations of between 20 and 50%, while it occurs in about 30% of the women 
in childbearing age globally[13-15]. BV is highly associated with several pregnancy 
complications such as preterm labour (PTL), neonatal sepsis [16], premature rupture of 
membranes (PROM), low birth weight (LBW) [17], preterm delivery (PTD) and 
possibly spontaneous abortion [18-20]. These complications have been found to be 
more prevalent in HIV-infected women compared to uninfected women, regardless of 
ART treatment [21, 22]. On the other hand ART regimens vary substantially in their 
association with some poor birth outcomes [23].  Since BV is prevalent in women of 
African descent, it has been demonstrated that more adverse birth outcomes related to 
BV occur in these women [5, 24-26].   
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A high prevalence of BV has been reported in Zimbabwe among HIV-infected (36%) 
and HIV-uninfected (26%) women of child bearing age [27]. Prevalence of BV in 
Zimbabwean pregnant women is reported at 32.6% [28]. To date there is no 
documented data on vaginal microbiota in relation to pregnancy outcomes in sub-
Saharan Africa. Although vaginal microbiota has been studied in different populations, 
contrasting findings have been reported in different populations and ethnic groups, 
therefore the need to consider geographical diversity. Identification of specific 
organisms associated with adverse pregnancy outcomes could lead to interventions or 
diagnostic algorithms to prevent and predict these outcomes in this population. 
 
It is with this background in mind that this study was conducted, with the overall goal 
of providing insight into the role that bacterial commensals and/or infections and 
resultant inflammatory responses play in adverse pregnancy outcomes in Zimbabwe. 
This was achieved through the use of next generation sequencing techniques which 
permit deconvoluting of microbial communities with greater resolution. The 
sequencing of the bacterial 16S ribosomal RNA gene broadens and deepens the scope 
of characterisation of bacterial communities. This study aimed to first improve our 
understanding of the burden of certain maternal and neonatal adverse outcome-related 
vaginal pathogens in Zimbabwe. We further aimed to examine the mechanisms by 
which these microbes may lead to adverse outcomes, including host immune and 
inflammatory responses. In a cohort of pregnant Zimbabwean women, we investigated 
potential organisms associated with adverse pregnancy outcomes and HIV.  
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1.2 Literature review 
1.2.1 Pregnancy and neonatal morbidity and mortality 
Pregnancy outcomes are key population and life expectancy indicators and are one of 
the major determinants of infant mortality. Infant mortality rate is an indicator of  the 
health and wellbeing of a nation [29]. Poor pregnancy outcomes are experienced in 
developing countries more frequently than in developed countries, partly due to 
different social and economic factors that affect the health systems  [30]. Worldwide, 
the early childhood mortality in 2017 was 4.1 million, of which 75% of all under-five 
deaths occurred within the first year of life [3]. Preterm neonatal mortality contributes 
significantly to the high incidence of death among neonates; The  World Bank (2015) 
reported that 85% of the neonatal mortality occurring around the globe is contributed 
by preterm birth [31]. Furthermore, the World Health Organization (WHO) reported 
that the risk of a child dying before their first birthday was over six times higher in the 
African region (52 per 1000 live births), than in the European region (8 per 1000 live 
births)  [3, 32]. This is attributable to neonatal causes (26%), child pneumonia (21%), 
malaria (18%), diarrhoea (16%), HIV/AIDS (6%), measles (5%), accidents (2%) and is 
exacerbated by the lack of health infrastructure [33], economic, geographic, and social 
factors  [32, 34]. 
 
Medical advances in public health have helped increase the number of deliveries 
conducted in the health facilities worldwide, but despite this effort, the adverse birth 
outcomes in most geographical areas have not decreased [30, 35]. Infant mortality rate 
remains high and is a significant challenge in sub-Saharan Africa despite the UN 
“Millennium Development Goals” which sought to reduce this [36]. Infant mortality 
and adverse birth outcomes are also affected by racial and ethnic disparities between 
and within countries  [37]. For example, in the United States, black and Hispanic 
women have the highest rates of preterm and small for gestational age (SGA) infant 
deliveries compared to their non-Hispanic white counterparts [37]. These findings 
generally agree across studies showing a higher risk of PTB and LBW in black 
populations compared to white [38-40]. Adverse birth outcomes such as PTB, still birth, 
SGA, PROM, and LBW cause more than 80% of neonatal deaths and intensify post-
neonatal mortality risk and long term neurodevelopmental impairment [41, 42]. 
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1.2.2 The vaginal microbiome 
Neonatal and post neonatal mortality are often caused by infections, intrapartum 
conditions, and PTB complications, among other factors [41-43]. During pregnancy, 
gross metabolic changes occur which support growth and development of both the 
mother and the foetus [44]. Among these changes are shifts in the human microbiome, 
including the microbes housed in the vaginal canal. The vaginal microbiome exerts 
many beneficial homeostatic functions in the human vagina, although there are factors 
that can lead to changes causing vaginal dysbiosis [45]. Numerous studies have 
evidenced the influence of the vaginal microbiome on adverse birth outcomes, with 
disparate results [46-49]. Therefore, there is a need to explore these findings in different 
geographical areas and populations. 
 
The vaginal microbiome consists of complex physiologic microbial communities 
composed of different niches with metabolic and genetic diversities [6]. Vaginal 
bacterial communities (microbiota) play an important role in maternal and neonatal 
health [48]. Vaginal dysbiosis, which is the imbalance of the vaginal microbiota where 
Lactobacillus spp. are replaced by diverse anaerobic bacteria, has been associated with 
poor birth outcomes [48] [46]. 
 
 The human body hosts more than a billion microorganisms that reside on body surfaces 
and in cavities, forming ecological communities of microbial species [50, 51]. The 
human microbiome maintains a mutualistic relationship with the host, providing the 
first line of defense against infections [52]. Additionally, this relationship between the 
human body habitats and the diverse microorganisms is important for development, 
health and nutrition [53].   
 
1.2.3 Healthy vaginal microbiota 
A healthy vagina is described as consisting of a balanced symbiotic relationship 
between it and the bacterial community within. The host maintains this balance by 
reducing the number of bacteria through sloughing of the vaginal epithelial cells. 
However, the indigenous bacterial community feeds on the nutrients provided by 
glandular secretions and sloughed cells to replenish their numbers [54]. A healthy 
vagina is characterised by abundance of Lactobacillus species, which were first 
described by Albert Döderlein in 1892 as gram-positive, non-spore forming rods which 
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produced lactic acid that could inhibit the growth of pathogenic bacteria [55]. During 
this time, it was considered that any depletion or reduction of the Lactobacillus species 
was a sign of invasion by pathogenic bacteria that could cause diseases [55, 56]. 
However, recent studies have shown that the composition of the vaginal communities 
is not static, but instead, changes over time and undergoes shifts in representation, 
abundance, and virulence (Figure 1.1) [57, 58]. Furthermore, composition is also 
influenced by factors such as menstrual cycle, age, puberty, menopause, nutrition, 
ethnicity, geographical area, pregnancy and genetic factors, which are not yet fully 
understood[59], among others (Figure 1.1) [57]. The role of resident indigenous 
bacterial communities cannot be underestimated, as they play a crucial protective role 
in host resistance to colonization by exogenous pathogenic microorganisms [60].
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Figure 1. 1 Changes in the vaginal mucosae during different stages of a woman's life.  
During prepuberty, the low levels of oestrogen result in thin mucosae and low levels of 
glycogen, which stimulate the growth of diverse microbial species. In adult stage of life, the 
glycogen levels increase, due to the increase in the levels of oestrogen. The degradation of 
glycogen to glucose selects for glucose-fermenting microorganisms such as Lactobacillus spp., 
which lower the vaginal pH and prevent growth of pathogenic bacteria. Post menopause, the 
levels of oestrogen once again decline, reducing the deposition of glycogen thereby selecting 
for a high diversity of bacterial species (Petrova . 2013).
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1.2.3.1 Protective role of Lactobacillus 
There are about 130 known species of lactic acid-producing lactobacilli and of these, 
about 20 have been detected in the vagina [59]. The most common species that 
characterise the vaginal microbiota of healthy non-pregnant and pregnant women are 
L. crispatus, L. iners, L. gasseri, and L. jensenii [10, 61]. Lactobacilli are known as 
protective resident microorganisms which possess various homeostatic properties that 
play a role in balancing the vaginal environment [11, 62]. They provide defence against 
infection, in part, by producing hydrogen peroxide and lactic acid, which maintains an 
acidic pH and inhibits growth and colonization by pathogenic bacteria [63, 64]. 
Furthermore, they also produce bacteriocins which inhibit the growth of omnipresent 
pathogens and biosurfactants which reduce adhesion of pathogens. Co-aggregation 
molecules also help to block the spread of pathogens [65, 66]. 
 
In the presence of high concentrations of oestrogen vaginal epithelial cells (VEC) 
produce glycogen which is fermented by Lactobacillus spp (L. crispatus, L. gasseri, 
and L. jensenii) to produce D- lactic acid isoforms. However, L. iners possess genes 
responsible for vaginal glycogen degradation and use it as a source of carbon  [67], 
producing L-lactic acid isoforms [68]. This acid directly affects host immune responses 
and microbial interactions [69]. L-lactic acid has been evidenced to inhibit HIV while 
D-lactic acid inhibits some bacteria [70]. Overall, lactic acid production creates an 
acidic environment that inhibits the growth of a wide range of BV-associated bacteria 
while favouring survival of Lactobacillus spp [71, 72]. Additionally, vaginal acidity 
increases the trapping of the HIV-1 virions by the cervicovaginal mucus [73]. It has 
further been demonstrated that lactic acid can also affect host immune functions by 
inhibiting the production of pro-inflammatory cytokines including IL-6, IL-8 and IL-
1ra associated with acquisition of HIV  [74, 75] Alternatively, lactate can elicit an anti-
inflammatory response from VEC [76]. In addition to the acidic pH created by the 
lactobacilli species, production of lactic acid, the production of H2O2, lysostaphin, and 
bacteriocins also drastically inhibit the growth of potentially pathogenic organisms such 
as Escherichia. Coli (E. coli), Klebsiella, Enterococcus faecalis (E. faecalis), N. 
gonorrhoeae [77], HSV-2 [78], Staphylococcus aureus  [79, 80] (Figure 1.2). However, 
recent studies have questioned the importance of H2O2 and found it less important 
especially under hypoxic conditions which are usually found in the vaginal 
environment [76, 81]. Lactobacilli produce less H2O2 in an oxygen deficient 
environment as compared to an oxygen abundant environment [81, 82]. Additionally, 
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H2O2 is inactivated by the high antioxidant capacity of cervicovaginal fluid and semen  
[72, 83]. Furthermore, recent findings have demonstrated that H2O2 is considered more 
bactericidal to vaginal lactobacilli viability than to17 tested BV associated bacteria 
species as compared to exogenous added H2O2  [72, 84]. 
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Figure 1. 2 Lactobacilli’s protective role against vaginal pathogens 
Lactobacilli produce mainly lactic acid and hydrogen peroxide (H2O2). The latter releases 
oxygen and has a disinfecting effect. Bacteriocins inhibit the growth of pathogens which are 
always present in the vagina. Biosurfactants cover the surface of the vaginal wall, inhibiting the 
adhesion of pathogens while co-aggregation molecules block the spread of pathogens (Sylvie 
Miquel et al., 2015)
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1.2.4 Bacterial vaginosis 
Bacterial vaginosis (BV) is a vaginal dysbiosis characterized by high pH, and 
occasionally vaginal discharge  [19]. A concomitant reduction in the quality or quantity 
of lactic acid producing lactobacilli results in an overgrowth of anaerobic bacteria, or 
microaerophilic species (BVAB1, BVAB2,  Megasphaera spp.,  L. amnionii, S. 
sanguinegens, Gardnerella vaginalis, Atopobium vaginae)  [85] (Esber, 2015 #51}. 
When symptomatic, BV clinically presents as malodorous and copious off-white, thin, 
homogenous vaginal discharge  [13, 86]. However, a high proportion of BV cases are 
asymptomatic in both the general population and in pregnant women  [19, 64] 
Additionally, asymptomatic BV is not treated according to  current CDC guidelines, 
unless during pregnancy  [87, 88] 
 
Although BV is extremely common worldwide  [12, 89, 90], prevalence is reportedly 
low in pregnant white women from Asian Pacific regions 11.1%, Colombia 9.6% and 
Canada 7.1% [91]. Conversely, a high prevalence of between 20 and 50% has been 
reported among pregnant African women  [13-15], with a longitudinal study conducted 
on a sub-population of sub-Saharan African women (in Ethiopia, Kenya, Rwanda and 
South-Africa), finding a BV prevalence was 38% [25, 92]. BV prevalence is found to 
vary from country to country and may be dependent on risk factors. A study conducted 
in the United States including non-pregnant women of reproductive age showed lower 
rates of BV; 23% in white women compared to non-white women (51% in African-
Americans and 32% in Mexican Americans) [89]. 
 
The epidemiology and pathogenesis of BV remain unclear, thus making it difficult to 
classify (Figure 1.3) [26]. It is thought that an imbalance in the vaginal environment is 
created when there is an increase or decrease in certain hormones such as oestrogen, or 
any other factor which alters microbiological balance [11]. Due to this imbalance, 
lactobacilli fail to metabolize glucose from vaginal glycogen into lactic acid. Anaerobic 
bacteria then transform glucose into fatty acids [93]. These fatty acids are favourable 
to the growth of potentially pathogenic bacteria and contribute to the development of 
BV [11, 93]. For example, during the postnatal period, the vaginal microbiome of 40% 
of women will be depleted of Lactobacillus spp. due to hormonal changes leading to 
dysbiosis [10]. Furthermore, the malodor that often accompanies BV is attributed to 
metabolism of amino acids by anaerobic bacteria, which produces biogenic amines [94] 
which degrade vaginal mucin [95, 96]. On another hand, a divergent conceptual model 
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by Schwerbek et al., (2014) and some epidemiological findings suggest that BV may 
be a sexually transmitted infection [97, 98]. Even though some studies have found BV 
to be associated with the prevalence and incidence of some sexually transmitted 
infections no clear evidence exists that it is a cause of STIs [99, 100]. Factors such as 
hygiene practices such as vaginal douching, social factors (multiple sexual partners) 
[101, 102] and fat rich diet,  have been reported by various studies to be associated with 
BV development while vitamin A and folate are associated with decreased risk of BV 
[93, 103]. 
 
Pregnant women are generally more vulnerable to bacterial infections, since they are 
considered to be in an immunocompromised state. The fluctuating levels of steroid 
hormones (oestradiol and progesterone) [104] have been correlated to susceptibility to 
Listeriosis [105], gingivitis and pyogenic granulomas [97] which are strongly linked to 
the risk of preterm delivery [106]. As previously mentioned, BV has been associated 
with poor pregnancy outcomes such as PTB, still birth and PROM, and therefore BV 
diagnosis is imperative for the management of pregnancy in order to reduce the risk of 
poor outcomes. 
 
Figure 1. 3 The vaginal environment during alternative states of eubiosis and BV. A. During 
eubiosis, lactic acid-producing bacteria acidify the vaginal milieu pH <4.5 (average ~3.5) with 
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lactic acid as the predominant metabolite. Lactic acid potently inactivates STI while lactic acid-
producers, such as Lactobacillus, generate a non-inflammatory environment. B. During BV, 
the vaginal environment has a lower redox potential conducive to the growth of diverse 
anaerobic bacteria and higher bacterial load. The concentrations of mixed SCFAs and amines 
also increase, and are accompanied by loss of vaginal acidity, pH >4.5. The diverse anaerobic 
bacteria generate virulence factors which compromise epithelial barrier integrity, degrade 
mucin, and generate a pro-inflammatory environment(Aldunate et al.,2015) 
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1.2.5 Diagnosis of BV 
BV diagnosis is done using the Amsel criteria, Hay/Ison technique, Nugent scoring, or 
for places without laboratory facilities, the BVBlue [107] bedside point-of-care test.  
Amsel criteria: This is a widely accepted as it is partly based on clinical symptoms. 
To be confirmed BV positive, 3 of 4 criteria should be met:  1) vaginal pH > 4.5;  
2) clue cells in the vaginal fluid; 3) a milky, homogeneous vaginal discharge; 4) and 
the release of an amine (fishy) odour after addition of 10% potassium hydroxide to the 
vaginal fluid [108].  
Hay/Ison technique: For this method, women are classified into 3 main groups 
according to the abundance of Lactobacillus and Gardnerella morphotypes only in a 
Gram-stained vaginal smear (Table 1.1) [109]. 
 
Table 1. 1 The Hay/Ison classification for BV 
 Lactobacillus Morphotypes Gardnerella Morphotypes 
Normal (group 1) Many Few 
Intermediate (group 2) Equal amount Equal amount. 
BV (group 3) Few Many 
 
Nugent score: This is the gold standard for BV diagnosis and is based on Gram-
staining of a vaginal smear and scoring by morphotypes per visual field: Lactobacillus 
morphotypes (large Gram-positive rods), G. vaginalis and Bacteroides species 
morphotypes (small Gram-variable and gram-negative rods) Mobiluncus species 
morphotypes (curved Gram-variable rods; Table 1.2) [110, 111]. Women are classified 
as normal (score: 0-3), intermediate (4-6), or BV (7-10).  
 
Table 1. 2 The Nugent’s scoring system: Morphotypes per visual field 
Score Lactobacillus morphotype 
 
G. vaginalis morphotype Mobiluncus morphotype 
0 >30 0 0 
1 5—30 <1 1—5 
2 1—4 1—4 >5 
3 <1 5—30  
4 0 >30  
Scores: Normal = 0-3, Intermediate = 4-6, BV = 7-10. 
BVBlue tests: Bacterial pathogens associated with BV such as G. vaginalis, 
Mobiluncus, Bacteroides and Prevotella produce an enzyme called sialidase. The 
BVBlue test is a chromogenic diagnostic test-based point of care tests which detects 
elevated vaginal fluid sialidase activity. Results are obtained in ten minutes where a 
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blue or green color indicate a positive result (increased sialidase activity) while a yellow 
color indicate a negative result (no increased sialidase activity). 
 
1.2.6 Molecular analysis 
Microscopy and culture dependent diagnosis can detect only limited types of organisms  
[56, 112]. These methods limit our ability to accurately assess the microbial world. 
Many microbial species are difficult to culture in the laboratory; therefore, 
characterisation of the human microbiota using these methods was not comprehensive 
[113]. However, recent advances in molecular methods such as polymerase chain 
reaction (PCR) and Next Generation Sequencing (NGS) have provided substantially 
more detail regarding the microbes present at mucosal surfaces  [114, 115]. The advent 
of molecular techniques such as 16S rRNA gene deep sequencing for characterisation 
of the vaginal microbiome has led to a growing list of organisms that may constitute 
BV, differing from the culture based characterisation which named Gardnerella species 
as the main BV-associated organisms [57, 116, 117].  
 
Molecular methods have shown that any combination of the following genera may be 
highly predictive of BV positive women: Gardnerella, Mycoplasma, 
Atopobium, Mobiluncus, Prevotella, Sneathia, Leptotrichia, Peptostreptococcus, and 
BV-associated bacterium 1-3 [BVAB1 to BVAB3 (M. indolicus)] [15, 63, 64, 85, 117]. 
Studies conducted in Europe show that Gardnerella, Atopium vaginae, Prevotella, and 
Sneathia are commonly prognostic of BV [118-122]. Furthermore, these studies 
strongly agree that the combination of Gardnerella vaginalis (GV) and A. vaginae, and 
a low abundance of lactobacillus spp. is highly predictive of BV [118-122].  However, 
the importance of culture methods cannot be ignored as it helps identify viable 
organisms. Culture methods are time and cost effective as the samples will need less 
manual labour compared to manual preparation of samples before DNA extraction and 
possibly batching samples before processing. The two methods however complement 
each other depending on the setting, clinical or research and workload. Additionally, 
shotgun 16S rRNA amplicon sequencing detects only bacterial species, while the 
microbiome is also comprised of other taxa, including fungi and viruses.   
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1.2.7 BV treatment 
The CDC guidelines recommend the treatment of BV in pregnant  and nonpregnant 
symptomatic women to alleviate signs of infection and reduce risk of STI infection.  
CDC recommends the use of  mainly metronidazole or clindamycin cream with 
tinidazole as an alternative. There have been several trials that evaluated  BV treatment 
during pregnancy to reduce adverse outcomes, however these studies have yielded 
contrasting findings. In some studies, treatment of BV in pregnant women at risk of 
preterm delivery reduced the risk of PTB [123, 124]. However, in other studies, 
treatment of asymptomatic BV did not reduce occurrence of preterm delivery [125, 
126].  In a meta-analysis  by Brocklehurst et al. (2013),  antibiotic treatment effectively 
eradicated BV but the overall risk of PTB was not reduced. In a randomized controlled 
trial, Guise and colleagues (2001)  reported no benefit to routine BV screening and 
treatment, finding that some subgroups at high risk would benefit whilst  BV treatment 
increased the risk of PTB in other subgroups [127]. Currently there is no consensus on 
the benefits of screening and treatment  of BV in pregnant women, as there is no 
sufficient evidence of reduction of adverse birth outcomes[128, 129]. However this may 
be because current BV treatment recommendations are inadequate and also that a full 
understanding of microbiologic, epidemiologic, and sociologic determinants of BV is 
imperative in order to develop effective treatment strategies for BV in pregnancy[87]. 
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1.2.8 Vaginal Microbiota classification 
Molecular analysis has revealed that different populations and ethnic groups possess 
varied vaginal microbial communities, leading to diverse classifications of vaginal 
communities [51, 130]. In a study of North American women using NGS, Ravel et al., 
(2011) classified vaginal bacterial communities into five main community state types 
(CST): CST I ( L. crispatus-dominated), CST II ( L. gasseri-dominated), CST III (L. 
iners-dominated), CST IV (diverse), and CST V (L. jensenii-dominated) [51] (Figure 
1.4). In this study, four CSTs were dominated by Lactobacillus spp., while CST IV had 
a paucity of Lactobacillus. Similar to BV, CST IV was characterised by highly diverse 
microbiota with a mixture of facultative anaerobic bacteria such as 
Prevotella, Dialister, Atopobium, Gardnerella, Megasphaera, Peptoniphilus, Sneathia
, Eggerthella, Aerococcus, Finegoldia, and Mobiluncus. According to this 
classification, CST I, II, and III, which are considered “healthy”, were prevalent in 
Asian and white women, while CST IV, associated with diseases such as BV [131, 
132], was found to be common in Hispanic and black women. It was initially concluded 
that Hispanic and black women were more likely to be unhealthy; however, several 
studies have subsequently shown that communities with a paucity of Lactobacillus are 
more common in women who are classified as having a normal microbiota [51, 56, 85, 
133]. Since then, several African studies have found different CSTs depending on 
cohort characteristics [134, 135]. 
 
It has become clear that geography and /or genetics likely play a role in the microbial 
communities that dominate in the vagina. For example, L. iners is the dominant 
Lactobacillus spp. found in vaginas of women in Brazilian, Japanese, Belgian, and 
generally in black African women [5, 116, 133, 136], while L. crispatus dominated 
communities are common in Swedish, Germany, Turkish, and generally in white 
European women [136-138]. L. gasseri and L. reuterii are dominant in Indians and 
Bulgarian women (Figure 1.5) [5, 139-141], while both L. iners and L. crispatus are 
more prevalent in Chinese women [142]. However, it is important to note that there are 
some limitations in using CST for classification of vaginal microbiota, since CSTs are 
based on relative abundance in the study population whose results may not have 
external validity. Dominant species are used to name the CST, thus ignoring rare taxa 
which may be clinically important and may have impact on observed outcomes. 
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Figure 1. 4 Composition of vaginal microbiota in adult women as defined by Ravel et al., 
(2011). Ravel et al., (2014) sequenced the V1–V2 hypervariable region of the 16S rRNA gene 
of vaginal bacteria from North American adult women and described five community groups. 
Group I, II, III, and V are dominated by Lactobacillus spp., namely L. crispatus, L. gasseri, L. 
iners, and L. jensenii respectively, while group IV is diverse in composition. Community group 
IV can be separated into two subgroups – IV-A and IV-B. Community group IVA is 
characterized by the presence of L. crispatus or L. iners and strict anaerobes, while IV-B has a 
higher proportion of members of the genera Atopobium, Prevotella, Parvimonas, Sneathia, 
Gardnerella, and Mobiluncus. (Petrova et al., 2013) 
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Figure 1. 5 Pie charts illustrating the proportions of each vaginal bacterial community 
group by ethnicity. The different distributions of dominant community state types (CSTs) in 
each ethnic group are displayed, with larger slices of the pies indicating the largest ethnic 
groups for each particular CST, while the smaller slices show the smallest ethinic groups for 
each CST. The numbers in square brackets show the sample sizes for each CST (Jacques 
Ravel and Larry J. Forney, 2011). 
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1.2.9 The vaginal microbiota of African women 
Understanding population differences, common influential factors and the host and its 
interactions with the vaginal microbiota will help define normal or healthy vaginal 
environments [54, 143, 144]. The few studies that have been done in African women 
and women of African descent have shown that their vaginal microbiota is often 
dominated by L. iners and diverse communities commonly associated with BV [135, 
145]. In a Tanzanian study, the core members dominating in every woman’s vagina 
were G. vaginalis and L. iners. Contrary to the findings of Ravel et al., (2011), eight 
clusters of vaginal communities were identified in the Tanzanian cohort, in which two 
were dominated by L. crispatus and L. iners, where L. crispatus was associated with 
lowest pH and in the absence of L. crispatus, L. iners was used to predict low pH [145]. 
Furthermore, a study including young females from Durban, South Africa found four 
distinct community types which were termed cervicotypes (CTs) [135]. In women from 
Cape Town and Soweto, South Africa, Lennard et al., (2017) found only three different 
vaginal community subtypes using fuzzy clustering of Bray Curtis distances [134]. 
Despite the use of different clustering techniques and varied definitions of a cluster, in 
all of these African studies, the diverse microbiota community types dominated, while 
a low prevalence of Lactobacillus community types was found [135]. Therefore, the 
“normal” vaginal microbiota for sub-Saharan Africa and women of African descent 
may be dominated by high diversity profiles, or if Lactobacillus-dominated, the most 
prevalent is L. iners [24, 57, 146]. L. iners is different from other common lactobacilli 
species and possesses genes that enable adaptation to different vaginal environments 
[24, 67, 147]. Longitudinal studies show that the vaginal microbiota of some women 
shifts between cluster types and depends on their factors such as sexual activity, 
menstrual cycle and oestrogen production [56, 130]. However, BV is present in every 
population, despite differences in microbial community types, and is detrimental to 
health particularly in pregnancy, with several studies demonstrating a relationship 
between poor birth outcomes and BV  [18-20, 148]. 
 
1.2.10 The vaginal microbiome and birth outcomes 
The vaginal microbiome harbours numerous bacteria that have important effects on 
health and disease states [149]. Reproductive health outcomes are likely to be 
influenced by the composition and interactions of the maternal vaginal microbiome 
throughout pregnancy [150]. A normal pregnancy is characterized by a highly stable 
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microbiome with low diversity dominated by Lactobacillus species; this stability is 
thought to be a result of the absence of cyclical hormones and the menstrual cycle, 
among other factors [61]. This is further demonstrated in a longitudinal study, done by 
Romero et al., (2014) which reported that vaginal microbiota was highly stable in North 
American women for the duration of pregnancy compared to their non-pregnant 
counterparts [58].  
 
BV has been associated with several pregnancy complications such as preterm labour, 
PROM, LBW, preterm delivery  [18, 20] and possibly spontaneous abortion [19, 148]. 
Additionally, BV may increase susceptibility to sexually transmitted infections such as 
Neisseria gonorrhoeae, Chlamydia trachomatis [64], Trichomonas vaginalis [148], 
HSV-2 [151] and HIV [152-154] which  are also associated with poor birth outcomes. 
A study by Gupta et al. (2013) showed that 23.5% of women with BV detected in early 
pregnancy <28 weeks had preterm births compared to 7% of those with normal vaginal 
microbiota [19]. A meta-analysis by Leitich et al. (2007) demonstrated that in pregnant 
women, asymptomatic BV doubled the risk of preterm delivery, as well as increased 
the risk of late miscarriages and maternal infections [155]. Additionally, in multiple 
studies, delivery of infants who were SGA or had LBW was significantly associated 
with symptomatic and asymptomatic BV [16, 17, 156]. BV carriage during early 
pregnancy increases the risk of fetal mortality between 14-24 weeks 6-fold and is a 
strong risk factor for late miscarriage [16, 155]. This concurs with reports in studies 
done in Danish pregnant women [49], Turkish pregnant women with a history of 
previous poor outcomes [47] and Nigerian pregnant women [18]. These findings 
suggest that the presence of BV in early pregnancy is more of a risk factor for adverse 
birth outcomes such as LBW, SGA, and miscarriage when compared to late pregnancy 
exposure. 
 
It is postulated that specific organisms, rather than BV itself, may increase risk for 
adverse birth outcomes. For example, detection of Mycoplasma hominis, G. vaginalis 
and/or A. vaginae in isolation or in combination was associated with preterm delivery 
[157]. Foxman et al., (2014) similarly reported that Mycoplasma was most strongly 
correlated with preterm birth followed by Mobiluncus and A. vaginae [158]. U. 
urealyticum and M. hominis are considered opportunistic pathogens and are suspected 
of inducing proinflammatory cytokines, which trigger pathways leading to preterm 
labour, PTD and pregnancy loss [159]. Moreover, Nelson et al., (2014) found increased 
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abundance of BVAB1, Megasphaera phylotype 1, and Leptotrichia/Sneathia spp. in 
vaginas of women who reported having a previous preterm delivery [160]. However, 
Foxman et al., (2014) reported that Mageebacillus indolicus (BVAB3) was associated 
with a reduction in preterm delivery risk among BV+ women and thus concluded that 
some BV-associated organisms are not associated with poor birth outcomes [158]. The 
concurrent presence of previously named Bacteroides (since assigned to Prevotella or 
Porphyromonas) and M. hominis in the vaginas of pregnant women was found to be 
associated with a risk of PTB and LBW [161], whilst in another study, the combination 
of G. vaginalis and M. hominis predicted the same outcomes [117]. However other 
studies have found conflicting evidence on preterm birth and association with vaginal 
microbiome. Stout et al., (2017) found that, although no specific taxa were associated 
with preterm birth, a significant decrease in vaginal microbial community richness and 
diversity was associated with preterm birth [48]. Population and ethnic differences in 
the reported microbial causes of adverse birth outcomes and differences in methods 
used in analysis have made it difficult to establish specific etiologies. 
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1.2.11 HIV and the vaginal microbiome 
HIV-infected women have a higher prevalence of vaginal microbial dysbiosis than the 
general population [56, 162]. Vallone et al., (2012) reported that dysbiosis in pregnant 
HIV infected women worldwide ranged from 47% in Western countries, to 89% in 
African countries [14]. However, it is unclear whether this increased prevalence of BV 
is due to HIV, or is only a result of BV increasing a woman’s chance of contracting 
HIV [24, 163]. In a study by Roberts et al., (2012), BV prevalence was similar in the 
same women pre- and post-infection [164], suggesting the latter may be true. 
 
Multiple studies and meta-analyses have demonstrated that BV is an independent risk 
factor for HIV acquisition [163]. While BV (defined as Nugent score ≥7) was found to 
be associated with a 1.6-fold increased risk of HIV acquisition compared to women 
without BV [165, 166], women with high diversity vaginal communities defined by 
16S rRNA gene amplicon sequencing were predicted to have a 4-fold increased risk of 
acquiring HIV compared to their counterparts with L. crispatus dominant vaginal 
microbiomes [167]. Since BV is so prevalent, it is thought to be one of the major causes 
of incident HIV infections. For example, of the estimated 50% of HIV infections in a 
cohort of Ugandan and Zimbabwean women attributable to sexually transmitted 
infections and dysbiosis, 26% were attributable to HSV-2 infection, 17% to BV 
(Nugent score ≥7) and 12% to intermediate microbiota (Nugent score 4-6)  [25, 168].   
 
When examining specific taxa and the risk of HIV, in a recent study of five cohorts, 
McClelland et al., (2018) reported that high relative abundance of the following taxa 
were strongly associated with HIV acquisition risk in women: M. hominis, 
Parvimonas spp, Eggerthella spp., Gemella asaccharolytica, Sneathia 
and Megasphaera and contrasted these same relationships with low relative abundance 
of L. iners  [9]. In an African study, Gosman et al., (2017) found that relative abundance 
of Prevotella, Sneathia, and other anaerobes were linked with increased inflammation 
and HIV infection [167]. A review done African studies by Passmore et al., (2018) 
confirm the presence of higher vaginal diversity in women who later seroconverted, 
concluding that BV contributes to increased risk of HIV acquisition [152, 169]. 
 
Once a woman becomes HIV infected, there seems to be a relationship between BV 
and HIV RNA levels in genital tract samples [131, 170, 171]. Sha et al., (2005) found 
a strong correlation between G. vaginalis and M. hominis counts in cervicovaginal 
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lavage and HIV-1 RNA levels in contrast to an inverse relationship with lactobacilli 
counts. This led to their conclusion that BV-associated vaginal microbiota influences 
genital tract HIV shedding [171]. Propionibacterineae, Anaerococcus and Citrobacter 
taxa were uniquely found in HIV-infected women in a study by Spear et al., (2008) 
[172], while in a different study, it was found that BV+ HIV-infected women had 
increased microbial diversity compared to BV+ HIV-uninfected women, suggesting an 
association between HIV infection and genital microbial diversity [171]. This 
collection of findings would suggest that altered vaginal microbiota may be partly 
related to immune status (Figure 1.6). On the other hand, studies by Goel et al., (2014), 
Bhattar et al., (2011) and Micheletti et al., (2009) found no correlation between high 
HIV-1 plasma viral load and BV [173-175].  
 
It seemed that G. vaginalis and possibly other microbes may reduce the efficacy of 
some forms of topical antiretroviral pre-exposure prophylaxis, since these organisms 
have been reported to metabolise tenofovir gel, leading to women with abundant G. 
vaginalis in their genital tracts using topical tenofovir being poorly protected from HIV 
infection [176]. This relationship may be restricted to tenofovir when used 
intravaginally, as a study by Heffron et al., (2017) found no significant difference in 
the efficacy of oral tenofovir pre-exposure prophylaxis between women with normal 
and abnormal vaginal microbiota [177]. 
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Figure 1.6 Vaginal microbiota and HIV susceptibility 
Showing cervicotype 1 with more Lactobacillus crispatus and less CD4+T cells and cervicotype 
4 showing a vaginal microbiota dominated with diverse anaerobes and increased number of 
CD4+ cells. Some vaginal microbial species are capable of increasing susceptibility to HIV 
infection (Gosmann et al., 2017)  
 
 
25 
1.2.12 HIV, antiretroviral treatment (ART) and risk of adverse 
pregnancy outcomes. 
Peripartum complications due to vaginal infections, which include chorioamnionitis, 
post-partum endometritis, and puerperal sepsis, are more frequent in HIV-infected 
women [14, 19, 27]. These complications may also increase the risk of mother-to-child 
transmission of HIV during pregnancy [12, 13, 152]. Gray et al., (2007) observed that 
perinatal HIV transmission depends on various other factors, including the stage of 
disease in the mother, timely antenatal care and clinical management of labour and 
delivery [178]. Preterm birth, and delivery of LBW and SGA infants, among other 
adverse outcomes, are also associated with increased neonatal and infant mortality and 
morbidity in HIV-exposed uninfected infants [56, 178, 179].  
 
However, studies have conflicting findings regarding associations between HIV and 
pregnancy outcomes, because some outcomes may be influenced by ART exposure.  
HAART which is considered as ART combination therapy and single dose therapies 
such as AZT and NVP, have also been studied in relation to pregnancy outcomes. In 
India, Patil et al., (2011) did not find any association between LBW or SGA and HIV, 
in HIV infected women who were receiving extended-dose nevirapine, but on the other 
hand, there was a higher risk of poor birth outcomes in HIV-infected women who did 
not receive regular antenatal care compared to HIV-infected who received antenatal 
care [180]. In a systematic review, no convincing association between HIV status and 
birth outcomes was found in the different studies which were included [181]. In a South 
African cohort, Rollins et al., (2007) found an increased risk of LBW and mortality in 
infants born to HIV infected compared to HIV uninfected women [182]. This study was 
conducted before the widespread availability of combination ART. Contrastingly, a 
recent study done comparing HIV infected pregnant women on ART and HIV 
uninfected pregnant women as controls, found no significant difference between HIV 
status and outcomes of PTB or IUGR although women who were HIV-infected were 
more likely to have PTB and IUGR as compared to HIV uninfected [183].  
The use of certain antiretroviral drugs has been associated with adverse birth outcomes, 
which may confound the relationship between HIV status and birth outcomes.  
Goldstein et al., (2000) noted a significant increase in the proportion of HIV-exposed 
neonates that were LBW, but an even higher proportion born to women who did not 
receive antepartum Studies conducted on ART/HAART [184] in Toronto, Ontario 
[185], Tanzania [186] and Côte d'Ivoire [187] found a high risk of delivery of LBW 
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infants associated with the use of ART in HIV-infected women. This is consistent with 
a meta-analysis conducted by Alemu et al., (2015) which concluded that there was an 
association between HIV and use of HAART and adverse birth outcomes in developing 
countries [188]. In this meta-analysis, it was further found that the specific ART 
regimen may be influential, with protease inhibitors (PI) considered a greater risk factor 
than other regimens. The results of this study concur with the findings of studies 
conducted in Europe [189, 190], Germany and Australia [191], Latin America and the 
Caribbean [192], in which increased frequency of LBW infants and/or  premature birth 
was found in women receiving PI-based therapy. In another study conducted in Western 
India, Darak et al., (2013) found that women who received HAART even without PI 
had a higher risk of poor outcomes than those who received dual therapy with 
antepartum azidothymidine (AZT) with intrapartum nevirapine [193]. 
 
In studies including pregnant women in Europe, America and the Caribbean, no 
significant difference in pregnancy outcomes was found when comparing the effects of 
nucleoside reverse transcription inhibitors + non-nucleoside reverse transcription 
inhibitors (NRTI+NNRTI) versus NRTI+PI (protease inhibitors) regimens on birth 
outcomes [194]. Additional studies have found no association between HAART and 
birth outcomes [195, 196] There was no risk associated with use of tenofovir and 
efavirenz reported in  studies including pregnant women from Uganda, Zimbabwe and 
Botswana  [195, 196]. Similarly, in Nigerian [197] and South African studies, no 
association between  HAART and poor pregnancy outcomes was found [198, 199]. 
Therefore, studies conducted in different regions show contradictory evidence of the 
potential risks of adverse pregnancy outcomes in HIV-infected women and in those 
using HAART. Putting all this analysis together we conclude that not only do the 
presence of certain vaginal bacteria or HIV status matter when considering the risk of 
adverse birth outcomes but also that the population being studied, and its geographical 
and social status may play an important role to be considered in these studies. 
 
1.2.13 Vaginal innate immunity 
Innate immunity refers to non-specific defense mechanisms naturally present in a host, 
and not due to prior sensitization to an antigen, whereas adaptive immunity refers to 
antigen-specific memory immune responses (in particular B and T cells). Although an 
oversimplification, in general, innate immunity involves all physical and chemical 
barriers such as skin, mucous membranes, blood, immune cells (phagocytic leukocytes, 
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neutrophils, dendritic cells, natural killer cells), and innate immune proteins and 
peptides (cytokines and antimicrobial proteins/peptides) which are activated by the 
presence of antigens [200]. Together, these components maintain a homeostatic 
environment that protects against disease and acts as the first line of defense against 
invading pathogens [201, 202].  
 
The structure and function of the female genital tract (FGT) itself are important in 
innate immunity. The vagina is lined by non-keratinized stratified squamous 
epithelium, which consists of elongated and a nucleated basal cells that form a natural 
barrier to pathogens [203, 204]. The intermediate and superficial basal cell layers 
possess vacuoles containing considerable amounts of glycogen and mucin [205]. There 
are tight junctions composed of transmembrane regulatory proteins that prevent free 
movement of molecules across the epithelial sheet [206, 207]. Nonetheless, 
permeability is altered during an immune response to allow passage of effector 
molecules secreted by VEC [203, 207]. The upper layers of the stratified squamous 
epithelium are shed naturally every 4 hours; VEC also lose their tight junctions and 
detach from the basement membrane as a defense mechanism against pathogens that 
could have ascended and attached to the epithelial cells [208, 209]. Additionally, this 
shedding of VEC rich in glycogen is essential for provision of nutrients to Lactobacillus 
spp. Glycogen is metabolized by the VEC a-amylase to produce glycogen breakdown 
products such as maltose, maltotetraose and maltotriose, which Lactobacillus spp. are 
then able to utilise. Therefore, a decrease in this enzyme in the FGT may lead to a 
shortage of nutrients needed by Lactobacillus spp. and consequently to the depletion of 
Lactobacillus as seen in BV+ women [210, 211].  
 
The VEC and mucins limit contact between the microbiota and host tissue, thereby 
contributing to antimicrobial activity [212]. VEC possess pathogen recognition 
receptors (PRR), such as toll-like receptors (TLRs), that recognize pathogen-
associated molecular patterns. These receptors trigger cellular pathways leading to 
secretion of proinflammatory cytokines and antimicrobial peptides into the lumen 
[213]. This then attracts phagocytic and antigen-presenting cells which enter the 
epithelial cell layer by chemotaxis [214]. 
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1.2.14 BV and inflammation  
Although BV causes subclinical increases in proinflammatory mediators and is 
associated with adverse reproductive health outcomes that are mediated by 
inflammatory processes, BV is not widely considered a clinical inflammatory condition 
[215]. BV is a multidimensional process that involves numerous interactions between 
bacterial communities [38, 63, 216]. BV induces immune responses which result in 
elevated proinflammatory cytokine levels in the vagina and has been associated with 
several adverse birth outcomes such as PTD [217]. Specific BV-associated organisms 
have been implicated in alterations in immune responses that may result in unexpected 
pregnancy outcomes [64]. A number of studies have found elevated cervicovaginal 
cytokine concentrations when certain BV-associated species, such as A. vaginae [218], 
Prevotella spp., G. vaginalis [219] and bacteria causing STIs such as C. trachomatis 
and N. gonorrhoeae [220, 221], were found to be colonizing the vagina. 
  
Eades et al., (2012) demonstrated that IL-6, IL-8, G-CSF, IP-10, MIP-1β, RANTES, 
and GRO-α production by three epithelial lines were upregulated by BV associated 
bacteria as compared to commensal lactobacilli [222]. On the other hand, Kyongo et 
al., (2015) observed that IP-10 concentrations were higher in cervicovaginal samples 
from women with Lactobacillus spp. dominance (except L. gasseri) compared to 
women with abundant G. vaginalis and A. vaginae [220, 223, 224]. These findings led 
the authors to suggest that BV-associated organisms may evade an immune response 
through tolerogenic mechanisms [223]. South African studies that included young 
women at risk of HIV demonstrated upregulated concentrations of multiple pro-
inflammatory (Intereforn gamma (IFN-γ), tumor necrosis factor (TNF-α), Granulocyte 
macrophage colony-stimulating factor (GM-CSF), IL-1α, IL-6, IL-8, IL-1β, IL-12p70) 
and anti-inflammatory (IL-10) cytokines in the presence of BV-associated microbiota 
[134, 135, 223] while other studies have found a down regulation of IP-10 [220, 221, 
224]. A longitudinal study comparing cervicovaginal lavage of BV- and BV+ women 
where they measured subclinical vaginal inflammation (before and after treatment with 
metronidazole) reported that BV was associated with select soluble immune mediators 
and an increase in HIV target cells, thus potentially increasing susceptibility to HIV 
infection [225]. On the other hand, women with persistent BV had higher levels of 
intercellular adhesion molecule 1 (ICAM-1), IL-1β and TNF-α compared to women 
with resolved BV [225]. 
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However, there is evidence that expression of certain cytokines in BV+ women may 
differ between individuals due to factors such as environmental influences and genetic 
polymorphisms [215, 226]. For example, BV+ women who possessed a TLR4 single 
nucleotide polymorphism(SNP) (rs1554973) had higher IL-1β than those without said 
allele [227]. Correspondingly, Genc et al., (2002) in a case control study of pregnant 
women, investigated polymorphisms in fetuses of spontaneous preterm delivery and 
found that cytokine responses (e.g. TNFα and IL-1β) to BV-associated organisms were 
highly influenced by maternal genomic variations [228]. Pregnant women possessing a 
TNF-α polymorphism (TNFA-308G > A) in their blood had a higher expression of 
TNF-α in the presence of G. vaginalis and anaerobic gram negative bacteria compared 
to non-carriers [226, 229]. As a result, BV+ women with TNFA-308G > A 
polymorphism had a 6-fold increased risk of poor birth outcomes compared to BV+ 
women without this polymorphism [229]. It is thus important to investigate the specific 
organisms that are present in individual women and how these organisms interact with 
the vaginal host immune system since no single organism is present during all cases of 
BV and specific organisms may differentially influence the immune environment and 
pregnancy outcomes [230]. 
 
Proinflammatory cytokines such as interleukin (IL)-6, IL-8, Granulocyte colony- 
stimulating factor (G-CSF), Interferon gamma-induced protein (IP-10/CXCL10), 
Macrophage inflammatory protein (MIP-1β/CCL4), Regulated on Activation, Normal 
T Expressed and Secreted (RANTES/CCL5) and growth-related oncogene alpha 
(GRO-α) were found elevated in vaginal fluids during dysbiosis  [208, 219]. However, 
in some studies, certain chemokines were found down regulated in genital secretions of 
women with BV [220]. Furthermore, in a review by Liebenberg et al., (2017) microbial 
diversity has been found to be associated with increased inflammatory cytokines and 
cervical HIV target cells [231] however, in contrast, Lennard et al., (2018) did  not find 
an association between microbial diversity and HIV target cells [134]. These changes 
in immune mediators and immune cell populations may contribute to the increased risk 
of HIV associated with BV, as well as increased risk of poor pregnancy outcomes.  
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1.2.15 Specific vaginal microbes and innate immunity 
1.2.15.1 Lactobacillus spp. 
Homeostasis in the gut is maintained and controlled in part by the presence of lactic 
acid-producing bacteria which mitigate inflammation and preserve the barrier function 
(e.g. gut lactobacilli prevent microbial translocation during HIV infection) [40, 232]. 
Likewise, a number of studies have reported that the vaginal microbiota play an 
essential role in immune regulation in the vaginal mucosa [214, 233, 234]. Given the 
general agreement that Lactobacillus spp. are protective in the FGT, it follows that 
vaginal microbiota dominated by Lactobacillus spp. are associated with health, low 
proinflammatory cytokine production and normal birth outcomes (Figure 1.7) [235, 
236].  
 
Women who have L. crispatus and L. jensenii in their vaginal microbiota generally 
exhibit a negative association with cellular inflammatory markers [237]. A high 
percentage (83.3%) of women who had no Lactobacillus spp. present in their vaginal 
fluid were found to have a high vaginal IL-8 concentrations and these women were 
associated with a high risk of premature delivery [236]. However, it is becoming 
recognised that not all lactobacilli are the same. Generally, L. crispatus and L. jensenii, 
which are considered to be the optimal Lactobacillus species, are associated with good 
birth outcomes. They do not stimulate significant proinflammatory cytokine production 
in vitro and tend to dampen expression of IL-6, IL-8 and TNF-a in VEC in the presence 
of exogenous TLR antagonists [203, 218].  
 
L. iners concentration was found to be positively correlated to SLPI, a known anti-
inflammatory molecule that is present at minimal levels in a vaginal dysbiotic state, 
while L. gasseri was associated with high IL-1β in vivo [238, 239]. By mechanisms not 
yet established, L. iners and L. jensenii stimulate PRR, but this does not lead to an 
increase in proinflammatory cytokines IL-8 and IL-6 [240]. Jespers et al.,(2017) 
observed that L. iners abundance was significantly positively associated with IP-10 and 
IL-8, while negatively associated with IL-1α concentrations, in the FGT [116]. L. iners 
has been reported to express CRISPRs system related genes, which may play a role in 
its adaptability and response to altered environmental load and furthermore, it has an 
ability to express cholesterol dependent cytolysin and metabolic enzymes related to 
glycerol & mucin transport under BV positive condition [241]. Consequently this has 
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led to the conclusion by some that L. iners could be marker of vaginal dysbiosis and 
could be associated with BV-causing bacteria [242]. Although relative abundance of L. 
iners are lower in BV- women, L. iners is however found in both BV+ and BV- women 
showing their adaptability. L. iners has a small genome indicative of a symbiotic 
lifestyle unlike other lactobacilli and that the genes they possess encode for factors that 
are niche specific [243]. However, it has been reported that L. iners may not prevent 
HIV penetration through the cervicovaginal mucosal barrier, as opposed to L. crispatus 
which reinforces it [244]. Production of IL-1b and IL-8 by VEC is reported to be 
enhanced by lactic acid, showing the complexity of the synergistic relationship between 
microbiota and immunity [74]. While in contrast, a recent study found evidence that 
lactic acid has anti-inflammatory effect on the female lower genital tract inhibits pro-
inflammatory mediators associated with susceptibility to HIV [76].  
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Figure 1. 7 Vaginal microbiota and immunity: A The vaginal microbiota in a healthy 
individual is dominated by Lactobacillus spp. The Lactobacillus spp. produce lactic acid, as 
well as antimicrobial compounds to control the growth of microbes. Other soluble factors, such 
as antimicrobial peptides (AMPs), mannose-binding lectins (MBLs), and immunoglobulins 
(Igs), contribute to the homeostatic immunity of the vaginal surface. In addition, the 
surveillance of commensals and pathogenic microbes is achieved by pattern recognition 
receptors (PRRs). B In cases of disrupted vaginal microbiota, such as bacterial vaginosis, 
community state type IV type microorganisms dominate to initiate an inflammatory response. 
Short-chain fatty acids produced by these microorganisms are likely to induce the production 
of proinflammatory cytokines. IL-33 has recently been identified as the key cytokine in 
association with antiviral immunity modulation by the vaginal microbiome. IL-33 is also 
responsible for the Th2-type immune response elicited by proteases that are secreted by 
pathogenic microbes (Park, Y. J. and Lee, H. K., 2017) 
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1.2.15.2 Gardnerella vaginalis (GV) 
GV was named by Garner and Duke in 1953 when it was described as an etiological 
agent of non-specific bacterial vaginitis [245]. It belongs to the 
family Bifidobacteriaceae. It is a small, non-motile, non-capsulated gram variable 
organism that grows best in carbon dioxide. It is catalase, oxidase and beta glucosidase 
negative, whilst it ferments a wide range of sugars except for sorbitol, mannitol, 
rhamnose and melibiose.  
 
The surface of the cell wall of GV is covered by fimbriae that are responsible for 
attachment to VEC both in vitro and in vivo [246, 247]. Patterson et al., (2010) describes 
GV as the most virulent BV-associated organism since it contains three virulence 
factors, has biofilm formation and adhesion capabilities, and produces cytolysin [247]. 
Gardnerella is associated with pathogenicity because of possessing vaginolysin activity 
and an ability to form a scaffold for bacterial biofilms [246, 248]. A biofilm is formed 
when bacterial cells adhere to the host surface and to each other and produce a slimy 
extracellular matrix composed of a polymeric substance. This protects the bacteria and 
assists with immune evasion and resistance against antibacterial activities, causing 
chronic disease or recurrent infections [249]. When analysing GV biofilms, a number 
of other organisms were found to be incorporated within the biofilm layer [250]. 
 
GV causes inflammatory responses, with studies showing upregulation of IL-8, SLPI 
and RANTES in vivo and in vitro in response to GV [251.]. Furthermore, the 
cytoskeleton protein, vimentin, which supports cell strength and tissue integrity, was 
upregulated in VEC within eight hours of exposure to GV, while tight junction proteins 
(ZO-1 and ZO-2) were downregulated  [252] (Figure 1.8). GV has over 95% positive 
predictive value for BV when molecular based techniques are compared to Gram stain 
or Nugent score [120] and over 95% of women with recurrent BV had biofilms 
composed of GV and A. vaginae [249, 250]. Danielsson et al., (2011) attributed the 
resistance of Gardnerella to H2O2, lactic acid and metronidazole to its ability to form 
biofilms [252, 253].  
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Figure 1. 8 Response in to Gardnerella vaginalis in vaginal epithelial cells 
Exposure of vaginal epithelial cells to Gardnerella vaginalis results in upregulation of 
proinflammatory cytokines, namely IL-6, IL-8, TNF-α, and IL-1β. Vimentin is upregulated 
after G. vaginalis exposure. Upregulation of vimentin influences uptake and internalization of 
bacteria. Tight junction (TJ) proteins ZO-1 and ZO-2 are downregulated in vaginal epithelial 
cells exposed to G. vaginalis. Downregulation of TJ proteins could result in HIV passing in 
between cells (paracellular transport) en route to the vaginal submucosa where subepithelial T 
cells and macrophages reside and are highly permissive to HIV infection. Trafficking of 
infected T cells by resident lymph nodes would facilitate HIV dissemination via the blood 
(adapted from Alcendor 2016). 
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1.2.15.3 Atopobium vaginae 
A. vaginae is a fastidious anaerobe gram positive coccus, which occurs as a single cell 
or in chains. It has a variable morphology, though in culture its usually masked by other 
coliforms. It is capable of producing large amounts of lactic acid [254], which makes 
its role uncertain. 
 
A. vaginae has been identified in more than 90% of BV+ women compared to 12% in 
BV- women [118], and in 50% of women with gynaecological disorders [139]. 
However, although it has been isolated from BV- women, its high prevalence in BV 
may qualify it as a marker or predictor of BV [120]. A. vaginae correlates well with 
three out of four of Amsel’s criteria and has been found together with GV in 75% to 
98% of BV samples compared to less than 10% in BV- women [255]. Through qPCR, 
16S rRNA amplicon sequencing and microarray techniques, GV and A. vaginae have 
been found associated with biofilm formation in more than 80% of BV cases [85, 256, 
257]. 
 
A. vaginae accounted for 1-40% of the total mass of biofilms adherent to the vaginal 
mucosa in 70% of samples from BV+ women [249]. Therefore, biofilm formation could 
be the major reason why A. vaginae is resistant to metronidazole and is found in most 
BV recurrent cases [117]. In vitro, A. vaginae notably enhances proinflammatory 
cytokine, chemokine and antimicrobial protein expression by VEC, including IL-8 
[222], MIP-3α (CCL20) [218], RANTES (CCL5) [251], HBD-2, and IL-1β, as well as 
TLR2, MyD88 [258] and NF-κB [259] signaling pathways. Moreover, A. vaginae 
elicits consistent signatures associated with disruption of the vaginal epithelial 
membranes during innate immune responses [218]. In vitro models have observed high 
levels of TNF-α, HBD-2, IL-6, IL-8 and HBD-4 following A. vaginae stimulation [222, 
258]. These studies agree with clinical studies that confirmed the same upregulations 
associated with GV and A. vaginae, with the latter notably the most abundant taxa in 
South African women with the highest levels of cervico-vaginal inflammatory 
mediators [135, 223]. 
 1.2.15.4 “Bacteroides” group (Prevotella and Porphyromonas)  
What were once thought to be Bacteroides morphotypes on gram stain for Nugent score 
classification were found to be Prevotella and Porphyromonas in a deep sequencing 
study conducted by Srinivasan et al., (2012)[85]. These organisms are gram negative 
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pleomorphic, anaerobic and non-motile rods. In many studies, Prevotella spp. have 
been found in most women regardless of Nugent score but relative abundance 
significantly increases with increasing Nugent score [156, 255, 260]. Prevotella 
produce polyamines during normal metabolic activity which produces a characteristic 
fishy odour associated with BV. The produced amines increase vaginal pH and create 
an environment that stimulates GV and Peptostreptococcus anaerobius growth [261, 
262]. 
 
Prevotella spp., particularly P. bivia and P. disiens, produce fibrinolysin which disrupts 
mucosal surfaces, while sialidase and prolidases cause exfoliation of VEC [242]. 
Prevotella spp., particularly P. bivia, have also demonstrated the ability to prominently 
modify the cervicovaginal mucosal environment in an in vitro model by stimulating the 
production of MIP-3α, RANTES, IL-8, and IL-1β, and activating the proinflammatory 
transcription factor NF-κB [218, 251]. These studies concurred with in vivo studies 
conducted by Hedge et al.,and Jespers et al., (2017) in which P. bivia was associated 
with higher levels of proinflammatory cytokines IL-1α, IL-1β, IL-8, MIP-3α and TNF-
α and negatively associated with IP-10 in African women with both intermediate 
microbiota and with BV  [116, 263].  
 
1.2.15.5 Anaerobic cocci: Peptostreptococcus.  
Peptostreptococci are anaerobic cocci that have been grouped with newly proposed 
genera like Anaerococcus, Parvimonas, Finegoldia, Peptoniphilus, and Gallicola 
[264]. Zozaya et al., (2010) found Peptostreptococcus spp. in almost all specimens 
from BV+ women [255]. Onderdonk et al., (2016) found increasing 
Peptostreptococcus abundance with increasing Nugent score [117], and found that 
these bacteria have an ability to form biofilms, however are unable to adhere to 
epithelial cells [247]. On the other hand, Peptoniphilus, which is a butyrate-producing 
genus with the ability to adhere to vaginal epithelial cells, was found to persist in 
women who failed BV treatment  [265]. This genera is generally resistant to 
metronidazole, penicillins and clindamycin [255]. 
 
1.2.15.6 Megasphaera 
 Several studies have found that Megasphaera is highly associated with BV [90, 266, 
267] in fact, is one of the four main BV genera [248]. In an in vivo study measuring 
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cytokines and microbial peptides, Megasphaera spp were found inversely associated 
with IL-8  quantities [219], while in another study, Megasphaera was found associated 
with high salisidase activity in BV [268].  
  
1.2.15.7 Sneathia 
Sneathia is the new name that was given to Leptotrichia in 2012 [269]. Sneathia amnii 
was found in more than 7% of women with BV [246]. In a separate study, Sneathia 
amnii was found prevalent in both BV+ and BV- women with a strong association with 
sexual activity [246, 248]. However, S. amnii was highly associated with mostly clinical 
signs and symptoms of BV; therefore, is implicated in BV pathogenesis [85]. 
 
S. amnii is able to produce collagenase and fibrinolysin which degrade VEC and 
promote their detachment [242]. S. amnii possess a number of virulent, cytotoxic factors 
such as potential invasins and adhesins, proteins involved in degradation of sialylated 
proteins and haemolysin [246]. In an in vitro study, Sneathia spp. were found to 
upregulate IL-1α, IL-β, TNF-α, and IL-8 [135]. 
 
 1.2.15.8 Mobiluncus 
Mobiluncus are motile fastidious, gram variable rod-shaped bacteria and are made up 
of two main species: Mobiluncus mulieris and Mobiluncus curtisii. M. mulieris is 
genera is said to be common in healthy women, while M. curtisii has been highly 
associated with BV [270-272]. The association of the Mobiluncus with BV has been 
established in numerous studies identified both by Nugent score and molecular 
techniques [273-275], and may be responsible for some of the malodor of BV [242].  
 
Mobiluncus has the ability to produce both sialidase and mucinase in the FGTs of 
women with BV, which suggests the use of mucin as a substrate and may result in the 
depletion of this protective layer [276]. Culhane et al.,and Hedge et al., (2006) found 
an upregulation of cervicovaginal sialidase, but not IL-1β and IL-8 in women with 
abundant Mobiluncus [263]. However, in an in vitro study, stimulation of immortalised 
human VEC with Mobiluncus culture isolates was associated with a significant 
upregulation of proinflammatory cytokines including IL-1α, IL-1β, TNF-α, and IL-8  
[135] 
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1.2.15.9 Mycoplasma and Ureaplasma  
Mycoplasma and Ureaplasma are facultative anaerobic organisms without a cell wall 
which replicate in a parasitic manner [117]. Therefore, they have been missed with 
Gram staining due to lack of cell wall and its associated structures which are difficult 
to stain. Mycoplasma hominis is the main Mycoplasma species associated with BV and 
poor birth outcomes [277]. It was isolated in 93(43%) of non-pregnant women with 
BV, while it another study it was found highly associated with risk of PTB regardless 
of cervical length [158, 277]. M. hominis and Ureaplasma urealyticum were detected 
in the vaginas of 75% of BV+HIV-infected pregnant women in Gauteng, South Africa 
[278]. M. hominis has been found in several studies in a symbiotic relationship with 
STIs [279]; it localises itself inside the T. vaginalis protozoa [280] where it replicates, 
thereby protected from host immune responses and antimicrobial treatment [281]. 
Although U. urealyticum colonisation was found to be higher in BV+ women in some 
studies [156, 282], others have found no significant differences in U. urealyticum 
colonization between BV+ and BV- groups [283].  
 
U. urealyticum has the ability to produce enzymes, such as elastase and IgA protease, 
that compromise mucosal immunity. In addition it contains hydrolytic enzymes, urease 
and phospholipase C, that convert urea to cytotoxic ammonia which enhances the 
symptoms and pathogenesis of BV [242]. It also has the ability to induce the production 
of proinflammatory cytokines TNF-α and IL-6 by macrophages [284]. M. hominis 
possesses unique adhesins called TLR2-dependent, macrophage-activating, P50-
related adhesins which may play an important role in triggering the inflammatory 
cascade [285].  
 
1.2.15.10 Dialister 
In a study conducted in North America, Dialister micraerophilus was found in almost 
80% of women with BV [85] and is more likely to colonise African American and 
women of African descent [5] than Caucasian women. Virulence factors and the role 
played in BV have not yet been explored. 
 
1.2.15.11 BVAB1 to BVAB3 (Mageeibacillus indolicus) 
BVAB1, 2 and 3 have been recently described and are classified under the phylum 
Clostridium [267]. Molecular identification has shown 80% nucleotide identity with 
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Mobiluncus [117]. The three bacteria have been detected in >90% of women with BV 
and with high Nugent scores [267, 286]. BVAB3 (gram positive rods), renamed to 
Mageeibacillus indolicus [287], has been found to be associated with cervicitis [288]. 
Lennard et al., (2018) found that BVAB-1 was highly inflammatory in young women 
at high risk for HIV infection [134]. However, Zozaya-Hinchliffe et al., (2010) did not 
find any association between BV and BVAB1 despite higher abundance found in 
specimens from BV+ women [255]. The role of the BVAB group of organisms is thus 
unclear and further studies to explore these organisms are still needed. 
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1.2.15.12 Streptococcus agalactiae, a vaginal pathobiont during 
pregnancy 
Streptococcus agalactiae or group B streptococcus (GBS) is a gram-positive 
encapsulated coccus, that is usually present as a single coccus, but can be present in 
chains. GBS is catalase negative and Christie-Atkins and Munch-Peterson-(CAMP) test 
positive and colonises the gastrointestinal tract, as well as the female genitourinary 
tract, intermittently [289, 290]. Colonisation can be intermittent, transient or persistent 
in individual women but the factors that determine colonisation are unclear [291]. 
Recto-vaginal GBS carriage prevalence worldwide ranges from 10% to 40% in healthy 
pregnant women [292, 293]. According to the WHO, Africa has the highest burden of 
GBS, with 54% of all estimated global cases, while 65% of stillbirths and infant deaths 
in Africa are due to GBS [3, 294, 295]. Studies in different settings have reported 
vertical transmission between mother and offspring of 29-85%, depending on the 
burden of colonisation in untreated mothers [296, 297]. GBS has been associated with 
adverse birth outcomes, including LBW [291], early and late onset sepsis and 
meningitis in neonates [297, 298], still birth [299], PTB [45] and PPROM [300]. 
However, in an study of over 1000 African women performed in urban and rural 
settings in pregnant women, GBS colonisation was not associated with poor birth 
outcomes [301] 
 
Few culture independent studies have examined the relationship between GBS and 
vaginal microbiota in Africa [302, 303]. However, no significant relationship between 
the overall vaginal microbiota and GBS colonisation was found in non-pregnant 
women; although, positive trends toward significance were observed for 
Staphylococcus, Corynebacterium and Aerococcus taxa [304]. 
 
GBS has the ability to adhere to mucosal surfaces using factors such as surface serine 
proteins  [290, 305], pilus proteins, alpha C proteins [306]and bacterial surface adhesins 
(BsaB, BsapA, BibA), which are also linked to GBS pathogenesis [307]. Some 
serotypes of GBS express β haemolysin/cytolysin and carotenoid pigment which 
influence cervicovaginal adherence and vaginal persistence [308]. GBS has 9 
polysaccharide serotypes which have been described [309] and among these serotypes 
GBS serotype (ST) 17 strongly produces biofilm in an acidic environment in vitro, 
whereas in neutral environment, ST17 and ST19 only weakly produce a biofilm [310]. 
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However, studies done using in vivo models have not been able to confirm the formation 
of biofilms by GBS [311].  
 
GBS possesses α2,3-linked terminal sialic acid which mimics a critical host glycan and 
confers the ability to evade innate immunity [312] as it is identical to a host cell epitope 
expressed on glycoproteins and glycolipids on mammalian cells. This GBS molecule is 
identified as self-epitope and causes sialic acid-binding immunoglobulin-like lectins 
(Siglecs) to downregulate macrophage and neutrophil release and action [313, 314].  
 
1.2.16 Inflammation and pregnancy outcomes  
The maternal immune system during gestation is highly tolerogenic in order to prevent 
loss of the growing semi-allogeneic foetus in the womb [315]  [316, 317]. Inflammation 
during pregnancy is thought to alter the homeostatic environment required for foetal 
growth leading to poor birth outcomes [318]. The presence of a stable microbiota and 
low vaginal pH during pregnancy possibly contributes to a state of relative immune 
quiescence [69, 209]. Preterm labour is thought to be a result of inflammation or 
imbalance in this tolerogenic state  [319]. Most studies investigating the relationship 
between cytokines and pregnancy outcomes have been done in cord blood, amniotic 
fluid and maternal plasma/serum, while few have investigated cervicovaginal fluid. 
During maternal infection, the production of plasma cytokines such as interferon 
gamma and tumor necrosis factor alpha results in elevated prostaglandin levels that 
causes early labour [320]. Women who experienced complicated pregnancies, 
including cases of preeclampsia, PROM, PTD and spontaneous miscarriage, had high 
levels of serum cytokines throughout pregnancy, such as TNF-α  [321], IL-6 and G-
CSF  [322], compared to women who had normal pregnancies.  
 
In two studies performed by Romero et al., (1992) including pregnant women recruited 
between 1989 and 1992, IL-6 was found to be elevated in the amniotic fluid of those in 
preterm labour and those who delivered preterm neonates [323-325]. IL-1 was 
hypothesized to have played a role in initiation of preterm labour associated with intra-
amniotic infection [324], and TNF was significantly higher in patients with PROM and 
premature labour [325]. This concurs with other studies that report that IL-8 and TNF-
a polymorphisms in placentas, and IL-1α and/or IL-1β concentrations in vaginal fluid, 
are associated with spontaneous preterm delivery [326, 327]. In African and Hispanic 
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women, Genc et al., (2002) found associations between spontaneous preterm delivery 
and foetal carriage of a mutation in IL-1 gene complex [228]. 
 
Increased vaginal concentrations of TNF-α or IL-1β in BV are hypothesized to 
stimulate amniotic membrane degradation or myometrial contractions to initiate the 
process of early labour, increasing the risk of preterm delivery [327]. This agrees with 
studies conducted in nonhuman primate models in which IL-1β and TNF-α were 
inducers of preterm labour, but not IL-6 or IL-8 [328]. IL-6 and IL-8 have however 
been known to cause some inflammatory changes in the foetal membranes [329]. Since 
BV is an inflammatory condition, it is therefore not surprising that it may be a cause of 
preterm labour. 
 
Ethnicity may have an influence on the relation between cytokines and pregnancy 
outcomes. Velez et al., (2008) observed differences in the relationship between 
amniotic fluid IL-1β, TNF-α, sTNFR1 and sTNFR2 concentrations and PTB in African 
American versus Caucasian women [330]. In African American women, IL-1β was 
associated with PTB, while this relationship was absent in Caucasian women. 
Therefore, there might be different mechanisms leading to PTB in different ethnicities 
 
In a study conducted by Wilkinson et al., (2017) increased TNF-α in maternal plasma 
of HIV infected mothers was highly associated with early delivery and LBW, while 
elevated umbilical cord IFN-γ and IL-12p70 concentrations were associated with 
significantly lower birth weights [331]. In several studies in HIV negative women, 
positive associations between serum proinflammatory cytokines (IL-1β, IL- 6, and IL-
8) and PTB were found [332-334]. Similarly, IL-8 concentrations in vaginal fluid were 
significantly higher in pregnant women with pathologic findings on vaginal wet mount 
and spontaneous PTD [335-337].  This, however, contradicts with the findings of a 
study conducted by Kalinka et al., (2005) where no significant difference in IL-1α, IL-
1β, IL-6 and IL-8 concentrations in vaginal fluid of preterm versus term delivery groups 
were found [338]. 
 
Laskowska et al., (2007) postulated the possibility of IL-8 and TNF-α having an active 
role in preeclamptic pregnancies with or without IUGR and reported a possible role of 
IL-8 in sequelae of preeclamptic pregnancies complicated by IUGR  [339]. Another 
study found high levels of IFN-γ and increased production of TNF-α in peripheral blood 
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of pregnant women with recurrent pregnancy loss (RPL) [340]. Consequently Talukdar 
et al., (2008)concluded that increased inflammatory cytokine IFN-y and IL-17-
producing gamma T cells were associated with generating inflammatory cytokines that 
could contribute to loss of pregnancy in women with recurrent pregnancy loss 
compared to normal [341]. 
 
1.2.17 Cytokines as biomarkers for adverse birth outcomes 
As most women with BV and many infections that lead to adverse birth outcomes lack 
clinical signs or symptoms, a substantial amount of research has focused on the 
identification of potential biomarkers to predict PTD, although few have proven 
sufficiently reliable or accurate for prediction of PTD [342]. However, bedside tests 
that would offer quick and timely clinical results for treatment studies are being 
developed to identify potential biomarkers for diagnosis for intraamniotic inflammation 
in preterm labour [343, 344]. Amniotic fluid (AF) point of care (POC) tests were 
evaluated against enzyme-linked immunosorbent assay (ELISA) measuring IL-6 
concentration, a key cytokine for intra-amniotic inflammation in women who presented 
with preterm labour [344]. Interleukin 6 was chosen since it has been used as an 
excellent method for detection of intra-amniotic inflammation.  Women in preterm 
labour would have increased concentrations of IL-6 and this could be ideal for 
evaluating the predictive values of the POC test [343, 344]. The ability of the AF IL-6 
POC to identify microbial invasion of the amniotic cavity was comparable to ELISA 
with a high specificity and sensitivity of 91% and 93% respectively for correctly 
assaying IL-6 levels. Furthermore, another POC test (AF IL-6 and IP-10) was evaluated 
which included Interferon-γ induced protein (IP-10) and IL-6 and was found to strongly 
correlate with ELISA results [343]. 
 
A large proportion of these studies have focused on biomarkers in the amniotic fluid 
[345] which could be useful after rupture of membranes, but it would not be feasible to 
perform amniocentesis routinely to screen women who are not in labour for PTD risk 
[346]. In non-pregnant South African women, it has been show that inflammatory 
cytokines (IL-1α, IL-1β and IP-10) measured in vaginal swab samples may serve as 
useful biomarkers to identify women with asymptomatic bacterial/protozoan STIs or 
BV [220, 347, 348]. A similar tool may prove useful for identifying pregnant women 
with asymptomatic dysbiosis and STIs who are at risk of adverse birth outcomes.  
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1.2.18 Microbiome Analysis 
The examination of DNA to study microbial communities is termed metagenomics. 
Metagenomics has two major approaches: shotgun sequencing, which randomly 
sequences all genomic DNA in a sample revealing the gene and taxonomic content 
[114] and amplicon sequencing, where only a selected part of the genome is sequenced, 
for example, the 16S rRNA gene. Metagenomics allows for characterization of relative 
abundances of microbes. It further allows characterization of the taxonomic diversity 
within samples, called alpha diversity, and between communities, called beta diversity 
[349] (Figure 1.9). Currently all studies investigating microbial communities employ 
high throughput sequencing and may also employ metabolomics and metaproteomics 
approaches [350]. In this study 16S rRNA is used for vaginal microbiota analysis it 
identifies a large number of vaginal bacterial, 16S rRNA identify microorganisms with 
a degree of accuracy as the highly conserved region are unique to genera, species and 
strains. It helps eliminate human and viral DNA, furthermore, the microbial genome is 
relatively smaller that it is cost effective  [351]. However, it has some limitations in that 
it sequences only a single region of the bacterial genome and has a short length read, it 
has limited resolution and sensitivity on assigning taxonomic affiliation for organism 
identification when compared to shotgun sequencing.  Shotgun sequences has 
advantage in that n it provides enhanced detection of bacterial species, increased 
detection of diversity and increased prediction of genes and also, improved the accuracy 
of species detection  [351] [352]. 
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1.2.19.1 16S rRNA gene sequencing 
For studying bacterial taxonomy and profiling, identification of a conserved gene 
common to all bacteria that is also variable and differs between individual genomes is 
imperative [353]. The 16S ribosomal ribonucleic acid gene (16S rRNA), which is a 
gene encoding the RNA component of the 30S subunit of the bacterial ribosome, is 
often used. This gene possesses adequate taxonomic coverage, and is significantly 
ubiquitous with highly conserved flanking bases of nine hypervariable regions (V1-V9) 
[354]. Targeted amplicon sequencing of the 16S rRNA gene (1.5 Kbp) is used for 
determining the taxonomic composition and community diversity of a given sample. 
The most commonly used hypervariable regions are V1-V6 [355]. 
 
Selected genes are amplified using target specific primers that amplify conserved 
regions flanking the hypervariable regions. The samples are barcoded, then barcoded 
samples are pooled and purified using AMPure XP beads ((Beckman Coulter, Brea, 
CA, USA). Quantification is done using picoGreen double stranded DNA (dsDNA) 
assay (Invitrogen, Carlsbad, CA, USA). Dual indices and Illumina sequencing adapters 
are attached by using the Nextera XT DNA Prep kit (Illumina). Samples are again 
purified and then purified libraries consisting of _96 pooled samples are paired-end 
sequenced on an Illumina MiSeq platform (300-bp paired-end reads with V3 chemistry) 
[134, 356]. Raw reads generated from microbiome sequences are quality controlled, 
removing ambiguous reads and chimeras, and demultiplexed (assigned to samples 
using barcodes) [114]. In some pipelines, such as QIIME, raw reads are then binned 
into clusters of closely identical genomes called operational taxonomic units (OTUs) 
according to sequence similarity accommodating divergence of between 95-99% [356] 
(Figure 1.9). However, newer methods include DADA2 (Divisive Amplicon Denoising 
Algorithm2) which yields amplicon sequence variant table (ASV) table (McMurdie and 
Holmes, Plos Comp Biol). Alignment and inference to phylogenetic trees is done using 
alignment programmes such as Fasttree, MUSCLE or PyNAST332  [357]. The final 
identification of the microbial data is performed by comparing it to gene databases that 
contain millions of referral sequences, such as the Ribosomal Data Base project (RDP), 
CAMERA, Green Genes, VAMPS, MG-RAST [358, 359] and SILVA. This assigns 
taxonomic lineages to each OTU [350]. OTUs are often identified down to the Family 
and sometimes Genus or species level. The Illumina MiSeq is an integrated instrument 
that performs clonal amplification, genomic DNA sequencing, and data analysis with 
base calling, alignment, variant calling, and reporting in a single run. The Illumina 
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Miseq platform is most commonly used for amplicon sequencing, but due to the limited 
read lengths of ~400bp (excluding primers and adapters), often species level annotation 
is difficult.  
 
Mothur [356] and Quantitative Insights Into Microbial Ecology (QIIME) are 
Bioinformatics tools commonly used to filter and analyse raw reads. Analysis with 
QIIME results in quality filtered OTUs generated using UCLUST, which can produce 
taxonomic tables, phylogenetic trees and visual diversity plots [360] (Figure 1.9). 
OTUs are presented as summarized data tabulated into abundances and annotated into 
taxa across samples, for downstream statistical analysis [21]. The tabulated data can be 
stored in a Biological Observation Matrix (BIOM) file for ease of use within different 
bioinformatics tools [21]. 
 
Figure 1. 9 QIIME based analysis 
QIIME-based analysis is performed in three steps: (1) pre-processing, (2) taxonomy 
classification, and (3) computation of diversity and visualization. Further statistical analysis of 
the data is performed in R programming environment (Jun Hang et al., 2014) 
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1.2.20.2 Statistical analysis of microbiome data  
Statistical approaches are important to assess diversity of microbial communities and 
their dynamic interaction with the environment and the host. The main challenges with 
microbial data include data sparcity (i.e. zero inflation), compositionality and sequence 
depth and distribution, which is not always comparable between samples. 
Nonparametric methods are used for analysis for data which is not normally distributed 
[21]. Rescaling and rarefying of reads has been employed in order to try and transform 
data to suit models to be used by different algorithms such as metagenomSeq, edgeR 
[361] and DESeq [362, 363]. Open access software such as Calypso [364] and STAMP 
[365] incorporate these tools. These software models focus on multivariate statistical 
approaches and permit quantitative visualization of microbial communities. 
 
Statistical analyses performed on microbiome data include comparisons of alpha and 
beta diversity metrics. Diversity within a sample that takes into account evenness 
(relative abundance of species), and richness (total number of species present) is called 
alpha diversity. The commonly used metrics are Chao1, Simpson, and Shannon indices 
[357]. Dissimilarity between each pair of samples or environmental gradients, 
characterised by the number of species shared between the communities, is called beta 
diversity. The commonly used beta diversity metrics are Bray-Curtis distances, 
unweighted and weighted UniFrac distances, depending on which is suitable to the 
parameter in question. Non-metric multidimensional scaling (NMDS) or principal 
coordinate analysis (PCoA) are commonly used for visualization of ordination data [21, 
357].  
 
Hierarchical clustering and heat maps are used to visualize the composition of 
communities [21]. LEfSe (Linear discriminant analysis Effect Size) has been used to 
determine biomarkers for relevant features of interest [366], while Random Forest is a 
combination tree predictor which depends on independently sampled random vectors 
[367]. Analyses used to assess statistical significance can employ nonparametric tests 
such as Kruskal-Wallis rank sum or Mann Whitney U test to determine groups or 
abundances with statistical differences [357].  
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1.3 Research hypothesis and objectives 
 
Hypothesis 
Ø There is an association between the vaginal microbiota and adverse pregnancy 
outcomes. 
Aim 
Ø To characterise the vaginal microbiota in relation to pregnancy outcomes. 
Specific objectives 
1. To determine the association between the vaginal microbiota and pregnancy 
outcomes. 
2. To compare the vaginal microbiota in pregnant women with or without HIV. 
3. To estimate the prevalence of BV and other vaginal pathogens in pregnant 
women.  
4. To determine the immunological and microbiological biomarkers or predictors 
of adverse pregnancy outcomes 
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Chapter 2: Methodology and Study Design 
2.1 Study cohort 
This was a prospective observational cohort study of pregnant women who attended the 
antenatal clinics (ANC) at Harare and Chitungwiza central hospitals. The study was 
carried out in  two central hospitals providing antenatal services for high density 
suburbs and for referral cases from peri-urban clinics and rural district hospitals.  
Inclusion criteria: All pregnant women were 13-35 weeks of gestation, 18 years of 
age and above, willing to provide written consent and participate in the study. 
Additionally,  all women were not receiving treatment for any STI (except HIV) nor 
received antibiotic treatment in the past one month with documented HIV testing results 
in pregnancy.  
 
2.2 Ethical considerations 
This study obtained approvals from all of the institutions involved. Harare Central 
Hospital (HCHEC 080416/21) and Chitungwiza Central Hospital ethics committees 
(dated 28/04/16) approved sample collection at their hospital antenatal clinics. The 
study was approved by the University of Cape Town Human Research Ethics 
Committee (HREC/REF 380/2016) and Medical Research Council of Zimbabwe 
(MRCZ A/2054). The Research Council of Zimbabwe (RCZ) also approved shipment 
of samples to University of Cape Town, South Africa. 
 
2.2.1 Consenting Processing 
The consenting procedure was done by qualified trained research nurses. The study, 
including aims, was explained in the language of choice to all pregnant mothers during 
the educational sessions. To ensure understanding of the study and the collection 
procedures, study participants were asked to repeat back their understanding,  and 
signed consent for storage of specimens and shipping for further testing in South Africa. 
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2.3 Study procedures 
At enrollment, socio-demographics, reproductive health history, antiretroviral use, CD4 
count and previous pregnancy outcomes were collected using a questionnaire. Vaginal 
samples were collected from consenting participants and labelled with a study code, 
e.g. BVDZIV001. The research nurses and assistants stationed at each clinic collected 
patient background data as indicated on the questionnaire, including ultimately, 
pregnancy outcomes.  
 
2.3.1 Sample size calculation  
Sample size was calculated using a single proportion estimate (BV prevalence) with 
specified precision.  It was found that a sample size of 340 would provide 80% power 
to detect the magnitude of difference in BV prevalence between HIV infected and 
uninfected pregnant women (alpha=0.05) [28]. 
Sample size to estimate a single proportion 
Estimated Proportion 0.33 
Confidence level 0.95 
Desired precision of estimate 0.05 
Population size unknown 
Results 
 
 
Sample size 
Infinite population 340 
The estimated sample size become approximately 340 + 5% attrition gives a total 
minimum sample size of 357 
 
2.3.2 Vaginal swab collection procedure and storage  
Two vaginal swabs were collected from each pregnant woman during their antenatal 
visit checkup at enrollment . The research nurses collected specimens aseptically by 
inserting the swab 2cm into the vagina, swabbing inside the vaginal canal by rotating 
the swabs for approximately 5 seconds. Upon removal of the first swab, it was touched 
on the pH paper and bedside pH was recorded. The swab was immediately placed into 
the transport tube with 1.5mL sterile phosphate buffered saline (PBS), placed in the 
cooler box with ice packs (2-8⁰C) and transferred to the laboratory within 4 hours of 
collection where it was stored in a -70⁰C freezer  and later shipped on dry ice to South 
Africa. A second vaginal swab was sent to the laboratory used for culture and 
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microscopy. All women were tested for syphilis and HIV during their first antenatal 
visit. 
 
2.4 Laboratory diagnosis  
2.4.1 Microscopy and culture 
Nugent score and Hay /Ison technique (gram stain) 
Diagnosis of bacterial vaginosis was done by Gram stain and microscopy by 
experienced staff using the Nugent scores and Hay Ison technique (Table1.1 & 
Table1.2). Swab samples were smeared onto glass slides and stained with Gram statin 
reagents. Women were grouped at BV negative (predominantly lactobacilli; score: 0-
3), BV intermediate (some lactobacilli and some gram variable coccobacilli and 
Mobiluncus; score: 4-6) or BV positive (few to no lactobacilli with abundant gram 
variable coccobacilli and Mobiluncus; 7-10) based on scoring conducted by three 
laboratory technicians. A wet prep was done for Trichomonas vaginalis diagnosis.  
Culture 
Swabs in Amies transport media were cultured on Columbia Blood agar (CBA) with 
5% sheep blood, MacConkey (MAC) agar plate (Oxoid, UK). These were incubated in 
anaerobic jars at 37°C for 18-48 hours and MAC was incubated aerobically at 37°C for 
18-48 hours. Gram positive cocci were sub cultured on Columbia colistin and nalidixic 
acid (CNA) agar and chromogenic agar (ChromID Strepto B agar; STRB; bioMérieux, 
Inc) for group B streptococcus. Biochemical tests were performed on suspected 
pathogenic organisms using sub-cultured pure fresh colonies of 0.5 McFarland standard 
equivalent suspension. Species level identification for gram negative organisms was 
done using API 20E (Biomerieux, UK). Suspected group B streptococcus was 
identified using the Christie, Atkins, and Munch-Peterson (CAMP) test and the 
serologically using Rapid latex agglutination test Streptex (ThermoFischer 
scientific.US), for quality control throughout culture methods the procedure 
Escherichia coli ATCC  25922 and Staphylococcus aureas 25923 were used Matrix 
assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF) 
was used for confirmation of identified GBS isolates 
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2.5 Microbiome analysis 
2.5.1 DNA extraction  
DNA extraction was done using an inhouse method as published by Anahtar 2016.  
Optimization was done using aliquots of stored vaginal samples and the yields 
quantitated by gel electrophoresis and Qubit. It was found that phenol chloroform 
extraction method   yielded a considerably greater amount of DNA compared to 
commercial Zymol kit. After this optimization study, samples were then processed.  
 
Vaginal swabs were thawed, scraped of vaginal fluid for maximum yields and 500µl 
was transferred to a sterile Eppendorf tube. To obtain lysis of gram-positive bacteria a 
cocktail of enzymes including 3µl lysostaphin (4kU, Sigma Aldrich), 6µl mutanolysin 
(25kU/ml, Sigma Aldrich) and 50µl lysozyme (450kU/ml, Sigma Aldrich) were added 
to the samples [368]. The mixture was incubated for 1hr at 37⁰C, vortexing every 10-
20 minutes. After enzymatic digestion Sodium deodecyl sulfate (SDS), 
Phenol:chloroform:isoamyl alcohol  and prepared buffer were added to the vaginal fluid 
mixture and then it was subjected to bead beating. DNA extraction was done using the 
phenol chloroform extraction method  [369] (URL: 
http://www.jove.com/video/53939). Isopropanol precipitation and ethanol wash was 
done and the nucleic acid pellet was resuspended in ultra-pure Tris EDTA buffer and 
DNA concentration was quantified using the Qubit dsDNA high sensitivity reagent 
(Invitrogen). DNA was run on a 1.5% agarose gel for visualisation. The extracted DNA 
was stored at -80⁰C for library preparation.  
 
2.5.2 Library preparation 
The V4 hypervariable region was selected in this study because it allows a better 
discrimination of BV-associated bacteria.  The hypervariable V4 region of the 16S 
rRNA gene was amplified by nested PCR using universal primers (515F/806R).(Table 
2.1) [370]. PCR1 specific primers with overhang adapters were used to amplify the V4 
template out of the DNA sample. Due to general high yields of DNA, samples were not 
processed in duplicate, but template was increased per sample during the first PCR to 
approximate 20ng DNA template. The first PCR conditions were as follows: 95°C for 
3 minutes, then 35 cycles of: denaturation at 95°C for 30 seconds, annealing at 55°C 
for 30 seconds and elongation at 72°C for 30 seconds, then termination at 72°C for 5 
minutes. Purification of the 16S rRNA gene V4 amplicon to remove free primers and 
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primer dimers was done using AMPure XP beads (Beckman Coulter, Brea, CA, USA). 
Quality control was done using Qubit for quantification and agarose gel electrophoresis 
for visualisation of bands. 
 
The purified amplicons were subjected to 2nd PCR: The Nextera XT Index Kit 
(Illumina) was used during this stage where engineered transposomes simultaneously 
fragment and tag ("tagment") input DNA adding unique sequencing adapters. These 
adapters are used during the PCR reaction to amplify the insert DNA. Index sequences 
are added on both ends of the DNA, enabling dual-indexing of pooled libraries. The 
reaction contained a total volume of 50μl with 5μl DNA amplicon from the 1ST PCR. 
The reaction started at 95°C for 3 minutes and went through 8 cycles at the same 
temperatures as in PCR 1 above. Quality control was done using the Qubit fluorometer 
(Invitrogen) for quantification and verification was done by gel electrophoresis for 
visualisation of bands. Samples were pooled in equimolar amounts and the pooled 
library was run on an agarose gel (1.5 %).  Purified libraries consisting of 96 pooled 
samples per library were stored in -20°C for shipment to Seattle USA for sequencing 
using Illumina MiSeq platform. 
 
2.5.3 Sequencing  
To quantify each library's amount of adapter-ligated DNA a combination of NEBNext 
Ilumina Quantification Kit and a Qubit dsDNA Broad Range assay were used. Libraries 
were sequenced from both ends using the 300-bp paired-end kit with v3 chemistry 
(MiSeq v3 2x300bp kit) and the resulting reads were demultiplexed on the MiSeq.  
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Table 2. 1 16S rDNA V4 Amplicon Library Primers 
Primer  Primer sequence (5’ to 3’)  
Primary PCR primers  
Modified 
515F  
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA 
Modified 
806R  
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT 
Secondary PCR primers  
501    AATGATACGGCGACCACCGAGATCTACACTAGATCGCTCGTCGGCAGCGTC  
502    AATGATACGGCGACCACCGAGATCTACACCTCTCTATTCGTCGGCAGCGTC 
503    AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCGTCGGCAGCGTC  
504    AATGATACGGCGACCACCGAGATCTACACAGAGTAGATCGTCGGCAGCGTC 
505    AATGATACGGCGACCACCGAGATCTACACGTAAGGAGTCGTCGGCAGCGTC 
506    AATGATACGGCGACCACCGAGATCTACACACTGCATATCGTCGGCAGCGTC 
507    AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCGTCGGCAGCGTC 
508    AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGTCGGCAGCGTC 
701    CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG 
702    CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG  
703    CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG  
704    CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG  
705    CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG  
706    CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG  
707    CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG  
708    CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG 
709    CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG 
710    CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG  
711    CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG  
712    CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG  
 
The adapter sequences are underlined in the 501 and 701 secondary primer sequences. 
The same sequences are found in each of the 500 and 700 primer series. The 8-
nucleotide sample indices are bolded. 
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2.5.4 Microbiome data analysis 
16S rRNA gene amplicon sequencing analysis was performed as previously 
described by Lennard et el. (2018). Briefly, after demultiplexing, raw reads were 
preprocessed as follows: forward and reverse reads were merged by using usearch7  
[371] allowing a maximum of three mismatches; merged reads were quality filtered by 
using usearch7 (reads with E scores of >0.1 were discarded); primer sequences were 
removed by using a custom python script; and merged, filtered reads were truncated at 
250 bp. Dereplicated sequences were sorted by abundance (highest to lowest) and 
clustered de novo into operational taxonomic units (OTUs) at 97% similarity using 
usearch7. Chimeric sequences were detected (against the Gold database) by using 
UCHIME [372] and removed. Individual sequences were assigned to the specific 
identifiers using a 97% similarity threshold. Taxonomic assignment was performed 
with QIIME 1.8.0 [355] using the RDP classifier (using the default confidence level of 
0.5) against the Greengenes 13.8 reference taxonomy for 97% identity. Down stream 
annotation to species level for few key taxa was performed using both NCBI and 
Lennard et al., (2018) databases (Supplemental material found at 
https://doi.org/10.1128/IAI.00410-17). Lennard et al., (2018) compared green genes 
assigned taxonomy,16S vaginal reference database taxonomy (updated from Fettweis 
et al.,2012) and BLAST against NCBI nucleotide database and constructed a consensus 
taxonomy for downstream analyses [134] 
 
Samples with ≥ 5,000 reads were selected for downstream analyses. The OTU table 
was standardized (i.e., transformed to relative abundance and multiplied by the median 
sample read depth) and filtered so that each OTU had at least 10 counts in at least 2% 
of samples or a relative abundance of at least 0.001%.  
 
2.5.5 Downstream statistical analysis 
Downstream analysis was done in R. The phyloseq package, which provides a set of 
classes and tools to facilitate the import, storage, analysis, and graphical display of 
microbiome census data, was used which (downloaded from Bioconductor 
"http://www.bioconductor.org/biocLite.R"). Alpha (a) diversity estimates (Shannon, 
Simpson) and richness (Chao1) were calculated using the R package vegan [373]. Beta-
diversity was estimated by NMDS of Bray-Curtis distances matrices or PCoA  [21]. 
The package ggplot2 was used to build various graphs from the same set of data.  
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Annotated heat maps were constructed using package NMF [374] on merged taxa at 
lowest taxonomic levels for visualization. Random forest analysis [367] was used to 
determine taxa most predictive of different conditions while differential abundance 
testing was done using metagenomeSeq [363]. A Bray distance object with silhouette-
optimal number of clusters was generated using the vegdist function which computes 
good rank order community dissimilarity indices, and fuzzy clustering produced the 
three community state types (CST1-CST3) named according to the dominant species in 
the clusters.  For calculating relative risk and odds ratio epitools, tidyverse and other 
packages nested in the custom function R script were used [134]Logistic, multivariate 
and multinomial regressions were performed in R using the lm(), glm() and mlogit() 
functions respectively. MetagenomSeq was used for differential testing of microbiota 
between groups where these OTUs were defined as differentially abundant as they met 
the threshold criteria of FDR adjusted p= 0.05 absolute FC 1.25 and percentage 
presence in at least one group of 20%. LEfSe (Linear discriminant analysis effect size) 
is a tool used to find biomarkers between 2 or more groups using relative abundances 
[375] 
  
2.6 Cytokine analysis 
Cytokines were measured to assess biomarkers for BV as well as predictors of adverse 
birth outcomes. Concentrations of 27 cytokines (FGF basic, Eotaxin, G-CSF, GM-CSF, 
IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-
13, IL-15, IL-17, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, PDGF-BB, RANTES, 
TNF-α, VEGF) were measured in vaginal fluid using Luminex (R&D).  
 
2.6.1 Measurement cytokines in vaginal fluid by Luminex 
Samples were thawed overnight at 4°C, the liquid phase separated from the solid phase 
through centrifugation at 13000 rpm for 10 minutes, and this liquid fraction filtered 
using a Spin-X tube (Corning Costar, 0.22um filter) at 13000 rpm for 10 minutes. 
Concentration of 27 cytokines were measured from the filtrate using a Bio-Plex Pro 
Human Cytokine 27-plex Assay (Bio-Rad Laboratories Inc., USA). Assay plates were 
read using a Bio-Plex Suspension Array Reader (Bio-Rad Laboratories Inc., USA). 
Data were analyzed using Bio-Plex manager software (version 4). Cytokine levels that 
were below the lower limit of detection of the assay were reported as the mid-point 
between zero and the lowest detectable level measured for that given cytokine. As 
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samples were spread across three plates, a reference panel of five samples was included 
on each of the plates (inter-plate controls), in addition to five samples being duplicated 
on each set of plates (intra-plate controls) for quality control measures. Spearman’s 
rank to measure intra-assay and inter-assay correlation coefficients was used to 
determine assay reliability and reproducibility (Appendix A).  
  
2.6.2 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of 
variables within the dataset. Comparison of unpaired non-parametric data was done 
using the Mann-Whitney U test. The Spearman’s rank test was applied to test for 
correlation between nonparametric data. Statistical inferences on binary sets of data 
were performed using the Fisher’s exact test and odds ratios calculated. Non-parametric 
assessments of variation between groups was carried out through Chi-square test and 
the Kruskal-Wallis Analysis of Variance (ANOVA), with Dunn’s post-test being 
applied to test for the effect of multiple comparisons. Statistical analyses were 
performed using mainly R software, and also GraphPad Prism version 7.0 (GraphPad 
Software, San Diego, California, USA). All tests were two-tailed and p-values of ≤0.05 
after adjusting for multiple comparisons were considered significant. Confirmatory 
factor analysis was used to group cytokines together and generate factor scores 
representing the overall level of inflammation in each woman. Women were grouped 
as having high inflammation (upper quartile; ≥ 75th percentile), medium inflammation 
(interquartile; <75th - >25th percentile) and low inflammation (lower quartile; <25th 
percentile). 
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Chapter 3: Results 
3.1 Cohort characteristics 
Four hundred and twenty-one women consented to participate in the study. One was 
excluded after she was later found to be ineligible due to gestational age.  Socio-
demographic characteristics such as marital status, level of education, smoking, alcohol 
intake, vaginal douching and referral reason, can be found in Table 3.1. There were 
more pregnant women recruited during their third trimester (63%; 265/420) compared 
to the 2nd trimester (37%; 155/420); Table 3.1). Five women were positive for syphilis 
(1.2%; 5/420), there were 48 (11.4%) HIV-infected women. The median gestational 
age at recruitment was 30 weeks while the median maternal age was 29.5 years. 
Surprisingly, most of the women were married (98%, 412/421), however there could 
be a potential information bias as this was self-reported data and could have been 
influenced by common stigma in the African society associated with being pregnant 
out of wedlock. Half of the women reported practicing vaginal douching (50.5%; 
212/420) during pregnancy. Fifty-one (12.1%; 51/420) had used antibiotics in the past 
3 months and of these, 10 were cotrimoxazole prophylaxis. Almost half of the women 
were referred due to poor obstetric history (49%; 206/420) in their prior pregnancies, 
which also included previous stillbirth, preterm birth and preterm labour (13%; 56/420, 
13%; 56/420, 16.8%; 71/420, respectively), among others. Other reasons for referral 
included conditions during this pregnancy such as anaemia (n=11), pregnancy induced 
hypertension (n=16), antepartum haemorrhage (n=5), multiple pregnancy (n=7), prior 
pregnancy complications (n=5), cervical insufficiency (n=5) and elderly primip (n=1). 
Bacterial vaginosis (BV) by microscopy was present in 99 (23.5%) women, 
intermediate scores 63 (15%), BV negative  258 (61.4%) and only 14 (3%) had 
Trichomonas vaginalis (Table 3.1). Women in this cohort were asymptomatic for BV. 
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Table 3. 1 Clinical characteristics of the cohort 
 Sample size 
N=420 
%  
Trimester:                 2nd (13-27 weeks)                                      155 36.9 
                                  3rd  (28-40 weeks) 265 63.1 
HIV Positive                    48 11.4 
HAART Regimen (n=48) n (%):   
             TDF, FTC, EFV 42 (89.1) 
Combivir ( AZT+3TC) 4  (8.3) 
Nugent score:           BV (7-10) 99 23.5 
                                 Intermediate (4-6) 63 15.0 
                                 Normal (0-3) 258 61.4 
T. vaginalis 14 3.0 
Antibiotic use past 3 months* 51 12.1 
Syphilis Positive                  5 1.2 
Smoking partner 36 8.6 
Level of education: Tertiary         17 4.0 
                                Secondary 384 91.4 
                                Primary 7 1.7 
Referrals with condition 206 49.0 
Non-referrals 214 51.0 
History Stillbirth 56 13.0 
History Preterm 56 13.0 
Previous preterm labour 71 16.9 
All previous poor outcomes 111 26.4 
Vaginal canal opening 37 8.8 
Vaginal douching 212 50.5 
Parity:                       Nulliparous 112 26.6 
                                 Parous 308 73.3 
Marital status:          Married  412 98.0 
                                 Single 7 1.7 
Divorced 1 0.2 
 Median Range /SD 
Median maternal age 29.5 (24.6-35.3) 
 
Median gestational age at recruitment, 
weeks 
30 (27-32) 
Blood CD4+ [cell/mm3(n=24)] [median  
(IQR)]  
495   (398.8, 643.5) 
Plasma viral load copies/ml (n=8) (mean 
(SD)  
128.85  (98.49) 
* 10 were using cotrimoxazole prophylaxis; SD: Standard deviation  
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3.2 Vaginal microbiota bacterial composition 
3.2.1 Sequencing 
Three hundred and ninety nine vaginal swabs from pregnant women were sequenced. 
Women with T. vaginalis (n=14) or Diabetes Mellitus (DM; n=7) were excluded to 
reduce bias, as T. vaginalis and DM are highly associated with poor reproductive 
outcomes. DNA was  quantified by using the Pico Green double-stranded DNA 
(dsDNA) assay (Invitrogen, Carlsbad, CA, USA) as elaborated in methodology. A total 
of 32 samples did not yield enough DNA on amplification as evidenced by lack of 
visible bands on gel electrophoresis after PCR 1, leading to sequencing of 367 samples.  
The total sequencing reads were 27,591,809 (range 61 reads to 352 921 as observed on 
the rarefaction curve to check quality) and furthermore, we considered samples  which 
passed quality control with 5,000 or greater reads for downstream analyses, resulting 
in 356 samples and 390 taxa retained. Three phyla with highest number of reads were 
Firmicutes, Actinobacteria and Bacteroidetes in that order (Figure 3.1). Greengenes 
was used to assign OTUs to sequences and 1185 OTUs were generated as described in 
detail in Chapter 2. A phylogenetic tree with 1165 tips and 1163 internal nodes was 
constructed. After standardizing, we filtered samples selecting OTUs where the row 
sum for that OTU had at least 20% of samples with a count of 10 each or where that 
OTU > 0.001% of the total median count.  
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Figure 3.1 Taxonomy phylum level showing the proportion of reads per phylum. There were 
20 phyla identified. The size of the circle is proportionate to the number of reads obtained from 
that particular phylum. 
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3.2 1.1 Annotating OTUs 
Renaming of OTUs that were not annotated to species level was done through blasting 
the OTU in the NCBI database where possible (Appendix B). The OTUs that were 
100% identified were renamed as per NCBI and some key taxa were annotated 
according to Lennard et al. (2018) database (Table 3.2) (Supplemental material found 
at https://doi.org/10.1128/IAI.00410-17).  They created a curated taxonomic database 
by using the Usearch_global command implemented in VSEARCH to search for 
representative sequences of de novo-picked OTUs against the updated custom vaginal 
16S reference database, accepting all hits with ≥97% identity. Annotations which 
conflicted with the corresponding Greengenes annotations were BLAST searched 
against the NCBI nucleotide database (excluding uncultured organisms) for all OTUs 
with hits against the custom vaginal 16S reference database and the results were then 
manually curated [134]. 
 
 
Table 3.2 Taxa annotation 
OTU Green genes NCBI Lennard et al., 2018 
OTU_11 Gardnerella Gardnerella vaginalis Gardnerella vaginalis 
OTU_ 11 Lactobacillus Lactobacillus crispatus & 
Lactobacillus acidophilus 
Lactobacillus 
crispatus_acidophilus 
OTU_745  Lactobacillus Lactobacillus jensenii, Lactobacillus jensenii, 
OTU_8 Prevotella Prevotella timonensis Prevotella timonensis 
OTU_13 Shuttleworthia No good hits BVAB1 
OTU_40 Neisseria cinerea N. gonorrhoeae N. gonorrhoeae 
OTU_110 Atopobium Atopobium minitum Atopobium minitum 
OTU_85 Atopobium Atopobium rimae Atopobium rimae 
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3.2.2 Relative abundance  
The median relative abundance at phylum level revealed that Firmicutes and 
Actinobacteria were the most abundant phyla. (Figure 3.2). At genus level 
Lactobacillus and Gardnerella had a high mean relative abundance; their microbial 
content was higher than 1% median sample read depth showing their level of 
dominance in the vaginal microbiota of this cohort (Figure 3.3). L. iners was present 
in majority of the pregnant women (>90%) at varying degrees of abundance. This was 
also true for Gardnerella vaginalis and L. crispatus, which were found in > 70 % of the 
women. 
                       
 
Figure 3. 2 Vaginal microbial community abundance in 356 pregnant women at phylum level. 
The relative abundance of phyla Firmicutes and Actinobacteria, which had > 0.01% median 
sample reads depth,  is shown. Phyla with <0.01 were all grouped as Remainder . 
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Figure 3. 3 Vaginal microbial community abundance in 356 pregnant women at genus level. 
The relative abundance of genera Gardnerella (red) and Lactobacillus (yellow), which had 
>0.01% median sample reads depth, is shown. Genera with <0.01 were grouped as Remainder 
and coloured in blue. 
 
3.2.3 Vaginal community state types in pregnancy 
The vaginal profiles of the pregnant women in this cohort clustered into three main 
CSTs using Fuzzy clustering of Bray Curtis distances. This was achieved by 
silhouetting the optimal number of clusters for the cohort which yielded three CSTs 
(Figure 3.4). Using the 16sRNA gene sequence count data, and the membership 
exponent of 1.25, with Bray Curtis as the dissimilarity measure used to form clusters, 
only members with a ≥60% probability of belonging to any of the three clusters were 
included in downstream analyses. The clusters were then named according to the 
dominant taxa in each optimal fuzzy cluster 1-3 as (CST1 - Lactobacillus iners, CST2 
– Lactobacillus crispatus, CST3 - Gardnerella vaginalis) respectively (Figure 3.5A). 
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Figure 3. 4 Average silhouette width and optimal clusters. The optimal number of clusters (k) 
according fuzzy clustering of Bray Curtis distance is 3 as shown in red 
 
Unsupervised hierarchical clustering of merged taxa with greater than 1% abundance 
in at least one sample was performed using Bray Curtis distances. A heatmap was 
constructed using the top 30 most abundant taxa merged at the lowest taxonomic 
annotation (Figure 3.5A). Ordination using the PCoA method with Bray Curtis 
distance was performed which also revealed three clusters visually (Figure 3.5B & 
C).  CST3 (G. vaginalis-dominant) was a highly diverse community composed of a 
diverse array of strict anaerobic or facultative bacteria. These bacteria represented 
nearly >50% of the most abundant taxa which included Prevotella, Dialister, A. 
vaginae, Megasphaera, Sneathia, Aerococcus, Gardnerella, Clostridium, Parvimonas, 
Coriobacteriaceae, Gemella, BVAB-1, Anaerococcus, Peptoniphilus and Finegoldia. 
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Figure 3. 5A Heatmap of unsupervised clustering using merged taxa according to Bray Curtis 
distance >0.01, showing the 30 most abundant taxa in all 356 pregnant women. Each column 
represents a woman and rows represent taxa.  Red colour represents most abundant while blue 
presents least abundant or absence of log2 transformed OTU counts. B & C Principal 
coordinates (PCoA) plot, (Bray-Curtis Distances) showing three clusters coloured by fuzzy 
cluster. B. Fuzzy cluster 1 (CST1) - dominated by Lactobacillus iners shown in red, Fuzzy 
cluster 2 (CST2) - dominated by Lactobacillus crispatus shown in blue, Fuzzy cluster 3 (CST3) 
- dominated by Gardnerella vaginalis shown in green. C. Ellipses of a t-distribution 
(continuous) and a normal-distribution (dashed). 
 
When comparing within sample microbial diversity (α-diversity) between the three 
CST groups, CST3 had significantly higher diversity by Shannon and Simpson 
measures, with Kruskal Wallis p < 2.2e-16 for both (Figure 3.6A). Furthermore, 
comparison of beta diversity using non-metric dimensional analysis of Bray Curtis 
distances based on Adonis with 999 permutations revealed significant differences 
between CST1, CST2 and CST3 (p < 0.001; Figure 3.6B). 
  
To visualize the most relatively abundant genera in the CST groups we used bar plots 
(including only taxa with genus or species level annotation). At genus level, higher 
relative abundances of Gardnerella, Atopobium and Dialister were observed in CST3 
as compared to CST1 and CST2 as expected (Figure 3.6C). Lactobacillus was 
abundant in all CSTs, but there was notably higher relative abundance of Gardnerella 
in CST1 as compared to CST2. At species level the bar plot demonstrated the 
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dominance of L. iners in the 3 CSTs in this cohort as previously described (Figure 
3.6D) and its ability to cohabit with BV associated microbiota (CST3) 
A                                                                        B 
          
C                                                                           D 
    
Figure 3. 6 Microbial diversity and clustering by CST status 
A. Alpha diversity (Shannon, Kruskal Wallis p= < 2.2e-16)  
B. Beta diversity (Bray Curtis Adonis p=0.001) comparing CST groups. 
C. Bar plot showing relative abundance of microbial communities at genus level.  
D. Bar plot showing relative abundance of microbial communities at species level using 
percentage of standardised sequence reads. 
 
CST3 was the most prevalent, present in 145/356 (41%) of women, whereas 102/356 
(29%) were CST2 and 109/356 (31%) were CST1 (Table 3.2 and Figure 3.5).  
Furthermore, women with CST3 had a mean vaginal pH of 4.40; higher than that of 
CST2 (4.01) and CST1 (4.13) (K. Wallis p or p<0.001 for both comparisons).However 
it is important to note that the magnitude of difference might not be clinically  
important. When comparing cohort characteristics according to CST in a univariate 
analysis, there were no significant differences in participant characteristics such as 
gestational age at swab collection, gravida, parity, maternal age, pregnancy induced 
hypertension, previous history of poor outcome, GBS carriage, partner smoker and 
antibiotic use between women in the three CSTs. However, statistically significant 
associations with CST were observed for HIV status (p =0.009), vaginal douching (p 
=0.016), vaginal pH (p <0.001) and BV (p <0.001) (Table 3.2). CST3 was associated 
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with higher Nugent score and higher pH compared to other CSTs as expected. 
Moreover, HIV-infected women were less likely to be in CST2. 
Table 3. 3 Cohort characteristics according to Community state types. 
 
CST1 
n=109 
CST2 
n=102 
CST3 
n=145 
p-value 
Gestational age at collection, mean (SD) 27.5 (6.09) 28.6 (5.10) 28.9 (7.09) 0.186 
Vaginal pH, mean (SD) 4.10 (0.57) 4.0 (0.59) 4.4 (0.77) <0.001 
Gravida, mean (SD) 2.9 (1.62) 2.9 (1.69) 2.8 (1.66) 0.775 
Para, mean (SD) 1.3 (1.20) 1.5 (1.30) 1.2 (1.14) 0.266 
Maternal age, mean (SD) 29.3 (6.45) 29.7 (6.13) 28.9 (6.60) 0.621 
Pregnancy induced hypertension n (%) 5 (4.6) 8 (7.8) 8 (5.5) 0.586 
Previous poor outcome n (%) 39 (35.8) 27 (26.5) 43 (29.7) 0.324 
GBS n (%) 45 (41.3) 42 (41.2) 52 (35.9) 0.594 
Partner smoker n (%) 8 (7.3) 8 (7.8) 10 (6.9) 0.961 
Antibiotic use n (%) 18 (16.5) 12 (11.8) 15 (10.3) 0.326 
HIV (%)                14 (12.8)       4 (3.9)      24 (16.6)    0.009 
Trimester  2nd n (%) 45 ( 40.9)       32 ( 31.4)       51 ( 35.4)    0.346   
Trimester  3rd n (%) 65 (59.6) 69 (67.6) 94 (64.8) 0.464 
Nugent score, mean (SD) 1.7 (2.74) 1.3 (2.65) 5.5 (3.15) <0.001 
Vaginal douching, n (%) 41 (37.6) 53 (52.0) 80 (55.2) 0.016 
Bacterial vaginosis (BV), n (%)    <0.001 
BV positive (Nugent 7-10) 10 (9.2) 9 (8.8) 69 (47.6)  
Intermediate (Nugent 4-6) 13 (11.9) 7 (6.9) 37 (25.5)  
BV negative (Nugent 0-3) 86 (78.9) 86 (84.3) 39 (26.9)  
CST=community state type, GBS= group B Streptococcus, LBW =low birth weight, 
SGA= small for gestational age 
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A multinomial regression model was performed to identify factors associated with CST 
including factors both in the literature and found associated in bivariate analysis such 
as HIV, gravida, previous poor outcomes and vaginal douching. CST2 (L. crispatus 
dominant) was used as the reference category and the results output was obtained using 
stargazer package in R (Hlavac, Marek; 2018). Vaginal douching was associated with 
CST1 (p <0.05). The significant association between HIV Infection and CST1 and 
CST3 persisted in the multinomial model (Table 3.4) 
Table 3. 4 Multinomial logistic regression of factors associated with bacterial 
vaginosis 
 
Dependent variable: 
         CST1                              CST3 
HIV 1.213**  
(0.602) 
1.529***  
(0.566) 
 
Maternal age -0.022 
 (0.026) 
-0.029 
(0.025) 
 
Gravida 0.049 
(0.099) 
0.021 
(0.095) 
 
Vaginal douching -0.482** 
(0.288) 
0.253 
(0.271) 
Note:     *p<0.1; **p<0.05; ***p<0.01 Odds ratio =number in brackets Beta-coefficient= number on top 
 
 
 
3.3 Vaginal microbiota and bacterial vaginosis associated bacteria in 
pregnancy 
There was a 75% agreement in BV classification by both Nugent and Hay Ison, 
therefore Nugent was chosen for downstream analysis as it is the most commonly used 
method in the literature. Interestingly, an equal proportion of women with normal 
Nugent scores fell within CST1 (86/211 (40.8%) and CST2 86/211 (40.8%). Though 
microbiological differences were evident, there were no differences in most 
demographic and clinical characteristics by BV status, including previous poor birth 
outcome (p=0.586), vaginal douching (p=0.591), pregnancy induced hypertension 
(PIH) (p=0.764), partner smoking status (p=0.228), GBS carriage (p=0.524), 
gestational age at collection (p=0.123) and parity (p=0.057) (Table 3.5). BV negative 
women tended to be older (30.3 years vs 27.9 for BV+ and 27.6 for intermediate BV), 
HIV-infected and have had more prior pregnancies. 
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Table 3. 5 Cohort characteristics according to BV status 
 BV 
n=88 
Intermediate 
n=57 
Normal 
n=211 
p-value 
Gestational age at collection, 
mean (SD)  
29.48 (7.87) 28.49 (5.62) 27.85 (5.64) 0.123 
Partner smoker n (%) 7 (8) 7 (12.3) 12 (5.7) 0.228 
HIV n (%) 18 (20.5) 7 (12.3) 17 (8.1) 0.010 
 Regimen n (%)                                                     0.636 
     AZT 3TC                            2 (11.8) 0 (  0.0) 2 (12.5)  
        TDF, FTC, EFV  15 (88.2) 7 (100.0) 13 (81.2)  
Blood CD4+ [cell/mm3(n=24)] 
[median  (IQR)]  
524 (544-546) 495 (497-493) 509 (508-509) 0.590 
CST n (%)    <0.001 
CST1 10 (11.4) 13 (22.8) 86 (40.8)  
CST2 9 (10.2) 7 (12.3) 86 (40.8)  
CST3 69 (78.4) 37 (64.9) 39 (18.5)  
Vaginal douching n (%) 47 (53.4) 26 (45.6) 101(47.9) 0.591 
Vaginal pH, mean (SD) 4.43 (0.83) 4.21 (0.57) 4.11 (0.62) 0.001 
Gravida, mean (SD) 2.51 (1.49) 2.81 (1.53) 3.04 (1.73) 0.038 
Para, mean (SD) 1.07 (1.08) 1.25 (1.21) 1.43 (1.24) 0.057 
Maternal age, mean (SD) 27.87 (6.3) 27.55 (6.16) 30.25 (6.35) 0.002 
Pregnancy induced hypertension 
n (%) 
4(4.5) 3(5.3) 14 (6.6) 0.764 
Previous poor outcome n (%) 24 (27.3) 16 (28.1) 69 (32.7) 0.586 
History of previous preterm birth 11 (12.5) 7 ( 12.3) 35 (16.6) 0.554 
GBS n (%) 33 (37.50 19 (33.3) 87 (41.2) 0.524 
Inflammation (%) 
   
<0.001 
High 43 (50.0) 14 (25.0) 24 (13.2) 
 
Low 6 (7.0) 6 (10.7) 67 (36.8) 
 
Medium 37 (43.0) 36 (64.3) 91 (50.0) 
 
CST=community state type, GBS= group B Streptococcus. Women were grouped into three categories based on 
the concentrations of inflammatory cytokines and chemokines (IL-1β, IL-6, TNFα, IL-8, Eotaxin, IP-10, MCP-1, 
MIP-1α, MIP-1β, RANTES) in their genital tracts by factor analysis as described in Masson et al. (2015). Women 
were grouped as having high inflammation if their inflammatory factor score was in the upper quartile (≥ 75th 
percentile), medium inflammation if their score was in the interquartile range (<75th - >25th percentile) and low 
inflammation if their score was in the lower quartile (≤25th percentile).  
 
 
 
 
Maternal age (p=0.002), gravida (p=0.038), CST (p<0.001), vaginal pH (p=0.001) and 
HIV status (p=0.010) differed significantly by BV status (Table 3.4). Women with 
normal Nugent scores were older, less likely to be HIV-infected, and had more prior 
pregnancies (Table 3.5).  A multivariate regression was performed to adjust for 
possible published confounding factors and factors that were significantly different in 
a univariate analysis (HIV, maternal age, vaginal douching and gravida). We excluded 
factors that were collinearly related to BV, such as CST and vaginal pH. After 
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multivariate logistic regression using BV as the outcome variable, HIV (p=0.003) was 
independently associated with BV (Table 3.6). This shows that BV positive women 
were 2.89 times more likely to be HIV-infected than BV negative women . 
 
Table 3. 6 Multivariate logistic regression of factors associated with bacterial 
vaginosis 
 Adjusted Odds Ratio 95 % CI P-value 
HIV 2.89 1.41-5.92 0.003 
Maternal age 1.036 0.983-1.095 0.189 
Vaginal douching 1.22 (0.74-2.00) 0.434 
Gravida 1.171 0.947-1.464 0.152 
CI= confidence interval, OR= odds ratio 
 
As expected, comparing within sample microbial diversity (α-diversity) between the 
three BV groups (BV+, BV- and intermediate BV+), there was greater alpha diversity 
using both Shannon (p < 2.2e-16) and Simpson (Kruskal Wallis p < 2.2e-16) diversity 
measures in the BV+ group (Figure 3.7A). Furthermore, comparison of beta diversity 
using non-metric dimensional analysis of Bray Curtis distances based on Adonis with 
999 permutations revealed significant differences between BV, intermediate and 
negative samples (p < 0.001; Figure 3.7B). Unsupervised clustering of samples using 
Bray Curtis PCoA revealed clustering of BV positive samples with CST3, and BV 
negative samples in CST 1 and 2. The majority of women who had BV+ and 
intermediate microbiota by Nugent score clustered within CST3 (106/145 (73%), while 
23 (15%) of the BV+ or intermediate clustered with CST1 and 16 (10%) with CST2 
(Figure 3.7; Table 3.3).  
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Figure 3. 7 Microbial diversity and clustering by BV status 
A. Alpha diversity (Shannon, Kruskal Wallis p= < 2.2e-16)  
B. Beta diversity (Bray Curtis Adonis p=0.001) comparing BV+, intermediate and BV- women. 
C. PCoA Clustering of BV classes according to CST types. BV and Intermediate cluster with 
CST 3 (Gardnerella dominated) p=<0.001.  
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To visualize the most relatively abundant genera in the BV groups, we used bar plots 
(Figure 3.8A & B). Notably higher relative abundances of Gardnerella, Atopobium 
and Prevotella in both the BV+ and intermediate BV+ groups were observed. Dialister 
and Aerococcus were drastically reduced in BV- women while Lactobacillus was the 
dominant genus in all three groups with a higher relative abundance in BV- women 
(Figure 3.8A). When looking at species relative abundance (including only those taxa 
with species-level annotation), As expected L. crispatus is more abundant in BV- 
(Normal) women as compared to intermediate and BV+ women while there is high 
abundance of G. vaginalis and A. vaginae in intermediate and BV+ women. (Figure 
3.7B). 
A 
 
B 
 
Figure 3. 9 A &B Bar plot showing relative abundance of microbial communities by BV status 
at A genus level and B species level using percentage of standardised sequence reads. 
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To explore which taxa were significantly differentially abundant between BV positive 
and negative status, metagenomeSeq analysis was performed on taxa merged at lowest 
taxonomic levels. Intermediate BV was not considered in order to get clear distinction 
between the BV+ and BV- groups, and because the model only allows for two group 
comparisons. Forty-five taxa met the threshold criteria of FDR adjusted p< 0.05, 
absolute fold change (FC) of 1.25 and percentage presence in at least one group of 20% 
(Figure 3.9). Collinsella aerofaciens, Oscilllospira, Dialister, Blautia, 
Corynebacterium stationis, Ruminicoccus bromii, L. crispatus and coleohominis, 
Nevskia ramosa, G. vaginalis, A. vaginae, to mention a few, were among taxa most 
differentially abundant between BV+ pregnant women and BV- pregnant women with 
adjusted p <0.0001. L. iners was not differentially abundant between the two groups. 
 
 
 
Figure 3.10 MetagenomeSeq supervised heatmap showing microbes differentially abundant 
between BV versus Normal vaginal microbiota.  Differential abundance testing was performed 
on taxa merged at the lowest taxonomic level. Each column represents a woman and rows 
represent taxa. Red colour represents the most abundant while blue presents least abundant or 
absence of log10 transformed OTU counts. 
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Community profiling and metagenomeSeq results were reinforced by Random forest 
(RF) analysis (Figure 3.10) in distinguishing BV+ and BV- women. As with the other 
analyses, this analysis identified a high level of distinction of taxa distinguishing BV+ 
from BV-. The model resulted in a 10-fold cross validation error of 17.5% with the 
training set having a sensitivity of 68%, specificity 90% while the test set had a 
sensitivity of 69% and a specificity of 90%. Both sets had a similar degree of accuracy 
of 83% showing Dialister as the most predictive of BV in this cohort with a mean 
decrease Gini index of 7.4. The ten genera found to be most predictive of BV by random 
forest in order were Dialister, Gardnerella, A. vaginae, Aerococcus, Megasphaera, 
Prevotella, Coriobacteriacae, Sneathia, Lactobacillus, and BVAB1. (Figure 3.10). In 
this model, L. iners was among the taxa that distinguished BV+ from BV-. 
 
 
Figure 3.11 Random forest using taxa merged at the lowest taxonomic level showing the 
taxa predictive of bacterial vaginosis. The X-axis shows the mean decrease in the Gini index 
(length of bar represents relative importance of each taxon in the model).  
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3.4 Discussion 
This chapter describes the vaginal microbiota of a cohort of Zimbabwean pregnant 
women, and its relationship with BV. Vaginal microbiota in both pregnant and non-
pregnant women has been studied in different ethnic groups but is underexplored in 
pregnant African women.  
 
In our study, examining the vaginal microbiota of pregnant women in this Zimbabwean 
cohort, three distinct clusters were evident; CST1 (L. iners-dominant), CST2 (L. 
crispatus-dominant), CST3 (G. vaginalis-dominant). Using exactly the same method 
as our study for both clustering (i.e. Fuzzy clustering) and sequencing of the V4 
hypervariable region of the 16S rRNA gene, three main vaginal microbiome clusters 
were obtained in a South African study of non-pregnant adolescents by our group [134]. 
The main clusters in Lennard et al., (2018) were L. iners- dominated, L. crispatus-
dominated and one diverse microbiota cluster.  In research conducted in non-African 
women, various clusters of vaginal microbial communities have been described, 
although methods of clustering and target variable regions differ. 
 Two main vaginal microbial clusters were described in Chinese women when 
sequencing the V3 hypervariable region [149], as opposed to five main clusters in North 
American women using data from sequencing of the V1-V2 hypervariable regions [51]. 
In sub Saharan African studies, different vaginal microbial clusters have been 
described, however studies also varied in the hypervariable region used for sequencing 
and the method used to define a cluster. Eight clusters were described in Tanzanian 
women using sequencing of the V6 hypervariable region using similarity of organism 
abundance and the similarity was visualized using neighbor joining trees [145]. Anahtar 
and colleagues found four “cervicotypes” in young South African women, however the 
clustering method was not clear as they report to have used the dominant bacterial 
species [369]  
 
At the phylum level, Firmicutes and Actinobacteria were the most abundant in the 
vaginal microbiota of these pregnant women, similar to that reported in previous studies 
in of non-pregnant [98, 118] and pregnant women [160]. Romero et al., (2014) reported 
that the vaginal microbiota during pregnancy was relatively healthy and stable, and that 
it would most often shift from one community dominated by one Lactobacillus spp to 
another dominated by another Lactobacillus spp [58]. This agrees with Freitas et al., 
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(2017) who reported that CSTs dominated by Gardnerella and Atopobium were not 
detected in pregnant as often as in non-pregnant women [6]. Our findings are divergent 
in that over half of the pregnant women in this cohort had a diverse vaginal microbial 
community (CST3; Gardnerella-dominant) with the remaining half almost equally 
shared between CST1 and CST2 (Lactobacillus dominant). It seems that a dysbiotic 
environment is characteristic of African pregnant women, however, genetic, cultural 
practices such as douching, and behavioural differences could be contributing factors. 
There is a need to consider a longitudinal study with multiple time points in order to 
further investigate the influence of these factors on the vaginal microbiota during 
pregnancy. 
 
Of the lactobacilli species, we found L. iners to be the most dominant in the vaginas of 
Zimbabwean pregnant women and was the taxon present in more than 50% of the 
samples regardless of Nugent score. L. iners is consistently found present in vaginal 
microbiota of African communities and women of African descent, and seems to 
comfortably coexist where BV-associated organisms dominate, unlike other 
Lactobacillus spp [24, 57, 133, 257]. Lactobacillus spp. other than L. iners produce the 
D-lactic acid isoform which may inhibit anaerobic bacteria preventing development of 
dysbiosis, while L. iners produce L-lactic acid isoform which inhibits only a few 
organisms such as HIV [67-70]. Based on this notion, since our cohort had a high 
abundance of L. iners, the production on L-lactate isoform would not inhibit the 
proliferation of anaerobic organisms thus leading to high abundance of dysbiosis 
causing vaginal imbalance.  Other studies have found L. iners to be ubiquitous in non-
African women also, present both in normal healthy microbiota and in dysbiotic 
environments, confirming further need of study to ascertain the role played by this 
bacterium in vaginal health  [51, 85, 130, 257]. 
 
Romero et al., (2014) found L. vaginalis, L. crispatus, L. gasseri and L. jensenii 
abundant in pregnant North American women, regardless of ethnicity, while they found 
very low relative abundance of L. iners. This further demonstrates the geographical 
differences between the vaginal composition of African women compared to other 
groups. More so, in our study of normal asymptomatic pregnant women we observed 
that vaginal microbiota of more than 50% of the women were G. vaginalis dominated 
regardless of BV status. Consistent with our study, Machado et al., (2017) found 67% 
of Portuguese pregnant women colonised with G. vaginalis despite the low prevalence 
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of clinically diagnosed BV [376]. Although the role of L. iners has not been established 
to our knowledge, a high level of coexistence of L. iners and G. vaginalis was observed 
in our cohort. In a review by Petrova et al., (2017) reports a symbiotic relationship 
which might exist between L. iners and G. vaginalis and has also observed that L iners 
gene encodes for a pore forming toxin (inerolysisn) related to vaginolysisn by G. 
vaginalis [67]. There is need for further studies to establish the relationship between 
these two taxa in the vagina and the role that L. iners might play in the vaginal 
environment.  
 
The association of HIV with dysbiotic vaginal microbiota (CST3) was evident in this 
cohort. This is in agreement with previous studies done in Africa, albeit in non-pregnant 
African women [143, 167]. On the other hand, a diverse cervicovaginal microbiota was 
reported to be one of the risk factors for with HIV acquisition [9, 135]. Therefore, it 
remains unclear whether HIV changes the microbiota, or dysbiosis is enriched in HIV-
infected women since it was what put them at risk for acquisition in the first place. 
However, in our study we are not able to explain which one posed risk to the other 
because we did not follow up HIV acquisition, since the women were already HIV 
positive at collection. Even though our study was a cross sectional study which cannot 
assess temporal relationships between HIV and BV, our observations reiterate 
previously published findings of an increased BV prevalence in women with HIV [154, 
165, 170] 
 
A diverse milieu of bacterial species is characteristic of BV, usually associated with 
poor health outcomes, although the mechanisms of BV are still poorly understood [85, 
158]. The presence of G. vaginalis was believed to be characteristic of BV+ status 
before the advent of molecular methods to more deeply characterise the vaginal 
microbiota [122, 149, 241]. Numerous studies since agree that there is no one organism 
that defines BV, as previously was thought [117]. Different taxa in different sub-
populations singly or in combination have been reported to be biomarkers of BV, such 
as G. vaginalis and A vaginae [120] in France pregnant women, Megasphaera type I, 
BVAB2, A. vaginae and G. vaginalis  [248] in university students and G. vaginalis, A. 
vaginae, Eggerthella, Prevotella, BVAB2, Megasphaera [122] and BVAB1 and 
BVBA2 [267, 377] in non-pregnant reproductive aged women. In our study of pregnant 
women, Dialister was the main predictive genus of BV as confirmed by RF and it was 
also among the most significantly differentially abundant by metagenomeSeq, followed 
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by Gardnerella, A. vaginae, Megasphaera, Prevotella and Aerococcus. Testing for 
Dialister could be explored in further studies as a potential test for BV in pregnancy in 
Zimbabwean women especially in areas where microscopy is not available. 
 
In summary, here we find a high prevalence of vaginal dysbiosis in pregnant 
Zimbabwean women, which highlights the importance of BV screening during 
antenatal visits.  
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Chapter 4: Vaginal microbiota and birth outcomes  
 
Reproductive health outcomes are likely to be influenced by the composition and 
interactions of the maternal vaginal microbiome throughout pregnancy [150]. BV has 
been associated with several pregnancy complications such as preterm labour, PROM, 
LBW, preterm delivery [18, 20] and possibly spontaneous abortion [19, 148]. 
Additionally, BV may increase susceptibility to sexually transmitted infections such as 
Neisseria gonorrhoeae, Chlamydia trachomatis [64], Trichomonas vaginalis [148], 
HSV-2 [151] and HIV [152-154] which  are also associated with poor birth outcomes. 
 
This chapter describes the vaginal microbiota of Zimbabwean pregnant women in 
relationship to birth outcomes. The vaginal microbiota is a key component of the 
defense system which confer protection against microbial and viral pathogens [216]. 
Nevertheless, vaginal microbiota undergoes significant changes during pregnancy due 
to metabolic and physiologic alterations that occur in a woman from conception to 
delivery [378, 379].  
 Numerous studies have been conducted on the composition of vaginal microbiome and 
its role in health outcomes [6-8, 380,Dunlop, 2015 #11]. Nonetheless, contrasting 
evidence has been reported regarding the vaginal microbiota and pregnancy outcomes, 
where some studies have found that vaginal microbiome is different [7, 381] or similar 
[58] between women who experience adverse versus normal birth outcomes. Several 
reports have demonstrated associations between vaginal microbiome and preterm birth, 
small for gestational age (SGA) and low birth weight (LBW) infants [6, 380]. Specific 
organisms, such as Mycoplasma hominis, G. vaginalis and/or A. 
vaginae,BVAB1, Megasphaera phylotype 1, and Leptotrichia/Sneathia spp. in the 
vaginas of  pregnant women have been reported  to be associated with adverse birth 
outcomes[157, 160] However, Foxman et al., (2014) reported that Mageebacillus 
indolicus (BVAB3) was associated with a reduction in preterm delivery risk among 
BV+ women and thus concluded that some BV-associated organisms are not associated 
with poor birth outcomes [158].  Although there are some contradicting findings, some 
of the variability can be attributed to racial, ethnic and geographical differences leading 
to no conclusive evidence whether a relationship exists between the vaginal 
microbiome and pregnancy outcome.  To our knowledge, few studies have been 
conducted in pregnant women of sub-Saharan Africa, therefore, our study seeks to 
describe findings on vaginal microbiota in relation births outcomes in this population.  
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4.1 Vaginal microbiota and preterm birth 
Out of the 356 sequenced samples, 97 women (27%) were lost to follow up, There were 
12 (3.4%) still birth deliveries,  1 (0.2%) miscarriage, 49 (13.8%) preterm births and 
197 (55%) term deliveries.  Of these, 244 women had singleton deliveries, complete 
data on birth outcomes and microbiota, 202 (83%) had term deliveries while 42 (17%) 
delivered preterm (Table 4.1). There were no differences in participant characteristics 
such as parity, HIV status, GBS status, BV status, vaginal pH, gestational age at 
collection or partner smoking status between preterm and term deliveries (Table 4.1). 
History of preterm delivery was not significantly predictive of PTB in the current 
pregnancy (p=0.533). Women who delivered preterm were more likely to be older 
(p=0.007), have LBW infants (p<0.001) and be multigravida (p=0.006) than women 
who experienced term deliveries.  
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Table 4.1 Characteristics stratified by preterm delivery 
 Term 
n=202 (%) 
Preterm 
n=42 (%) 
p-value 
 
Gestational age at collection in weeks, mean 
(SD) 
28.8 (6.7) 28.7 (4.72) 0.941 
pH, mean (SD) 4.2 (0.72) 4.28 (0.63) 0.541 
Gravida, mean (SD) 2.9 (1.65) 3.6 (1.85) 0.006 
Maternal age in years, mean (SD) 29.3 (6.37) 32.3 (6.64) 0.007 
Parity n (%) 59 (29.2) 7 (16.7) 0.141 
Partner smoker n (%) 13 (6.4) 1 (2.4) 0.507 
HIV-infected n (%) 20 (9.9) 9 (21.4) 0.066 
 Regimen n (%)                                                    NaN 
         AZT 3TC                          0 (0.0) 3 (16.7)  
        TDF, FTC, EFV  9 (100.0) 15 (83.3)  
Blood CD4+ [cell/mm3(n=24)] [median  
(IQR)]  
488.25 (481-
495) 
450.43 
(445.25-
454.75) 
0.590 
SGA n (%) 21 (11) 9 (21.4) 0.116 
LBW n (%) 10 (5.2) 25 (59.5) <0.001 
Vaginal douching n (%) 98 (48.5) 20 (47.6) 1 
CST n (%)   0.668 
                      1 58 (28.7) 10 (23.8)  
                      2 59 (29.2) 15 (35.7)  
                      3 85 (42.1) 17 (40.5)  
Pregnancy induced hypertension n (%) 10 (5) 5 (11.9) 0.176 
Previous poor outcome n (%) 58 (28.7) 18 (42.9) 0.106 
History of previous preterm delivery 28 ( 13.9) 8 (19.0) 0.533 
GBS n (%) 74 (36.6) 16 (38.1) 0.998 
Nugent score, mean (SD) 2.4 (3.09) 3.3 (3.51) 0.145 
BV n (%)   0.442 
                      BV 52 (25.7) 7 (16.7)  
                      Intermediate 33 (16.3) 7 (16.7)  
                      Normal 117 (57.9) 28 (66.7)  
LBW= low birth weight, GBS= group B streptococcus, BV=bacterial vaginosis, CST= community state type, 
SGA= small for gestational age  
 
A multivariate logistic regression was performed including characteristics significantly 
associated with preterm delivery in the univariate analysis.  Additionally, published 
factors such as gravida, maternal age, antibiotic use [382], gestational age at collection, 
HIV, and vaginal microbiota [8] were also included. BV and CST were adjusted for 
separately due to their collinear relationship, however, no significant associations were 
observed between preterm delivery and either BV or CST. Table 4.2 shows the model 
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with BV diagnosed by Nugent score. Pregnancy induced hypertension (p=0.04) [Odds 
ratio 3.66 (1.10- 12.33)] and HIV (p=0.03) [Odds ratio 3.18 (1.11- 8.74)] remained 
significantly associated with preterm birth in the multivariate model (Table 4.2).  
 
Table 4.2 Multivariate logistic regression of factors associated with preterm 
delivery 
 
Adj. OR 95% CI p-value 
Gravida 1.08 0.79-1.47 0.62 
Maternal age 1.04 0.97-1.11 0.23 
Antibiotic use 0.50 0.15-1.40 0.22 
Previous poor outcome 1.93 0.81-4.53 0.13 
BV by Nugent score 1.08 0.97-1.21 0.20 
Pregnancy induced hypertension 3.71 1.03-12.39 0.04 
HIV 3.05 1.09-8.20 0.03 
Parity 0.66 0.18-2.28 0.52 
    
CI= confidence interval, OR=odds ratio 
 
Microbial diversity comparisons showed no significant differences in alpha or beta 
diversity between women who experienced preterm deliveries as compared to term 
deliveries (Shannon; Kruskal Wallis p=0.37, Bray Curtis, Adonis=0.544) respectively 
(Figure 4.1A & B). Neither were there differences in CST distribution between women 
who delivered preterm versus term.  
 
In this study, exact gestational ages at collection of samples may have been inaccurate, 
because most women were not able to access fetal ultrasound scans. Therefore, 
gestational age estimation was based on last menstrual period dating and/or fundal 
height. This could have introduced inaccurate determination of preterm deliveries in 
the 35- 37 weeks of gestation zone. Therefore, due to this limitation we also performed 
an analysis using three categories; early preterm birth (EPTB; <35weeks of gestational 
age, n=16), late preterm birth (LPTB; 35-36.6 weeks, n=26) and term birth (≥ 37wks, 
n =189). There were no differences in gestational age at collection (p = 0.191), HIV 
status (p = 0.081), partner smoker status (p = 0.417), nor pregnancy induced 
hypertension (p=0.148) between these three groups. BV was not associated with 
increased risk of EPTB (OR 1.18; 95%CI 0.55- 2.46) nor late preterm birth (LPTB) 
(OR 0.60; 95%CI 0.30- 1.33) in this cohort. When comparing the means of the vaginal 
pH of the three groups: LPTB (4.42), EPTB (4.06), and term birth (4.19), no significant 
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difference in mean vaginal pH was evident (P=0.20, Kruskal Wallis). These findings 
were coherent with the findings of binarised analysis (term versus preterm). 
 
Consistent with the binarised comparisons, within sample diversity (alpha diversity) 
and beta-diversity of the vaginal microbiota between women who had EPTB, LPTB 
and term showed no significant differences (Shannon diversity (Kruskal Wallis p= 
0.47), Bray Curtis distances (Adonis P=0.939) (Figure 4.1C & D). Similarly, there 
were no differences in CST distribution between the groups.  
A                                                                                      B 
 .               
C                                                                                   D 
       
Figure 4.1 Diversity plots by preterm 
A. Shannon Alpha diversity between the preterm and term deliveries (p = 0.37),  
B. Shannon Alpha diversity between EPTB, LPTB and term deliveries (p = 0.47) 
C. Bray Curtis beta diversity between preterm and term deliveries (Adonis=0.544)  
D. Bray Curtis beta diversity between EPTB, LPTB and term deliveries (Adonis=0.94)  
             (Preterm <37 weeks, EPTB <35weeks, LPTB; 35wks - 36.6 weeks, term birth ≥ 37wks) 
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On observation of bar plots at genus level it was apparent that relative abundance of 
Lactobacillus was dominant and an almost equal proportion of Aerococcus Atopobium, 
Megasphaera, Prevotella, BVAB-1, Sneathia and Gardnerella were present in preterm 
and term births (Figure 4.2A & B). Relative abundance of Gardnerella and A. vaginae 
were high in women who experienced term deliveries while L. iners was more abundant 
(and conversely L. crispatus less abundant) in women who experienced preterm 
deliveries in the binary analysis, and EPTB in the three-group analysis (Figure 4.2C & 
D). These taxa had higher mean standardised read counts in healthy normal pregnancies 
as compared preterm birth pregnancies although these differences were not statistically 
significant (Wilcoxon rank sum test with continuity correction p >0.5) and welch t-
sample (p > 0.45). 
A                                                                      B 
      
C                                                                                D 
         
 
Figure 4.2 Bar plots by preterm categories. 
A & B Relative abundance using percentage sequences at genus level  
C & D Relative abundance using percentage sequences at species level 
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We then did a differential abundance testing using metagenomeSeq on the binarized 
groups (preterm versus term) and found that five taxa were significantly different in 
relative abundance between preterm and term birth. These taxa met the threshold 
criteria of FDR adjusted p= 0.05, absolute FC 1.25 and percentage presence in at least 
one group of 20%. Four taxa were significantly more abundant in preterm birth as 
compared to term were [Mogibacteriaceae] (adj. p=3.05e-07), Lactobacillus 
coleohominis (adj. p=1.17e-05), V. dispar (adj. p=5.55e-05), Fusobacterium (adj. 
p=0.0002) while P. pallens (adj. p=0.002) was more abundant in term than preterm 
(Figure 4.3). When attempting to use random forest model to predict taxa influential 
in preterm delivery, this model had poor specificity and positive predictive values were 
below 5%.  
 
                                                 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 4.3 Differentially abundant vaginal taxa merged at the lowest taxonomic annotation by 
preterm using metagenomeSeq.  Each column represents a woman and rows represent taxa. Red 
colour represents the most abundant while blue presents least abundant or absence of log2 
transformed OTU counts. 
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 4.2 Vaginal microbiota and low birth weight 
Low birth weight is defined as infants delivered with a birthweight below 2.5kg 
(<2500g). Infants who experience intrauterine growth retardation (IUGR) due to 
pathological processes do not reach their growth potential in-utero and are then 
delivered as LBW and/ or SGA even if they are born after 37 weeks (term) [383]. On 
the other hand, most preterm infants are usually delivered before they reach the weight 
of a term infant, and therefore are born LBW, although they may be appropriate for 
gestational age (AGA). Therefore, it is necessary to analyse LBW, SGA and preterm 
birth separately [383, 384], although LBW incorporates many of the adverse birth 
outcomes together. 
 
This analysis is based on 233 women with complete sequencing, birth weight, and birth 
outcomes data. Nine women who had still birth and 2 women who had term deliveries 
did not provide birth weight data were excluded. Of the 233 women, 35 (15%) delivered 
low birth weight (LBW) babies, while 198 (85%) delivered term infants 2.5kg and 
above (Normal birth weight; NBW). Comparable participant characteristics between 
the two groups were gestational age at collection, parity, partner smoking status, HIV 
status, vaginal douching, vaginal pH, gravida, maternal age and GBS carriage (p > 
0.07). However, there were significant differences in BV prevalence (p=0.026), PIH 
(p=0.001), previous history of poor outcome (p=0.034), SGA (p<0.001), and preterm 
delivery in the current pregnancy (p < 0.001) between women who delivered LBW 
versus NBW infants (Table 4.3).  
 
Women who delivered NBW infants were significantly more likely to have BV than 
those who delivered low birth weight infants (53/198 (26.8%) compared to 2/35 (5.7%). 
Women who delivered LBW infants were more likely to have delivered preterm 
(26/198 (74.3%) versus 17/35 (8.6%), have had previous poor pregnancy outcomes (17 
(48.6%) versus 57 (28.8%), have delivered SGA infants (15 (42.9%) versus 15 (7.6%) 
and had pregnancy induced hypertension during this pregnancy (7 (20%) versus 7 
(3.5%). Women who experienced a previous preterm birth were more likely to deliver 
a low birth weight infant; 10 (28.6%) compared to women who delivered a NBW; 25 
(12.6%). 
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Table 4.3 Cohort characteristics by low birth weight delivery  
 NBW 
n =198 
LBW 
n =35 
p- value 
pH, mean (SD) 4.2 (0.7) 4.3 (0.62) 0.415 
Gravida, mean (SD) 2.9 (1.66) 3.5 (1.99) 0.071 
Para, mean (SD) 1.3 (1.25) 1.5 (1.24) 0.365 
Maternal age in years, mean (SD) 29.2 (6.66) 31.1 (4.84) 0.12 
SGA n (%) 15 (7.6) 15 (42.9) <0.001 
Preterm n (%) 17 (8.6) 26 (74.3) <0.001 
BV n (%)   0.026 
BV 53 (26.8) 2 (5.7)  
Intermediate 31 (15.7) 7 (20)  
Normal 114 (57.6) 26 (74.3)  
Pregnancy induced hypertension n (%) 7 (3.5) 7 (20) 0.001 
Previous poor outcome n (%) 57 (28.8) 17 (48.6) 0.034 
History of previous preterm delivery 25 (12.6) 10 ( 28.6) 0.029 
Gestational age at collection in weeks, mean 
(SD) 
28.89 (6.66) 28.69 (4.61) 0.863 
Partner smoker status n (%) 11 (5.6) 1 (2.9) 0.802 
HIV n (%) 21 (10.6) 7 (20) 0.196 
 Regimen n (%)                                                    NaN 
     AZT 3TC                          0 (0.0) 3 (16.7)  
        TDF, FTC, EFV  9 (100.0) 15 (83.3)  
Blood CD4+ [cell/mm3(n=24)] [median  
(IQR)]  
488 (481-495) 450 (445-454.) 0.590 
CST n (%)   0.094 
1 52 (26.3) 14 (40)  
2 58 (29.3) 12 (34.3)  
3 88 (44.4) 9 (25.7)  
GBS n (%) 70 (35.4) 13 (37.1) 0.99 
Vaginal Douching n (%) 99 (50) 12 (34.3) 0.125 
LBW= low birth weight, GBS= group B streptococcus. BV=bacterial vaginosis, CST= community state type. 
SGA= small for gestational age  
 
A multivariate logistic regression analysis was performed including characteristics that 
were associated with LBW in the univariate analysis, as well as some factors associated 
with LBW in the literature such as gravida, parity [385, 386], maternal age [387], 
smoking partner [388], HIV infection and antibiotic use [382]. After multivariate 
logistic regression, BV (OR 0.82; 95% CI 0.70-0.94), prior history of poor birth 
outcome [Odds ratio (OR) 3.27; 95% CI 1.21, 9.00), HIV [OR 4.28; 95% CI 1.28, 
13.64)] and pregnancy induced hypertension (PIH) [OR 12.63; 95% CI 3.29, 51.77)] 
 
 
90 
were all independently associated with LBW (Table 4.4). Among these factors PIH had 
the greatest effect on delivery of a LBW infant (p<0.001). 
 
Table 4.4 Multivariate logistic regression of factors associated with low birth 
weight delivery 
 
Adj. OR 95% CI P value 
Gravida 1.08 0.78-1.55 0.45 
Maternal age 1.00 0.92-1.08 0.94 
Antibiotic use 0.82 0.24-2.47 0.66 
Nugent score 0.82 0.70-0.94 0.009 
Previous poor outcome 3.01 1.15-8.03 0.02 
Pregnancy induced hypertension 12.63 3.29-51.77 <0.001 
HIV 4.28 1.28-13.64 0.02 
Parity 0.76 0.18-3.00 0.96 
Smoking partner 0.33 0.01-2.54 0.42 
CI= confidence interval, OR=odds ratio, BV= Bacterial vaginosis 
 
Alpha diversity of the vaginal microbiota was significantly higher in women who 
delivered NBW versus LBW infants when calculated using both Shannon and Simpson 
diversity (p=0.02 and 0.001 respectively) (Figure 4.5 A). Between sample (Beta) 
diversity showed a trend towards a significant difference between samples with LBW 
and those without using Bray Curtis measures (p=0.055) (Figure 4.5 B). There was a 
trend towards more women with CST 1 (L. iners-dominated) vaginal microbiota 
delivering LBW and women with CST-3 (G. vaginalis-dominated) delivering NBW 
infants (p=0.094). 
 
Using bar plots to visualize mean relative abundance, a higher relative abundance of 
the Lactobacillus genus was observed in women who experienced LBW deliveries as 
compared to women who delivered NBW (Figure 4.5 C). At species level, L. iners and 
L. jensenii were increased in abundance in the LBW group with a corresponding 
decreased relative abundance of A. vaginae and G. vaginalis compared to NBW group. 
Interestingly, L. crispatus appeared at the same relative abundance regardless of infant 
weight. This might imply a specific influential relationship between L. iners and LBW 
delivery as compared to other Lactobacillus species as depicted at genus level. 
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A.                                                               B.                                   
  
 
C.  D. 
 
     
 
Figure 4.4 Diversity plot for LBW. A. Alpha diversity (Shannon; P=0.02) showing significant 
different within sample diversity and B. Bray Curtis (Adonis p=0.055) showing no difference 
in between sample diversity between women who delivered LBW and those who delivered 
normal birth weight babies. C. Bar plots showing relative abundant taxa at genus level by low 
birth weight. D. Bar plots showing relative abundant species by low birth weight. 
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MetagenomeSeq analysis was performed in order to identify taxa differentially 
abundant between women who delivered NBW infants compared to LBW deliveries. 
Thirteen OTUs that met threshold criteria of adj. p<0.05, absolute FC 1.25 and 
percentage presence in at least one group of 20 % were significantly different (Figure 
4.6). Higher relative abundance of L. coleohominis, Campylobacter, 
[Mogibacteriaceae], Suturella, A. minitum, V. dispar, N. gonorrhoeae, Jeotgalicoccus 
were observed in women who experienced LBW deliveries while Gardnerella, A. 
vaginae, Coriobacteriaceae and Streptococcaceae were higher in women with NBW 
deliveries using taxa merged at the lowest taxonomic level. In addition to 
metagenomeSeq random forest model was used to predict taxa most influential of LBW 
but the predictive model did not produce reliable results as it had a sensitivity of <1%.  
 
 
Figure 4.5 Heat map of differentially abundant taxa by LBW 
Log2 transformed and normalised counts using taxa merged at the lowest taxonomic level. Each 
column represents a woman and rows represent taxon. Red colour represents the most abundant 
while blue presents least abundant or absence of log2 transformed OTU counts. 
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Using LEfSe at the genus level, WAL_1855D (p=0.015) and Peptostreptococcus 
(p=0.044) were higher in the group of women who delivered LBW babies with the 
effect size LDA score of >3.7 but their significance did not persist after FDR 
adjustment. On the other hand, Gardnerella (p=6e-04), Mycoplasma (p=0.015), 
Unclassified Coriobacteriaceae (p=0.04) and Atopobium (p=0.0053) were higher in 
women who delivered normal birth weight babies (Figure 4.7A-C). Only Gardnerella 
(p<0.001) persisted after FDR adjustment confirming the results obtained by 
MetagenomeSeq. 
A 
  
B                                                                C 
 
 
Figure 4. 6 A LEfSe showing significantly different taxa by LBW groups before FDR 
correction. The colors represent which group that taxa were found to be more abundant 
compared to the other group. B. Genus with significant different relative abundances. 
Community profiles were transformed using total sum counts (TSS) converting read counts to 
relative abundance then any bias introduced by TSS were corrected with cumulative-sum 
scaling (CSS). Standard error is depicted by error bars. Significantly different taxa are shown 
in a bar chart (p<0.05, Mann-Whitney-U test). Standard error is depicted by error bars. Group 
comparisons are done by Mann-Whitney-U test and annotated as *: p<0.05, **: p<0.01, ***: 
p<0.001. 
  
Normal weight 
 
LBW 
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4.3 Vaginal microbiota and small for gestational age (SGA) infants 
Small for gestational age (SGA) is defined as infants below the 10th (or occasionally 
3rd) centile of birthweight for their gestational age  [389, 390]. These reference values 
are population-specific. For the purposes of this analysis, below 10th centile was 
calculated using an average weight of 3.200 kg at 40 weeks’ gestation, derived from 
the weights of Angolan infants whose mean birth weight at 40 weeks’ gestation was 
also 3.200kg [390]and since no published standard references for Zimbabwe were 
available.  
 
Of the 233 women with complete data, 30 (13%) women experienced SGA deliveries 
while 203 (87%) had average for gestational age (AGA) deliveries.  When stratifying 
characteristics by SGA, almost all variables including HIV status, BV, partner smoking 
status, maternal age, parity, and PIH had no significant association with SGA (p>0.1) 
Only GBS status and LBW had associations with SGA (both p<0.05) (Table 4.5). There 
were also observed trends towards more women with CST 1 (L. iners-dominated) 
vaginal microbiota delivering SGA and women with CST-3 (G. vaginalis-dominated) 
delivering AGA infants. In a multivariate logistic regression model, factors a priori 
considered as possible confounding factors (smoking partner, parity, HIV status, 
antibiotic use, gravida, and maternal age) were added to the model including GBS status 
and PIH which were significantly associated to SGA in univariate analysis. LBW could 
not be added due to its collinear effects with SGA as described above. Among these 
factors, GBS status and PIH were independently significantly associated with SGA 
(p<0.05) (Table 4.6). with a trend toward an association in maternal age where younger 
women were more likely to deliver SGA as compared to older women.  
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Table 4.5 Cohort characteristics by small for gestational age delivery  
 AGA 
 n=203 
SGA 
n=30 
 
p- value 
Gravida, mean (SD) 3.0 (1.7) 2.7 (1.86) 0.412 
Para, mean (SD) 1.4 (1.24) 1.2 (1.33) 0.533 
Maternal age, mean (SD) 29.8 (6.38) 27.7 (6.81) 0.115 
Gestational age at collection, mean (SD) 29.0 (6.53) 28.1 (5.34) 0.468 
Partner smoker (%) 11 (5.4) 1 (3.3) 0.968 
CST n (%)   0.101 
1 53 (26.1) 13 (43.3)  
2 61 (30) 9 (30)  
3 89 (43.8) 8 (26.7)  
HIV-infected n (%) 23 (11.3) 5 (16.7) 0.590 
 Regimen n (%)                                                   NaN 
     AZT 3TC                          3 (14.3) 0 (  0.0)  
        TDF, FTC, EFV  18 (85.7) 5 (100.0)  
Blood CD4+ [cell/mm3(n=24)] [median  
(IQR)]  
488 (481-495) 450 (445-454.) 0.520 
Nugent score, mean (SD) 3.2 (3.42) 2.7 (3.58) 0.488 
BV n (%)   0.484 
BV 50 (24.6) 5 (16.7)  
Intermediate 3 (16.7) 4 (13.3)  
Normal 119 (58.6) 21 (70)  
Vaginal douching n (%) 99 (48.8) 12 (40) 0.483 
pH, mean (SD) 4.2 (0.68) 4.3 (0.76) 0.269 
LBW n (%) 20 (9.9) 15 (50) <0.001 
Preterm n (%) 33 (16.3) 9 (30) 0.116 
GBS positive n (%) 67 (33) 16 (53.3) 0.049 
Pregnancy induced hypertension n (%) 10 (4.9) 4 (13.3) 0.162 
Previous poor outcome n (%) 64 (31.5) 10 (33.3) 1.000 
History of previous preterm delivery 29 (14.3) 6 ( 20.0) 0.586 
LBW= low birth weight, GBS= group B streptococcus, BV=bacterial vaginosis,  
CST= community state type, SGA= small for gestational age  
 
Table 4.6 Multivariate logistic regression of factors associated with Small for 
gestational age 
 
OR 95% CI P values 
Gravida 1.21 0.84-1.70 0.29 
Maternal age 0.92 0.84-1.01 0.08 
Pregnancy induced hypertension 4.39 1.00-17.5 0.04 
Partner smoker 0.4 0.02-2.59 0.42 
GBS positive 2.52 1.09-5.96 0.03 
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Parity 1.85 0.46-7.39 0.38 
HIV-infected 0.71 0.21-2.31 0.58 
Antibiotic use 2.31 0.66-7.08 0.16 
GBS= group B streptococcus. CI= confidence interval 
 
Higher alpha diversity was observed within vaginal microbiota of women who 
delivered AGA infants as compared to SGA deliveries by Shannon (p= 0.02) and 
Simpson (p= 0.01) indices after post hoc (Dunn’s) test adjustment (Figure 4.8A). Beta 
diversity measured using Bray Curtis distances revealed no significant differences 
between groups (p= 0.285) (Figure 4.8B).  Similar, to the LBW analysis, bar plots of 
the most abundant genera showed Lactobacillus at higher relative abundance in the 
SGA samples while Gardnerella was relatively more abundant in women who 
delivered AGA infants. (Figure 4.8C). At the species level, L. iners was more abundant 
in mothers of SGA infants, and A. vaginae and L. reuteri was less abundant as compared 
to AGA. However, statistics was not performed on these comparisons.  
 
A.                                                                     B.  
            
 
C. D. 
   
 
Figure 4.7 A. Alpha diversity in SGA versus AGA (p=0.02) B. Beta diversity (Adonis 
p=0.285). C. Bar plots showing relative abundant taxa at genus level by small for gestational 
age. D. Bar plots showing relative abundant species by small for gestational age. AGA=average 
gestational age SGA =small for gestational age.  
AGA       SGA  
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Figure 4.8 Heat map of results from MetagenomeSeq showing differentially abundant 
genera by SGA deliveries. Differential abundance testing was performed on taxa 
merged at the lowest taxonomic level. Each column represents a woman and rows 
represent taxa. Red colour represents the most abundant while blue presents least 
abundant or absence of log2 transformed OTU counts. 
  
 
 
 
 
 
 
Using LEfSe, there were three genera whose relative abundance was significantly 
higher in SGA deliveries namely Prevotella (p=0.042), BVAB-1 (p=0.005) and 
Atopobium (p=0.007) with LDA scores > 2.99, but none persisted after FDR 
adjustment. On the other hand no genera had statistically significantly higher relative 
abundance in AGA deliveries (Figure 4.10).  
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A. 
 
Figure 4.9 LefSe showing significantly different taxa by SGA groups. The colors represent 
which group that taxa were found to be more abundant compared to the other group. 
Community profiles were transformed using total sum scaling (TSS) converting read counts to 
relative abundance. Significantly different vaginal taxa are shown as bar chart (p<0.05, Mann-
Whitney-U test). Standard error is depicted by error bars. Group comparisons are done by 
Mann-Whitney-U test and annotated as *: p<0.05, **: p<0.01, ***: p<0.001. 
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4.4 Discussion 
Our study sought to identify an association between vaginal microbiota and birth 
outcomes such as preterm delivery, SGA and LBW, in Zimbabwean pregnant women. 
We did not find any strong associations between poor birth outcomes and vaginal 
microbiota. However, some associations were observed between birth outcomes and 
specific taxa, including L. iners. In line with our findings, other studies have reported 
the associations between L. iners and preterm deliveries, while in some, L. crispatus 
was denoted to be protective of poor outcomes [150, 391]. Interestingly, regardless of 
which outcome we assessed, high G. vaginalis relative abundance was seemingly 
associated with good birth outcomes.  
 
It has been demonstrated that BV and specific vaginal anaerobes are associated with 
poor birth outcomes in various ethnic groups, Nigeria [18], USA [16], India [47] and 
other areas [155]. This however was not the case with our findings. We found no 
association between BV and preterm, SGA nor LBW deliveries. Indeed, we observed 
trends that contrasts with published dogma, showing more BV negative women 
experiencing SGA deliveries and having a lower chance of delivering at term in this 
cohort. 
 
A decrease in richness and diversity has been observed in healthy pregnancy as 
compared to non-pregnant women [6], and a significant decrease in richness and 
diversity between the first and second trimesters has been associated with preterm 
delivery [48]. This agrees with our study findings, where we observed lower microbial 
diversity within vaginas of women who experienced SGA and LBW (significantly 
different; alpha diversity; Shannon) as compared to normal deliveries, although we did 
not follow women longitudinally therefore do not know whether this was a decrease in 
diversity as in Stout et al., (2017). When considering beta diversity, Subramaniam and 
colleagues did not find statistically significant differences between vaginal 
communities of pregnant women who delivered preterm infants and those who 
delivered term infants [46], concurring with our study findings. In fact, no significant 
differences in beta diversity measures were observed in all birth outcomes in question 
(SGA, LBW, PTB). Although the authors attributed it to small sample size and perhaps 
dynamic changes of the vaginal microbiota [46], our study had a much larger sample 
size yet had concurring findings. 
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In our observations, we did not find evidence of significant associations between CSTs 
and poor outcomes. There were more women in CST1 (L. iners-dominated) who had 
LBW and SGA deliveries while on the other hand more women with NBW and AGA 
deliveries were found in CST3 (G. vaginalis-dominated).  
 
In this Zimbabwean cohort, older age, being multigravida and/ or multiparous were 
associated with having PTB. Many prior studies have shown that poor outcomes were 
positively correlated with older age, including some in African women [387, 392-394]. 
However, in our study, young maternal age was associated with having an SGA and 
LBW delivery. This is also in agreement with some other prior studies  [395-398]. 
Likewise, having a history of a previous poor pregnancy outcome was independently 
associated with LBW, even after adjustment of possible confounders. These findings 
agree with studies conducted in northern Tanzania and Australia which reported the 
association of previous poor outcomes with subsequent PTB and LBW deliveries [399, 
400]. This points to the fact that many factors affecting risk for poor birth outcomes 
may be host-determined. In line with other studies, our study demonstrates that women 
who had PIH were highly likely to deliver LBW, preterm and SGA infants as compared 
to the normal deliveries. PIH has been unanimously associated with poor outcomes in 
all ethnic groups and geographical locations such as Zimbabwe [401], India [402] and 
Brazil [403], to name a few. In some settings, women with PIH may be more likely to 
deliver premature or LBW infants because of induction of labour or cesarean sections, 
however this only occurs in the case of emergency in Zimbabwe. 
 
We observed that women with vaginal GBS colonisation were more likely to have an 
SGA infant as compared to GBS negative women. Most previous data that suggest 
associations of GBS with premature birth, stillbirths but rarely SGA infants [298, 404]. 
Therefore, this association could be explored in future studies.  
 
HIV infection has been reported as a known risk factor for adverse birth outcomes  
[192]. HIV status was associated with PTB and LBW in our study in agreement with 
various studies where HIV status is highly associated with adverse pregnancy outcomes 
[181, 187]. Since all the women in our cohort were on antiretrovirals, it is difficult to 
ascertain whether it was HIV infection, or the drugs used to treat it that could be causing 
PTB and LBW. In prior studies it has been reported that some regimens such as Protease 
inhibitors (PIs)  [192] and AZT [193] were associated with PTB and LBW and that 
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generally HAART users were more at risk of poor pregnancy outcomes as compared to 
non-users [187, 188]. However, other studies found no significant associations between 
different regimens (NNRTI, PI, NRTI) and poor birth outcomes [194, 195]. In the days 
of Option B+, it will be difficult to tease apart whether HIV infection or ART contribute 
to poor outcomes, but studies on different regimens are warranted.   
  
In summary, from the findings of our study it is possible to conclude that factors 
influencing pregnancy outcomes are multifactorial, and vaginal microbiota may play a 
role. L. iners was associated with some poor birth outcomes while G. vaginalis was 
associated with good birth outcomes. Furthermore, there was no strong influence of BV 
status or CST observed on pregnancy outcomes, except for lack of BV which was 
associated with LBW. However, a longitudinal study would be ideal in future to further 
delineate these relationships considering limitations in our study. Microbiota samples 
were not collected at the same time point in all women and bias may have been 
introduced by lack of data on pregnancy outcomes on some women.  
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Chapter 5. Vaginal microbiota and cytokines during 
pregnancy 
 
Most adverse reproductive health outcomes are likely mediated by inflammatory 
processes that disrupt maternal fetal tolerance [405-409]. Successful pregnancies have 
been associated with the immunological switch from Th1 (T helper 1) to Th2 (T helper 
2) cytokines [334]. Th2 cytokines have been suggested to play an important role in 
successful pregnancies, while Th1 cytokines are deleterious to pregnancies  [334, 405, 
407]. The Mother’s immune system should tolerate the development of the “foreign 
foetus” [407]. However, a balance between immunosuppression in protection of the 
foetus and maintaining immunological functions to protect against infectious diseases 
is necessary [407]. Proinflammatory cytokines, such as IL-1β, IL-6, IL-8, have been 
found to be increased in various tissues in women who experience poor pregnancy 
outcomes such as pregnancy loss, spontaneous preterm labour and PTB [318, 337, 408, 
410]. 
 
As shown in previous studies, vaginal microbiota are known to influence the cytokine 
profile in the female reproductive tract [116], while it has further been suggested that 
proinflammatory cytokines may in turn serve as regulators of vaginal microbiota [411]. 
Certain proinflammatory (IL-1β, IL-6, IL-8) cytokines can promote the growth of 
Lactobacillus at lower concentrations, while at high concentrations these cytokines can 
stimulate the growth of opportunistic pathogens  [411]. The relationship between 
vaginal microbiota and cytokine levels in the vagina during pregnancy has not been 
established. 
 
Luminex was used to measure the concentrations of 27 cytokines in vaginal swabs. This 
analysis is based on 324 women selected by  HIV and BV status information. Not all 
samples were analysed due to limitation of resources. Of the 27 cytokines measured, 
IL-12p70, IL-15, IL-10, IL-5, G-CSF and IFN-γ did not pass quality control procedures, 
and these cytokines were thus excluded (Appendix A). Therefore, this analysis is based 
on 20 cytokines for which high quality data was generated (Figure 5.1). These 
cytokines were grouped according to primary biological functions, namely adaptive 
(IL-2, IL-13, IL-4, IL-17A), regulatory (IL-10, IL-1ra), growth factors (IL-7, IL-9, 
FGF-basic, PDGF-BB, VEGF, GM-CSF), chemokines (IL-8, Eotaxin, IP-10, MCP-1, 
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MIP-1α, MIP-1β, RANTES) and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) 
(Figure 5.1).  
 
Women were grouped into three categories based on the concentrations of 
inflammatory cytokines and chemokines (IL-1β, IL-6, TNFα, IL-8, Eotaxin, IP-10, 
MCP-1, MIP-1α, MIP-1β, RANTES) in their genital tracts by factor analysis as 
described in Masson et al., (2015). Briefly factor scores of grouped cytokines were 
generated in stata, with women grouped as having high inflammation if their 
inflammatory factor score was in the upper quartile (≥ 75th percentile), medium 
inflammation if their score was in the interquartile range (<75th - >25th percentile) and 
low inflammation if their score was in the lower quartile (≤25th percentile. Three 
community state types (CSTs) where identified; CST1: L. iners dominated, CST2: L. 
crispatus dominated, CST3: G. vaginalis dominated as described in chapter 3. The 
relationships between cytokines, cytokine functional groups and genital inflammation 
and vaginal microbiota and birth outcomes were then investigated. 
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Figure 5.1 The overall concentrations of cytokines in vaginal secretions of 324 women. Log10-
transformed, cytokine concentrations in pg/ml are depicted by box and whisker plots indicating 
the median concentrations (middle line), 25th (left) and 75th (right) percentiles and ranges 
(whiskers) of cytokine concentrations. Four functional groups of cytokines are represented on 
the left side. 
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5.1 Relationship between cytokines and the vaginal microbiota 
during pregnancy 
The relationships between genital inflammation, demographic and clinical factors and 
the microbiota were investigated using Mann Whitney U test and Chi-squared test. It 
was found that maternal age, Nugent score (BV), parity, and CST were each 
significantly associated with inflammation (p<0.05) (Table 5.1). 
  
Table 5.1 Characteristics of the cohort by level of vaginal inflammation 
 High 
inflammation 
(n=81) 
Medium 
inflammation 
(n=164) 
Low 
inflammation 
(n=79) 
p-value 
Partner smoker [n (%)] 5 (6.2) 14 (8.5) 3 (3.8) 0.376 
Antibiotics use past 3 months 
[n (%)] 
10 (12.3) 21 (12.8) 8 (10.1) 0.831 
SGA current pregnancy [n (%)] 4 (8.2) 20 (18.0) 4 (6.7) 0.058 
Preterm [n (%)] 7 (13.7) 22 (18.5) 13 (21.3) 0.58 
Still birth [n (%)] 3 (5.4) 7 (5.6) 2 (3.2) 0.762 
LBW [n (%)] 4 (8.2) 19 (17.1) 12 (20.0) 0.216 
Gestational age at collection in 
weeks, mean (SD) 
29.0 (5.74) 28.5 (6.98) 27.7 (5.62) 0.388 
Vaginal douching [n (%)] 41 (50.6) 80 (48.8) 40 (50.6) 0.946 
BV Nugent score [mean (SD)] 5.5 (3.41) 3.3 (3.33) 1.3 (2.54) <0.001 
GBS [n (%)]                       45 (40.9)      42 (41.2) 52 (36.1)    0.645 
BV (%)    <0.001 
BV 43 (53.1) 6 (7.6) 37 (22.6)  
Intermediate 14 (17.3) 6 (7.6) 36 (22.0)  
Normal 24 (29.6) 67 (84.8) 91 (55.5)  
pH, mean (SD) 4.2 (0.65) 4.2 (0.70) 4.2 (0.76) 0.711 
Gravida, mean (SD) 2.6 (1.39) 3.0 (1.84) 2.8 (1.54) 0.14 
Para, mean (SD) 1.1 (1.04) 1.5 (1.36) 1.4 (1.02) 0.024 
Maternal age in years, mean 
(SD) 
27.66(6.21) 29.3 (6.04) 30.4 (6.96) 0.025 
CST [n (%)]    0.019 
1 28 (34.6) 52 (31.7) 19 (24.1)  
2 16 (19.8) 39 (23.8) 33 (41.8)  
3 37 (45.7) 73 (44.5) 27 (34.2)  
Pregnancy induced 
hypertension [n (%)] 
3 (3.7) 13 (7.9) 4 (5.1) 0.388 
Previous poor outcome [n (%)] 22 (27.2) 52 (31.7) 28 (35.4) 0.527 
HIV [n (%)] 11 (13.6) 24 (14.6) 7 (8.9) 0.447 
LBW= low birth weight, GBS= group B streptococcus. BV=bacterial vaginosis, CST= community state type. 
SGA= small for gestational age, SD=standard deviation 
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We performed a multivariate model, considering the factors that may influence genital 
inflammation. The factors included HIV, vaginal douching, BV, maternal age and 
parity (BV was not included due to its collinearity with CST). CST2 was used as a 
reference here, CST3 and CST1 and maternal age were independently associated with 
inflammation (p=0.008, p=0.02 and p<0.002, respectively; Table 5.2). 
 
Table 5.2 Multivariate analysis of factors associated with inflammation 
 
OR 95% CI p- value 
Maternal age 1.11 1.04-1.18 0.002 
Vagina douching 1.41 0.62-3.29 0.42 
CST3 2.83 (1.30, 6.14) 0.008 
CST1 3.04  (1.32, 7.00) 0.02 
HIV 1.62  (0.59, 4.41) 0.35 
Parity 0.69 0.45-0.96 0.078 
BV= bacterial vaginosis, CI= confidence interval, OR= odds ratio 
 
We then went on to analyse vaginal microbiota of women in high versus low genital 
inflammation groups, using RF and metagenomeSeq in order to identify taxa associated 
with inflammation. Twenty-two taxa were significantly different between women with 
high versus low inflammation by metagenomeSeq (adj. p < 0.05, absolute FC > 1.25 
and percentage presence in at least one group of 20%) (Figure 5.3). Aerococcus, A. 
vaginae, G. vaginalis, Dialister, Megasphaera, Gemella, Mycoplasma, Prevotella 
timonensis and L. iners among others were associated with high inflammation. 
Conversely, some Lactobacillus species including L. crispatus and L. reuterii, and 
Staphylococcus and Roseburia were significantly associated with low inflammation. 
RF replicated some taxa produced by metagenomSeq, taxa such as L. crispatus, 
Megasphaera, Dialister, Prevotella, G. vaginalis, L. iners, L. reuteri, A vaginae, 
Aerococcus and BVAB1 were the most highly influential taxa for predicting 
inflammation with mean decrease in Gini score >3 by RF. (Figure 5.2B). The model 
displayed the top 20 taxa for predicting inflammation in the test set, with an OBB error 
rate of 25% with a positive predictive value of 71%; negative predictive value of 72% 
and a degree of accuracy of 71%.  
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Figure 5.2 Taxa most predictive of inflammation using taxa merged at the lowest taxonomic 
level. A Supervised hierarchical clustering (Bray Curtis distances) of differentially abundant 
taxa in women with and without genital inflammation determined using metagenomeSeq. The 
heatmap shows log2-transformed standardized counts. Each column represents a woman and 
rows represent taxa. B Most important taxa associated with inflammation identified using 
random forest. The X-axis shows the mean decrease in the Gini index (length of bars 
represent relative predictive ability of each taxon).  
 
Further analysis was done to find the direction of relationship between taxa identified 
as predictive of genital inflammation by random forest using Mann Whitney U test for 
independent samples and Welch Two Sample t-test of unequal variance to show the 
significant differences between the mean relative abundance of taxa in inflammation 
groups. G. vaginalis, Dialister, A. vaginae, Aerococcus, Prevotella (p<0.001), L. iners, 
Megasphaera, BVAB1(p<0.05) had significantly higher means in women with high 
inflammation while Staphylococcus (p<0.001) and L. crispatus (p <0.007 were 
significantly higher in women with low inflammation (Figure 5.3). It is interesting to 
note that L. iners was positively associated with inflammation which concurs with its 
Women samples 
 
B A 
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association with intermediate and BV+ status as described in the previous chapter.                
         
Figure 5.3 Summaries of median differences of taxa counts most predictive of inflammation 
(log2 counts). Relationships are depicted by box and whisker plots indicating the median 
(middle line), 25th (bottom line) and 75th percentiles (top line), and the range (whiskers) of the 
group cytokine concentrations (log10-transformed (pg/ml). Mann Whitney U for independent 
samples was used to show the significant differences between the mean relative abundance of 
taxa in inflammation groups. All p-values were adjusted for multiple comparisons using the 
false discovery rate (FDR) step-down approach (Columb and Sagadai, 2006). 
 
5.2 Cytokine concentrations by BV status 
One-way ANOVA was used to evaluate the relationships between log10-transformed 
vaginal cytokine concentrations and BV status. Pairwise comparisons by BV status 
showed significant differences between cytokine concentrations in women with BV 
(Nugent score: 7-10) or intermediate Nugent scores (Nugent score: 4-6) as compared 
to BV- women (Nugent score: 0-3), while few cytokines were significantly different 
between women with intermediate Nugent scores and BV+ women (Figure 5.4). Most 
of the cytokine concentrations followed the same pattern of being upregulated in the 
vaginal fluid of BV+ women followed by intermediate then BV- (Figure 5.4; Figure 
5.5). However, IP-10 was significantly downregulated in BV+ women as compared to 
women with intermediate and healthy microbiota, while concentrations were similar in 
intermediate and BV- women. The concentration of VEGF was lower in all women 
with intermediate microbiota as compared to BV+ and BV- groups. (Figure 5.5). 
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Figure 5.4 Heatmap summary of significantly different cytokines by BV status (BV, 
Intermediate and BV negative) using log10-transformed (pg/ml) vaginal cytokines 
concentrations. All significant p-values <0.05 are represented by red shades of colour, with 
deep red being the lowest p-value while all p-values >0.05 are represented but yellow/brown 
shades of colour with yellow being the highest p value. Significance testing was done using 
one-way analysis for variance (ANOVA) and Tukey Honest Significant Differences post hoc 
test for pairwise comparisons. All p-values were adjusted for multiple comparisons using the 
false discovery rate (FDR) step-down approach (Columb and Sagadai, 2006).  
 
Analysis of possible associations between individual cytokine concentrations by BV 
status were performed. Individual cytokine concentrations were significantly different 
between BV+, Intermediate and BV- (negative) women with p<0.001 except for VEGF 
and MCP-1 which were not significantly different p>0.05 in all the three groups 
(Figure 5.5) IP-10 was lower in the BV+ women as compared to intermediate and BV- 
women 
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Figure 5.5 Vaginal cytokines concentrations by BV status. Relationships are depicted by box 
and whisker plots indicating the medians (middle line), 25th (bottom line) of boxes and 75th 
percentiles (top line), and the ranges (whiskers) of the log10-transformed (pg/ml) cytokine 
concentrations by BV status. Non-parametric assessments of variation between groups were 
carried out through the Kruskal-Wallis Analysis of Variance (ANOVA) and Tukey Honest 
Significant Differences post hoc test being applied to test for the pairwise comparisons. All p-
values were adjusted for multiple comparisons using the false discovery rate (FDR) step-down 
approach (Columb and Sagadai, 2006). 
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Cytokines were grouped according to primary biological functions and factor scores 
(representative of each cytokine within each group) were generated for each functional 
group using factor analysis. The factor scores for all of the functional groups were 
highest in women with BV followed by those with intermediate microbiota and then 
BV- (normal) women. (Figure 5.6) 
 
 
Figure 5.6 Cytokine functional factor scores by BV status. Relationships are depicted by box 
and whisker plots indicating the medians (middle line), 25th (bottom line) and 75th percentiles 
(top line), and the ranges (whiskers) of the cytokine factors for each group by BV status. Non-
parametric assessments of variation between groups was carried out through the Kruskal-Wallis 
Analysis of Variance (ANOVA) and Tukey Honest Significant Differences post hoc test being 
applied to test for the pairwise comparisons. All p-values were adjusted for multiple 
comparisons using the false discovery rate (FDR) step-down approach (Columb and Sagadai, 
2006). 
 
5.3 Community state type and cytokine concentrations 
One way ANOVA was used to identify significant differences between log10-
transformed cytokine concentrations and CST, followed by a Tukey Honest Significant 
Differences post hoc test (Tukey HSD) for performing multiple pairwise-comparisons 
between the medians of groups. Multiple cytokines differed significantly between 
women with different CSTs (adjusted p<0.05): 15/20 for CST3 vs CST2, 9/20 for CST3 
vs CST1 and 4/20 for CST2 vs CST1 (Figure 5.7).  
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Figure 5.7 Heatmap summary of cytokine associations with microbial composition 
highlighting cytokines significantly different by community state type (CST1, CST2 and 
CST3). All significant p-values <0.05 are represented by red shades of colour, deep red being 
the lowest p-value and the most significant while all p-values ≥0.05 are represented but yellow 
/brown shades of colour with yellow being the highest p value.  Significance testing was done 
using one-way analysis of variance (ANOVA) and Tukey Honest Significant Differences post 
hoc test for pairwise comparisons. All p-values were adjusted for multiple comparisons using 
the false discovery rate (FDR) step-down approach (Columb and Sagadai, 2006).  
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GM-CSF, TNF-α, IL-1β, FGF-basic, IL-17A, IL-4, IL-2, IL-13, IL-7, IL-9, PDGF-BB, 
IL-8, MIP-1α, MIP-1β, Eotaxin, RANTES and IL-6, were all significantly higher in 
CST1 and /or CST3 as compared to CST2 while IP-10 was downregulated in CST3 as 
compared to CST1 and CST2 (Figure 5.8). 
 
 
 
Figure 5.8 Vaginal cytokine by community state type. Relationship are depicted by box and 
whisker plots indicating the medians (middle line), 25th (bottom line) of boxes and 75th 
percentiles (top line), and the ranges (whiskers) of the log10-transformed (pg/ml) cytokine 
concentrations by community state type. Non-parametric assessments of variation between 
groups were carried out through the Kruskal-Wallis Analysis of Variance (ANOVA) and Tukey 
Honest Significant Differences post hoc test being applied to test for the pairwise comparisons. 
All p-values were adjusted for multiple comparisons using the false discovery rate (FDR) step-
down approach (Columb and Sagadai, 2006). 
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Cytokines were grouped according to primary biological functions and factor scores 
were generated for each functional group using factor analysis. As expected the factor 
scores for proinflammatory, adaptive and growth factors were significantly higher in 
women with CST3 (G. vaginalis-dominated) as compared to CST1 (L. iners-
dominated) and CST2 (L. crispatus-dominated) (Figure 5.9).  
 
 
Figure 5.9 Cytokines functional factors score by community state type. Relationship are 
depicted by box and whisker plots indicating the medians (middle line), 25th (bottom line) and 
75th percentiles (top line), and the ranges (whiskers) of the cytokine factor scores for each 
group by community state type. Non-parametric assessments of variation between groups was 
carried out through the Kruskal-Wallis Analysis of Variance (ANOVA) and Tukey Honest 
Significant Differences post hoc test being applied to test for the pairwise comparisons. All p-
values were adjusted for multiple comparisons using the false discovery rate (FDR) step-down 
approach (Columb and Sagadai, 2006).  
 
The relative abundance of eight taxa were significantly associated with one or more 
cytokines after adjustment for multiple comparisons (R ≥ 0.3). Most of these eight taxa 
(≥ 7/8) correlated significantly with IL-2, IL-4 and IL-17A (adaptive), IL-1β and TNF-
α (pro-inflammatory), and FGF-basic and GM-CSF (growth factors). Gardnerella 
relative abundance was most strongly positively correlated with cytokine 
concentrations, while Lactobacillus was negatively correlated with 16/20 of the 
cytokines (Figure 5.11A). Interestingly, IP-10 was the only cytokine that was inversely 
associated with dysbiotic bacteria, including Megasphaera, Coriobacteriaceae, 
Dialister, Prevotella and Gardnerella (Figure 5.10A).  
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Figure 5.10 Spearman correlations between cytokines and bacterial relative abundance using 
taxa merged at the lowest taxonomic level. Only taxa significantly associated with cytokines 
shown after adjusting for multiple comparisons (adj. p<0.05) that had rho scores ≥ 0.3 are 
shown. Blue represents positive correlations while red represents negative correlations between 
bacterial relative abundance and vaginal concentrations of cytokines. A) Correlations between 
individual cytokines and 8 bacterial taxa. B) Correlations between cytokine functional groups 
and bacterial taxa. 
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5.4 Birth outcomes and immune factors 
Unsupervised hierarchical clustering was used to display the relationship between 
vaginal cytokine concentrations and birth outcomes (Figure 5.11). 
 
 
Figure 5.11 Unsupervised hierarchical clustering of all measured genital cytokines in pregnant 
women using log10 transformed cytokine concentrations. Each column represents a woman and 
rows represent individual cytokine. Red colour represents higher concentrations while blue 
presents lower concentrations. From top the figure shows clustering according to delivery 
(purple = preterm, cyan = term), birth weight (red = low birth weight (LBW), blue = normal 
birth weight (NBW), gestational age (green = small for gestational age (SGA), red = average 
for gestational age (AGA) and inflammation (purple = high, black = medium and cyan = low) 
 
5.4.1 Preterm delivery and immune factors 
Out of the 324 women who had cytokine analysis data, 244 women had pregnancy 
outcome information while of them 42 had preterm deliveries. In our univariate analysis 
using Mann Whitney U test (Wilcoxon rank sum test with continuity correction), 
growth factors and adaptive immune factors were significantly higher in women who 
subsequently delivered preterm, including PDGF-BB, IL-13 (both p<0.001) and 
Eotaxin, GM-CSF, FGF-basic, and IL-2 (all p<0.005) (Table 5.3).  
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Table 5.3 Cytokines significantly different between term and preterm delivery in 
univariate analysis 
 Mean cytokine concentrations 
[log10(pg/ml)] 
P values FDR adj. 
 Term Preterm   
PDGF-BB 1.261 1.041 1.56E-05 0.0003 
IL-13 -0.769 -1.699 3.73E-05 0.0003 
Eotaxin -0.013 -0.041 0.0008 0.006 
FGF-basic 1.223 1.125 0.002 0.012 
TNF-α 0.893 0.719 0.02 0.07 
IL-2 0.278 0.154 0.02 0.08 
GM-CSF 0.060 -0.022 0.04 0.11 
 
After performing a multivariate logistic regression, adjusting for possible risk factors 
for preterm delivery (including pregnancy-induced hypertension, trimester, maternal 
age, Nugent score (BV), HIV and previous poor outcomes) and log10 -transformed 
cytokine concentrations, lower levels of IL-13 (p=0.002), and PDGF-BB (p=0.041) 
remained significantly associated with preterm birth (Table 5.4; Figure 5.12A). 
 
Table 5.4 Multivariate analysis of factors associated with preterm delivery 
 
OR 95% CI Adj. p-value 
IL-13 3.22 1.57-7.01 0.002 
PDGF-BB 1.63 1.01-2.61 0.041 
FGF-basic 2.16 0.9-5.12 0.074 
Eotaxin 2.59 0.56-12.12 0.218 
TNF- α 1.52 0.67-3.57 0.323 
IL-2 1.31 0.55-3.07 0.531 
GMCSF 1.01 0.41-2.35 0.985 
Adjusted for HIV, maternal age, pregnancy induced hypertension, trimester, 
Nugent score (BV) and previous poor outcome 
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5.4.2 LBW and immune factors 
Concentrations of each of the 20 cytokines were compared in vaginal secretions of 
women who delivered normal birth weight (NBW)(n=198) infants versus women who 
delivered LBW infants (n=35). Univariate analysis was performed using Mann 
Whitney U test (Wilcoxon rank sum test with continuity correction), a number of 
immune factors were associated with LBW, including PDGF-BB, FGF-basic, IL-13, 
IL-2, GM-CSF, TNF-α (p<0.001), IL-9, IL17A, Eotaxin, IL-4 and IL-7 (p<0.05). 
Overall, 9 cytokines were downregulated, while only 2 were upregulated (IL-4 and 
GM-CSF) in women who subsequently delivered LBW infants as compared to NBW 
(Figure 5.12B). Growth factors and hematopoietic cytokine concentrations (PDGF-
BB, FGF-basic, GM-CSF and IL-9) were significantly lower (adj. p=0.0001, p=0.001, 
respectively; Table 5.5) in women who delivered LBW babies as compared to women 
who delivered NBW babies. 
 
Table 5.5 Cytokines significantly different by birth weight in univariate analysis 
 
Mean cytokine concentrations [log10(pg/ml)] Pvalues FDR adj. p-value 
 Normal birth weight Low birth weight   
PDGF-BB 1.228 0.913 4.52E-06 0.0001 
FGF-basic 1.226 1.061 5.50E-05 0.001 
IL-13 -0.824 -1.699 0.000202 0.001 
IL-2 0.335 0.061 0.0002631 0.001 
GM-CSF 0.064 -0.142 0.00047 0.002 
TNF-α 0.889 0.621 0.0005746 0.002 
IL-9 0.561 0.444 0.001692 0.005 
IL-17A 0.885 0.555 0.002859 0.007 
Eotaxin -0.032 -0.180 0.003726 0.008 
IL-4 -0.301 -0.398 0.01016 0.020 
IL-7 -0.237 -1.602 0.01358 0.025 
IL-1β 1.522 1.015 0.05515 0.092 
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Multivariate logistic regression analysis was performed to evaluate the relationship 
between each cytokine and birth weight adjusting for possible confounders, including 
pregnancy-induced hypertension, maternal age, Nugent score (BV), trimester, HIV and 
previous poor outcomes. PDGF-BB and IL-13, remained significantly associated with 
LBW (p<0.05) (Table 5.6: Figure 5.12B).  
 
Table 5.6 Multivariate logistic regression analysis of cytokines associated with 
low birth weight  
 
OR 95% CI Adj. p-value 
PDGF-BB 0.51 0.30-0.85 0.009 
IL-13 0.36 1.42-0.88 0.03 
FGF-basic 0.39 0.15-1.02 0.05 
IL- 7 0.6 0.33-1.06 0.08 
IL-2 0.51 0.19-1.39 0.19 
GMCSF 0.65 2.56- 1.72 0.37 
TNF-α 0.43 0.14-1.25 0.14 
IL-9 0.94 0.19-4.74 0.93 
Eotaxin 0.41 0.07-2.43 0.33 
IL-4 0.58 1.15-  3.31 0.52 
IL-17A 0.45 0.11-1.68 0.255 
Adjusted for HIV, maternal age, pregnancy induced hypertension, trimester, Nugent score (BV), 
previous poor outcome. (CI= confidence interval, OR=odds ratio). 
 
  
 
 
120 
A                                                            B                                                        C 
       
 
Figure 5.12 The relationship between log10 transformed vaginal cytokines and A. Preterm 
delivery, B. Low birth weight, C. Small for gestational age. Circles represent odds ratios 
generated using logistic regression and bars represent 95% confidence intervals. Bars and 
circles depicted in red represent significant associations (adj. p-values ≤ 0.05) while black 
represent lack of significance obtained using using logistic regression. The 20 cytokines and 
four functional groups of cytokines are represented on the left side. * (p<0.05) indicates 
associations that stayed significant after adjusting for possible confounders (including HIV, 
maternal age, pregnancy induced hypertension, trimester, Nugent score (BV) and previous poor 
outcome) using multivariate logistic regression. 
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5.4.3 Associations between cytokine concentrations and other factors 
 
SGA was significantly associated with low levels of both IL-13 and PDGF-BB (p<0.05) 
before adjustment of multiple comparisons (Figure 5.12 C). However, these 
associations were not upheld after FDR adjustment for multiple comparisons. There 
were no associations observed between vaginal cytokine concentrations and GBS 
carriage or and still birth. When comparing cytokine functional group factor scores 
according to trimester, growth factors, chemokines, adaptive immune mediators and 
pro-inflammatory factor scores were all higher in the third trimester as compared to the 
second trimester (Figure 5.13A). Several individual cytokines were significantly 
upregulated in the third trimester as compared to the second trimester. FGF-basic, GM-
CSF, MCP-1, MIP-1β, IL-13, IL-2 (p<0.05) and IL-6, RANTES and PDGF-BB 
(p<0.01). However, after FDR adjustment only PDGF-BB which remained 
significantly higher in third trimester as compared to second trimester p<0.001. There 
were more women in third trimester who had high (n=59; 28%) and medium (n=106; 
50%) inflammation as compared to women in second trimester (22 (19%), 60 (52%) 
respectively). Conversely, a higher percentage of women with low inflammation were 
observed in the second trimester (n=33; 25%) at collection as compared to third 
trimester (n=46; 22%) (Figure 5.13B). 
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     .  
Figure 5.13 A. Cytokine functional groups by trimester. Relationships are depicted by box and 
whisker plots indicating the medians (middle line), 25th (bottom line) and 75th percentiles (top 
line), and the ranges (whiskers) of the cytokine factor score (log10-transformed (pg/ml). B. Bar 
plots showing the percentages of women per trimester by inflammation categories. 
Confirmatory factor analysis was used to group these cytokines together and generate factor 
scores representing the overall level of inflammation in each woman, with women grouped as 
having high inflammation if their inflammatory factor score was in the upper quartile (≥ 75th 
percentile), medium inflammation if their score was in the interquartile range (<75th - >25th 
percentile) and low inflammation if their score was in the lower quartile (≤25th percentile. 
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 5.4 Discussion 
During pregnancy the stability and healthy development of the foetus from conception 
to delivery is critical. Thus, the increased incidence of adverse birth outcomes has led 
to a greater need to explore and identify underlying mechanisms including genital 
inflammation and/ or vaginal microbiota. Although causal relationships between 
cytokines, vaginal microbiota and pregnancy outcomes have been difficult to establish, 
the fact that these factors may play influential roles in pregnancy outcomes cannot be 
ignored. Vaginal microbiota influences vaginal cytokine profiles. Dysbiotic vaginas are 
highly associated with high inflammation in African women [134, 348, 412]. During 
pregnancy vaginal inflammation in turn is thought to be associated with poor outcomes  
[318, 337]. In this study, BV and high relative abundance of L. iners and G. vaginalis 
and other dysbiotic bacteria correlated with high levels of inflammation, whereas L. 
crispatus and other non-iners lactobacilli were associated with low levels of 
inflammation. Interestingly, lower concentrations of vaginal growth factors and 
hematopoietic cytokines were associated with adverse birth outcomes, including 
preterm delivery and LBW.  
 
The upregulation of vaginal cytokines in women with BV that was observed in our 
study has been previously reported in non-pregnant adult African women [224, 237, 
413]In these previous studies there was an increase in pro-inflammatory cytokines, with 
concomitant downregulation of chemokines. Similarly, in the present study, pro-
inflammatory cytokines were upregulated and the chemokine IP-10 was downregulated 
in women with BV compared to women with healthy microbiota. However, several 
other chemokines were upregulated, as well as adaptive cytokines and growth factors 
in the BV+ women. Similarly, the elevation of inflammatory cytokines (IL-1β, IL-6) in 
BV+ normal pregnancy laboring women [414] and BV+ normal pregnancy not in 
labour respectively were observed in a study by Donders and colleagues [415]. 
Summarising our findings and previous reports, it is apparent that BV seems to be 
associated with high levels of proinflammatory cytokines and most chemokines in 
pregnancy, similar to the non-pregnant state. 
 
We observed higher concentrations of proinflammatory cytokines (IL-1β, TNF-α, IL-8 
and IL-6) in the L. iners-dominated and G. vaginalis-dominated CSTs as compared to 
the L. crispatus community. The inflammatory nature of L. iners, the dominant 
Lactobacillus species in this cohort, agrees with many studies that have reported that L. 
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iners, unlike other Lactobacillus species, may not be as “healthy” as other lactobacilli 
as it may promote a favourable environment for dysbiotic microbes [13, 67, 135]. On 
the other hand, L. crispatus was inversely associated with inflammation in this study, 
which agrees with findings in other African cohorts [13, 134]In other studies of non-
pregnant women, it was shown that host inflammatory responses were stimulated by 
the presence of a dysbiotic environment, with cytokines such as IL-18, RANTES, IL-
2, MIF (Macrophage migration inhibitory factor), IL-1ra, IL-8, MIP-1α and TNF-α 
correlating with altered vaginal composition  [416]. Inflammatory cytokines may also 
in turn influence the vaginal microbiota, promoting the growth of opportunistic 
organisms[409, 411, 416]. 
 
We created an “inflammation” score that was representative of overall levels of 
inflammation, and binarised women into high and low inflammation categories, we 
observed that a high relative abundance of specific organisms such as G. vaginalis, 
Dialister, A. vaginae, Aerococcus, Prevotella, Megasphaera, and L. iners were found 
to be highly associated with inflammation. As expected, the same microbiota were 
highly predictive of inflammation by random forest and also significantly different in 
women classified as having high inflammation in a metagenomeSeq analysis. 
Therefore, these taxa may be possible biomarkers of inflammation during pregnancy in 
African women which could be validated in longitudinal studies. Of the 22 taxa 
significantly associated with high and low inflammation using MetagenomSeq analysis, 
Prevotella Gemella, Aerococcus, A. vaginae, G. vaginalis Megasphaera, L. reuterii, L. 
crispatus, Dialister and L. iners have been previously described as correlates of 
inflammation (or lack thereof) only in non-pregnant women [134, 135]. Our data adds 
to the literature as no study has analysd the relationship between the vaginal microbiota 
and inflammatory cytokines in pregnancy. We also found that some taxa that have not 
previously been associated with inflammation, including P. melaninogenica, 
Veillonella, Parvimonas, Slackia, Roseburia and Nesterenkonia, were more abundant 
in the high inflammation group.  
  
When looking at specific cytokines in relation to vaginal microbiota, there were 
significant associations between most cytokines evaluated and individual taxa. G. 
vaginalis was highly correlated with most of the cytokines, including IL-2, IL-17A, 
FGF-basic, IL-9, IL-8, TNF-α, IL-1β and IL-4. This agrees with in vitro studies where 
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G. vaginalis was seen to increase IL-8 and RANTES production by female reproductive 
tract epithelial cells in vitro [222, 259]. Other taxa such as Aerococcus, Prevotella and 
Coriobacteriaceae were also strongly correlated with inflammatory and adaptive 
cytokines.  Prevotella has been shown to induce secretion of inflammatory cytokines 
(IL-1β, IL-1α, and IL-8) in vitro from HeLa cells, while Aerococcus was associated 
with inflammation in the female genital tracts of non-pregnant women [135]. 
 
When looking at vaginal cytokines in the second versus third trimester, we observed 
upregulation of pro-inflammatory IL-6, chemokines (MCP-1, MIP-1α, MIP-1β, 
RANTES), growth factors (FGF-basic, GM-CSF) and adaptive immune mediators (IL-
13, IL-2) during the third trimester compared to second. This concurs with reports of 
previous studies which found that chemokines and cytokine expression is increased in 
decidua tissue of pregnant women in the first and third trimesters [417]. They further 
reported that these increased cytokines might play a role in maternal tolerance at the 
maternal fetal interface  [417, 418]. In contrast IL-6, IL-8 and IL-1ra were found to be 
downregulated in pregnant women as compared to non-pregnant although in third 
trimester the levels were higher compared to pre-pregnancy levels [415]. Nevertheless, 
sampling the same women longitudinally may better inform on the vaginal cytokine 
patterns during pregnancy. Maternal cytokines during pregnancy have also been 
investigated in several other studies with interesting observations although not 
necessarily they were not particularly from vaginal fluid. Upregulated serum 
inflammatory cytokines (IL-1β, IL-6, IL-12, IL-15, IP-10, and sCD40) have been 
reported to characterize the third trimester of pregnancy while an increase in serum 
growth factors characterises the first trimester, with a concomitant decrease in 
inflammatory markers IL-6, IL-17, IP-10, Eotaxin, and MCP-1 [419]. In a longitudinal 
study where, maternal plasma cytokines were collected from early to mid-gestation, an 
increase in IL-12 and IFN-γ and a decrease in IL-2 and GM-CSF levels were reported 
as pregnancy progressed [420]. In another longitudinal study Denney et al., (2011) 
found a consistent decrease in IFN-γ, TNF-α, IL-1β, and IL-6 throughout gestation in 
maternal plasma [420]. 
 
Here, we demonstrate a relationship between vaginal growth factors and poor 
pregnancy outcomes. We observed that LBW and PTB were significantly associated 
with low levels of PDGF-BB after adjusting for potential confounders. Growth factors 
within the maternal circulation are essential regulators of placental development and 
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function and have been found to be important for fetal growth  [421] as previously 
elaborated. Previous studies have found a relationship between placental growth factors 
and poor pregnancy outcomes [422]. In this study we observed that lower 
concentrations of PDGF and to a lesser degree FGF were associated with PTB and 
LBW. Similarly, in other studies of placental growth factors women with low 
concentrations of these factors were more likely to experience poor maternal outcomes. 
Low placental growth factors were associated with preterm deliveries [423] while lower 
plasma cytokines concentrations were associated with delivery of SGA neonates [424]. 
However, in contrast, Smith and colleagues found that high plasma placental growth 
factors were associated with SGA [425] while Lee et al., (2016) found that high levels 
of placental growth factors were associated with preterm delivery [426]. Growth factors 
are of paramount importance during pregnancy as they are responsible for blood cell 
formation and angiogenic processes that allow increase of surface area, exchange of 
nutrients and normal blood flow during foetal growth and development [422]. These 
are necessary processes for the healthy growth of the foetus. However, disruption of 
the normal balance of the angiogenic factors has been associated with poor pregnancy 
outcomes such as preeclampsia  [427], IUGR, SGA [424] and preterm delivery among 
others. It is possible that there may be a relationship between placental and vaginal 
growth factors. This might explain observed associations between the growth factors 
PDGF-BB and PTB, LBW and SGA; and FGF-basic protein and PTB.  
 
 
 
In prior studies [333, 410], IL-6 in cervicovaginal and amniotic fluid was strongly 
correlated with preterm delivery. A systematic review reported the role of subclinical 
infections in stimulating cytokine release during pregnancy. Proinflammatory 
cytokines such as IL-1α, IL-8, and IL-6 can lead to production of prostaglandins which 
in turn leads to premature labour [228, 410]. Furthermore, Torbe and Czajka (2004). 
reported high concentrations of vaginal IL-6 as the best predictive marker of preterm 
birth [408]. In agreement, Wei and colleagues specified that high IL-6 levels in vaginal 
and amniotic fluid but not in plasma was strongly associated with preterm delivery 
[410]. In neither IL-6 nor any other innate inflammatory cytokines were not associated 
with preterm delivery or any poor outcomes. 
 
 
 
127 
One of the functions of Th2 cytokines are as humoral immune mediators, but they also 
play a role in healthy pregnancies. As an adaptation during pregnancy, maternal-foetal 
tolerance has been suggested to be maintained by the shift of the maternal immune 
system from Th1 dominance to Th2. On the other hand, infection may favour cell 
mediated immunity (Th1 cytokines) associated with poor pregnancy outcomes [428]. 
As IL-13 is a Th2 and adaptive cytokine it is surprising that in our study IL-13 was 
highly associated with poor pregnancy outcomes (LBW, PTB and SGA) although in 
SGA although the association with SGA was not upheld. In contrast, as expected a 
recent study found that serum IL-13 and other serum cytokines were elevated in women 
who experienced preterm deliveries. Although they were measuring IL-13 and IL-8 in 
relation to prediction of preterm delivery their results could not validate that 
relationship [429]. These differences between studies could be attributed to the 
interactions between different immune factors, cytokines, diet and hormones during 
pregnancy. In this study it was beyond our scope to study all of the factors that influence 
physiological changes in pregnant women. This finding suggests that IL-13 could be a 
possible possible immune marker for preterm birth or poor pregnancy outcomes and 
should be further evaluated in future studies. 
 
Despite multiple studies having identified biomarkers associated with PTB, as the 
development of PTB biomarkers for clinical practice has proved challenging due to 
inconsistency and lack of agreement between different studies [430, 431]. Different 
study design, time of sample collection, physiological and ethnic differences and 
presumed asymptomatic infection have been suggested to be factors underlying the 
inconsistent findings related to PTB predictions using biomarkers.  
 
Our results should be interpreted with caution considering our cross-sectional study 
design. A longitudinal study with follow up throughout pregnancy would provide a 
better predictive model of factors associated with adverse birth outcomes. The lack of 
precise gestational age determination at collection due to the inability of many women 
to access ultrasound services could also affected the results and influenced trimester 
and gestational age classification. Another drawback is that half of the women in this 
cohort had high risk pregnancies since they had experienced multiple previous poor 
pregnancy outcomes. Although this did increase the proportion of women with adverse 
outcomes, the data may lack generalisability. Although all women were tested for STIs 
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(syphilis, T. vaginalis and HIV) during the visit, we were unable to control for other 
STIs.  
 
In conclusion, we find that vaginal cytokine concentrations vary during pregnancy 
depending on gestational age and vaginal microbiota state and may in turn influence 
pregnancy outcomes. Our study has established that dysbiotic vaginal microbiota and 
BV are associated with elevated cytokine concentrations and high inflammation, 
although high inflammation was not associated with any poor pregnancy outcomes. 
Furthermore, low growth factors and Th2 cytokines were highly associated with poor 
birth outcomes.  
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Chapter 6: HIV and vaginal microbiota during pregnancy 
 
HIV infected women  have a high prevalence of vaginal dysbiosis when compared to 
HIV uninfected women [27]. According to published studies, the prevalence of an 
altered vaginal microbial environment in HIV-infected pregnant women is between 
47% in western countries and 89% in some African cohorts [14]. HIV infection is 
associated with increased risk of poor pregnancy outcomes in pregnant women on 
ART[56, 178, 180, 432]. An important underlying mechanism for the relationship 
between HIV and poor pregnancy outcomes may be changes in the vaginal microbiota 
and/or inflammatory profile as a result of HIV infection [143, 433]. Previous studies in 
non-pregnant women have shown that HIV causes alterations in the vaginal 
microbiome and increases in pro-inflammatory cytokine concentrations [221, 224, 
348]. HIV-1 is known as an inflammatory condition that is associated with dysregulated 
and imbalanced cytokine production at mucosal and systemic sites which is a hallmark 
of disease progression [164, 434]. During pregnancy, placental concentrations of 
inflammatory cytokines, including TNF-α, IL-6 and IL-8, have been found to be 
elevated in HIV-infected women on ART as compared to HIV-uninfected women [435, 
436] as fully elaborated in Chapter 1. The use of HAART on cytokine levels in serum 
of HIV-infected pregnant women and found that HAART has a suppressive effect on 
circulating pro-inflammatory cytokines levels [437-439]. 
 
The vaginal microbiota have also been associated with increased risk of HIV 
transmission [143]Additionally, studies conducted by Roberts et al., (2012) and Cortez 
et al., (2014) in non-pregnant HIV-infected women both demonstrated that vaginal 
inflammatory cytokines (TNF-α, IL-6, MIP-1α, IFN-α2 and MIP-1β) were associated 
with increased viral shedding [164] {Cortez, 2014 #728. Therefore, changes in the 
vaginal microbiome and inflammatory markers during pregnancy may influence the 
likelihood of mother-to-child transmission of HIV and transmission to their uninfected 
partners. 
 
In order to improve our understanding of the changes in vaginal microbiota and 
cytokines that occur during HIV infection that may influence pregnancy outcomes and 
HIV transmission, in this Chapter we compare the vaginal microbiota and cytokine 
profiles of HIV infected and HIV uninfected pregnant women between 13-35 weeks of 
gestation.  
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Out of the 420 women recruited, 356 women had complete data on HIV status and 
microbiota. Of these 356 women, 314 (88%) were HIV-uninfected and 42 (12%) were 
HIV-infected (Table 6.1). There were no differences in characteristics such as 
gestational age at collection, parity, GBS colonization, vaginal douching, vaginal pH 
and gravida between the two groups (Table 6.1). Of the 42 HIV-infected women, 24 
had available CD4+ counts and 8 had viral load results, of which the mean CD4+ count 
was 532.8 cells/mm3 and viral load was 128.85 copies/ml. The majority of these women 
were on the fixed dose combination drug which consist of Tenofovir (300 mg) + 
Lamivudine (300 mg) + Efavirenz (600 mg) (Tenolam E) [35/42 (87,5%)] HAART 
regimen. Preterm deliveries tended to be more frequent in HIV-infected women 
compared to HIV-uninfected women (31% vs 15.3%, p=0.066 respectively). Women 
who were HIV-infected were more likely to have a smoking partner (p=0.03) and have 
BV by Nugent score (p=0.01) compared to HIV-uninfected women.  
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Table 6.1 Characteristics stratified by HIV Status  
 
HIV Negative 
(n=314) 
HIV Positive 
(n=42) 
p-value 
Gestational Age collection, mean (SD) 28.32 (6.44) 28.64 (5.00) 0.754 
Partner smoker (%) 19 ( 6.1) 7 (16.7) 0.030 
SGA (%) 25 (12.2) 5 (17.9) 0.590 
Blood CD4+ [cell/mm3(n=24)] [mean 
(SD)]  
NA 532.8  (208.2)  
Plasma viral load copies/ml (n=8), mean 
(SD)  
NA 128.85 
(98.49)  
 
HAART Regimen (%)   NA 
AZT 3TC NA 4 (10.0)  
Tenofovir NA 1 ( 2.5)  
TDF, FTC, EFV NA 35 (87.5)  
LBW (%) 28 (13.7) 7 (25.0) 0.196 
Preterm (%) 33 (15.3) 9 (31.0) 0.066 
Vaginal douching [n (%)] 148 (47.1) 26 (61.9) 0.102 
Nugent score, mean (SD) 2.98 (3.43) 4.36 (3.63) 0.016 
BV (%) 
  
0.010 
BV 70 (22.3) 18 (42.9) 
 
Intermediate 50 (15.9) 7 (16.7) 
 
Normal 194 (61.8) 17 (40.5) 
 
pH, mean (SD) 4.18 (0.67) 4.36 (0.76) 0.124 
Gravida, mean (SD) 2.82 (1.69) 3.26 (1.33) 0.102 
Para, mean (SD) 1.26 (1.20) 1.67 (1.20) 0.041 
Maternal age, mean (SD) 29.02 (6.39) 31.05 (6.41) 0.066 
CST (%) 
  
0.009 
1 95 (30.3) 14 (33.3) 
 
2 98 (31.2) 4 ( 9.5) 
 
3 121 (38.5) 24 (57.1) 
 
Pregnancy induced hypertension (%) 21 ( 6.7) 0 ( 0.0) 0.168 
Previous poor outcome (%) 97 (30.9) 12 (28.6) 0.898 
GBS (%) 123 (39.2) 16 (38.1) 1.000 
Inflammation (%)   0.447 
High 70 (24.8) 11 (26.2)  
Low 72 (25.5) 7 (16.7)  
Medium 140 (49.6) 24 (57.1)  
LBW= low birth weight, GBS= group B streptococcus. BV=bacterial vaginosis, CST= community state type.  
SGA= small for gestational age. SD= Standard deviation, NA= not applicable 
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A multivariate model was used to further evaluate correlates of HIV infection, including 
those identified in prior literature, including maternal age {Liuzzi, 2013 #750}, vaginal 
douching [440], and those that were significant in a univariate model (Table 6.1). BV 
status and CST were excluded due to their collinearity with Nugent score. Nugent score 
[OR 1.14; 95% CI 1.03-1.26] (p=0.01) and having a partner who smoked [OR 3.57; 
95% CI 1.25-9.39] (p=0.01) were significantly independently associated with HIV 
status (Table 6.2).  
 
Table 6. 2 Multivariate analysis of demographic, behavioural and clinical factors 
associated with HIV status 
 
OR 95% CI p-value 
Nugent score 1.14 1.03-1.26 0.01 
Para 1.18 0.9-1.61 0.30 
Partner smoker 3.57 1.25-9.39 0.01 
Vaginal douching 1.74 0.85-3.64 0.13 
Maternal age 1.05 0.98-1.12 0.13 
CI= confidence interval, OR= Odds ratio 
 
 
Correlates of HIV infection were further evaluated, including  CST and those identified 
in prior literature, including maternal age [441], vaginal douching [440], and those that 
were significant in a univariate model (Table 6.1).  Nugent score were excluded due to 
their collinearity with CST. CST3 [OR 4.90; 95% CI 1.64-14.60 (p=0.002), CST1 [OR 
3.57; 95% CI 1.14-11.24 (p=0.02) and having a partner who smoked (p<0.03) [OR 
3.57; 95% CI 1.25-9.39] were significantly independently associated with HIV status 
(Table 6.3). With CST2 set as the reference, CST3 and CST1 and smoking partner were 
independently associated with HIV (p<0.05) (Table 5.2). Women with CST3 
microbiota were 4.90 times more likely to be HIV positive compared to women in CST2  
 
 
Table 6. 3 Multivariate analysis of demographic, behavioural and clinical factors 
associated with HIV status 
 
OR 95% CI p-value 
CST3 4.90 (1.64, 14.60) 0.002 
CST1 3.57 (1.14, 11.24 0.02 
Para 1.20 0.88-1.66 0.21 
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Partner smoker 3.89 1.35-10.41 0.01 
Vaginal douching 1.76 0.85-3.74 0.13 
Maternal age 1.04 0.97-1.10 0.27 
CST= community state type 
Using hierarchical clustering of taxa merged at the lowest taxonomic level, the women 
in this cohort clustered into three CSTs as described previously in Chapter 3: CST1 (L. 
iners dominant), CST2 (L. crispatus dominant) and CST3 (G. vaginalis dominant). 
HIV-infected women were less likely to have CST2 microbiota and more likely to have 
CST3 microbiota (p=0.009) than HIV negative women (Table 6.1). A CST distribution 
analysis revealed that the majority of HIV-infected women were found in with CST3 
[24/42 (57%)], followed by CST1 [12/42 (33%)], confirming microbial differences by 
HIV infection status. Moreover, CST2 was rarely observed in HIV-infected women 
[4/42 (9.5%)] as compared to HIV uninfected women [98/314 (31.2%)] (Figure 6.1; 
Table 6.1). 
 
Figure 6. 1 Heatmap showing community state type (CST) distribution by HIV status using 
supervised hierarchical clustering (Bray Curtis distances) of log2 transformed standardized 
counts of taxa merged at the lowest taxonomic level. Each column represents a woman and 
rows represent taxa or operational taxonomic units (OTU). Red colour represents the most 
abundant while blue presents least abundant or absence of log2 transformed OTU counts. 
Significant differences in microbial diversity (alpha and beta-diversity) were evident 
between HIV-infected and HIV-uninfected women (Shannon index p=0.004 and Bray 
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Curtis Adonis p=0.003, respectively) (Figure 6.2A & B). A low relative abundance of 
the Lactobacillus genus with high relative abundance of some BV-associated organisms 
was observed in HIV-infected women (Figure 6.2C). These findings were consistent 
with the findings of diversity measures we previously described where HIV infection 
was more closely associated with CST3 than the other CSTs.  
A.                                                               B. 
                
               C.                                                             D.  
 
Figure 6. 2 Diversity and composition of the vaginal microbiota by HIV status. A. Shannon 
alpha diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women B. Bray 
Curtis beta diversity in HIV infected and uninfected women. Results were significant by 
Kruskal-wallis and evaluated by Dunn’s post hoc test. C & D. Bar plots showing relative 
abundance of the most abundant bacteria by HIV status at genus and species levels, respectively 
 
Thirty-eight OTUs were identified as being significantly different between HIV-
infected vs. HIV-uninfected women using MetagenomSeq (Table 6.4 and Table 6.5). 
At species level there was a higher relative abundance of L. iners in HIV-infected 
women, while conversely L. crispatus was higher in HIV-uninfected women as 
compared to the other group (Table 64). 
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Table 6. 4 Differentially abundant taxa by HIV status (Family, genus and species 
level where available) 
Family Genus Species HIV-
uninfecte
d (N=314) 
% (n) 
HIV-
Infected 
(N=42) 
% (n) 
Adj. p-value 
Lactobacillaceae Lactobacillus coleohominis 21.3 (67) 14.3 (6) <0.001 
Lactobacillaceae Lactobacillus crispatus 100 (314) 100 (42) 0.013 
Lachnospiraceae NA NA 26.8 (84) 7.1 (3) <0.001 
Actinomycetaceae Varibaculum NA 33.8 (106) 11.9 (5) <0.001 
Lachnospiraceae Blautia NA 32.5 (102) 19 (8) <0.001 
Prevotellaceae Prevotella copri 28.7 (90) 21.4 (9) <0.001 
Ruminococcaceae Ruminococcus bromii 23.2 (73) 4.8 (2) <0.001 
Aerococcaceae Facklamia NA 37.3 (117) 21.4 (9) <0.001 
Veillonellaceae Veillonella dispar 20.7 (65) 11.9 (5) <0.001 
[Tissierellaceae] Jan-68 NA 35.7 (112) 33.3 (14) <0.001 
Brevibacteriaceae Brevibacterium NA 30.3 (95) 16.7 (7) <0.001 
Ruminococcaceae Faecalibacteriu
m 
prausnitzii 31.8 (100) 26.2 (11) <0.001 
Coriobacteriaceae Atopobium NA 21.7 (68) 11.9 (5) <0.001 
Lachnospiraceae Roseburia NA 25.8 (81) 16.7 (7) <0.001 
Micrococcaceae Nesterenkonia NA 28.3 (89) 11.9 (5) <0.001 
Moraxellaceae Enhydrobacter NA 37.6 (118) 28.6 (12) <0.001 
Alcaligenaceae Sutterella NA 25.5 (80) 16.7 (7) <0.001 
Lactobacillaceae Lactobacillus iners 100 (314) 100 (42) 0.023 
Veillonellaceae Dialister NA 94.3 (296) 88.1 (37) 0.009 
Bifidobacteriaceae Gardnerella NA 100 (314) 100 (42) 0.025 
Prevotellaceae Prevotella timonensis 99.4 (312) 97.6 (41) 0.012 
Aerococcaceae Aerococcus NA 82.2 (258) 85.7 (36) 0.009 
Actinomycetaceae NA NA 13.4 (42) 40.5 (17) <0.001 
Leptotrichiaceae Sneathia NA 93 (292) 90.5 (38) 0.006 
Clostridiaceae Clostridium NA 78.7 (247) 81 (34) 0.001 
Coriobacteriaceae Atopobium vaginae 97.1 (305) 97.6 (41) 0.005 
Prevotellaceae Prevotella melaninogenic
a 
22.9 (72) 31 (13) <0.001 
Lachnospiraceae BVAB-1 NA 87.6 (275) 95.2 (40) 0.003 
Rs-045 NA NA 14.6 (46) 31 (13) <0.001 
Gemellaceae Gemella NA 66.9 (210) 71.4 (30) <0.001 
Coriobacteriaceae NA NA 76.8 (241) 83.3 (35) <0.001 
[Tissierellaceae] Parvimonas NA 70.7 (222) 78.6 (33) <0.001 
Actinomycetaceae Arcanobacteriu
m 
NA 15.6 (49) 23.8 (10) <0.001 
Leptotrichiaceae NA NA 5.7 (18) 23.8 (10) <0.001 
Veillonellaceae Megasphaera NA 97.5 (306) 97.6 (41) <0.001 
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Mycoplasmatacea
e 
Mycoplasma NA 48.4 (152) 71.4 (30) <0.001 
Prevotellaceae Prevotella pallens 15.9 (50) 33.3 (14) <0.001 
 
 L. iners, G. vaginalis, Megasphaera, P. timonensis, BVAB1, A. vaginae, Sneathia, 
Mycoplasma, P. melaninogenica, Lachnospiraceae, Actinomycetaceae, 
Coriobacteriaceae, Gemella, P. pallens, Aerococcus, Rs-045, Parvimonas, Clostridium, 
Dialister, Bacteroidales, Arcanobacterium and L. coleohominis were more abundant in 
HIV-infected women than HIV-uninfected (adj. p<0.05) (Figure 6.3). P. copri, 
Leptotrichiaceae, Atopobium, Facklamia, Roseburia, R. bromii, Brevibacterium, F. 
prausnitzii, Enhydrobacter, Varibaculum, Blautia, V. dispar, Jan-68, Nesterenkonia 
and, Sutterella were less abundant in HIV-infected compared to HIV-uninfected 
women (adj. p<0.05). 
 
Figure 6.3 Supervised hierarchical clustering (Bray Curtis distances) including significant 
differentially abundant taxa by HIV status identified using MetagenomSeq analysis. Taxa were 
merged at the lowest taxonomic level and log2-transformed standardized read counts are shown. 
HIV and bacterial vaginosis (BV) status are shown. Each column represents a woman and rows 
represent taxa or operational taxonomic units (OTU). Red colour represents the most abundant 
while blue presents least abundant or absence of log2 transformed OTU counts.  
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We compared the standardized read counts of individual taxa predicted by RF in HIV-
infected versus uninfected women to see the direction of the relationship Using Mann 
Whitney U test for independent samples to compare differences between the means by 
HIV status. It is interesting to note that Mycoplasma (p=0.0002), Megasphaera 
(p=0.0004) Coriobacteriaceae (p=0.001), Parvimonas (p=0.001), A. vaginae (p=0.01), 
Dialister (p=0.02), P. timonensis (p=0.02), Clostridium (p=0.03), Actinomycetaceae 
(p=0.03), Corynebacterium (p=0.03), Aerococcus (p=0.03) and Prevotella (p=0.04) 
read counts were significantly higher in HIV-infected compared to uninfected women, 
while L. crisptatus (P=0.03) was significantly higher in HIV-uninfected women 
(Figure 6.4). L. iners, G. vaginalis, Peptoniphilus, P. pallens and P. melaninogenica, 
(p>0.05) had non-significantly higher read counts in HIV-infected women, while and 
Anaerococcus (p>0.05) had a non-significantly higher read count in HIV-uninfected 
compared to infected woman. Only Mycoplasma and Megasphaera remained 
significant (p<0.05) after adjusting for multiple comparisons. 
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Figure 6.4 Box plot summaries log2-transformed standardised read counts of individual taxa 
that differed according to HIV status in random forest. Box and whisker plots indicate the 
median (middle line), 25th (bottom line) and 75th percentiles (top line), and the range 
(whiskers) of log2-transformed taxa read counts. Mann Whitney U test for independent samples 
was used for comparisons of read counts by HIV status. All p-values were adjusted using the 
false discovery rate (FDR) step-down approach (Columb and Sagadai, 2006). * shows p-values 
which were significant after multiple comparisons correction. Corynebacterium and 
Mycoplasma had interquartile ranges of zero thus the graphs are not displaying for the HIV 
uninfected women  
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MetagenomeSeq results were supported by Random forest (RF) analysis (Figure 6.5). 
The ten genera found to be most predictive of HIV status by RF in order were 
Prevotella, Actinomycetaceae, L. iners, G. vaginalis, Dialister, Coriobacteriacae, A. 
vaginae, Megasphaera, Peptoniphillus, Aerococcus. The model resulted in a 10-fold 
cross validation error of 12.8% (87% accuracy, 3% sensitivity and 99% specificity). 
However, the positive predictive value was only 33%, indicating that the model missed 
77% of the HIV positive samples. Prevotella was the most predictive of HIV status in 
this cohort with a mean decrease Gini index >0.4 (Figure 6.5).  
 
 
Figure 6.5 Random forest using taxa merged at the lowest taxonomic level showing the taxa 
predictive of HIV status. The X-axis shows the mean decrease in the Gini index (length of bar 
represents relative predictive ability of each taxon). The left shows taxa predictive of HIV 
status  
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6.1 HIV and vaginal cytokines 
We sought to explore vaginal cytokine levels and their relationship with microbiota and 
HIV status in pregnant women. As described in the previous Chapter 5, the 
concentrations of 20 cytokines, representing four functional groups, adaptive (IL-2, IL-
13, IL-4, IL-17A), regulatory (IL-10, IL-1ra), growth factors (IL-7, IL-9, FGF-basic, 
PDGF-BB, VEGF, GM-CSF), chemokines (IL-8, Eotaxin, IP-10, MCP-1, MIP-1α, 
MIP-1β, RANTES) and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), were 
measured in vaginal secretions collected from 356 women. Of these cytokines, IL-4, 
IL-17 and IL-13 were found at very low concentrations in both HIV-uninfected and 
infected women, while the remainder was readily detectable. A larger proportion of 
HIV-uninfected women were grouped as having low levels of genital inflammation as 
defined in Chapter 5 as compared to HIV-infected women (16 vs 25%, respectively), 
but this was not statistically significant (p=0.45) (Table 6.1). In a univariate analysis, 
only PDGF-BB was significantly lower in HIV-infected compared to uninfected 
women, however this association was not upheld after adjusting for multiple 
comparisons (p=0.02, adjusted p=0.2) (Table 6.5). 
 
We went on to perform multivariate logistic regression in order to adjust for potential 
confounders that may influence genital cytokine concentrations and/or HIV status  
[440, 441] as well as factors that were associated with HIV in the univariate analysis in 
Table 6.1. Importantly, since microbiota and genital cytokines are so closely linked, we 
included variables to account for this including Nugent score in Model 1 and CST in 
Model 2.  It was found that the relationship between PDGF-BB and HIV status was not 
upheld after adjusting for potential confounders including Nugent score, partner 
smoker, parity (p>0.05), while low levels of IL-13 (p=0.01) [OR 0.42; CI (0.21-0.82)] 
were found independently associated with HIV status after adjustment (Table 6.5).  
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Table 6.5 Multivariate analysis of cytokines associated with HIV status 
  
OR 95% CI p-value Adj. OR Adj. 95% CI Adj. p-
value 
IL-2 2.77 0.20-57.80 0.48 1.10 0.48-2.69 0.82 
IL-4 0.13 0002-8.13 0.34 1.23 0.28-6.2 0.79 
IL-17A 1.13 0.07-18.09 0.93 1.27 0.51-3.07 0.60 
IL-13 0.24 0.09-0.57 0.08 0.43 0.21-0.82 0.01* 
IL-7 0.90 0.50-1.62 0.73 0.75 0.38-1.05 0.08 
IL-9 0.35 0.02-6.59 0.46 0.60 0.17-2.55 0.46 
FGF-basic 0.56 0.13-2.90 0.46 0.72 0.3-1.92 0.47 
PDGF-BB 0.99 0.47-2.17 0.02 0.72 0.47-1.14 0.2 
VEGF 0.45 0.17-1.14 0.09 0.86 0.44-1.66 0.64 
GM-CSF 3.99 0.70-24 0.12 0.97 0.4-2.73 0.95 
IL-8 1.58 0.71-3.51 0.26 1.25 0.86-1.8 0.23 
Eotaxin 1.41 0.08-26.81 0.82 0.74 0.19-3.19 0.67 
IP-10 0.80 0.41-1.54 0.50 1.14 0.75-1.74 0.53 
MCP-1 0.32 0.06-1.54 0.18 0.84 0.36-1.86 0.67 
MIP-1α 56.7 5.92-628.09 0.19 1.25 0.68-2.28 0.47 
MIP-1β 0.08 0.01-0.73 0.70 1.05 0.53-2.05 0.87 
RANTES 3.72 0.83-16.69 0.08 1.68 0.77-3.53 0.18 
IL-1β 0.45 0.19-1.18 0.07 1.18 0.8-1.73 0.40 
IL-6 0.12 0.02-0.6 0.72 0.64 0.27-1.38 0.28 
TNF-α 4.13 0.80-21.46 0.09 1.38 0.66-2.87 0.38 
* significant after adjusting for Nugent score, partner smoker status, maternal age, para, vaginal douching. Cytokine concentrations 
were log10-transformed. 
 
  
 
 
142 
Additional multivariate logistic regression analyses were performed in order to adjust 
for CST instead of Nugent score, as CST and Nugent score could not be included in the 
same model due to collinearity.  Similarly, the relationship between PDGF-BB 
(p=0.38),  and HIV status were not upheld after adjusting for potential confounders 
including CST, maternal age, partner smoker, parity while high levels of TNF- α 
(p=0.04) [OR 2.48; CI (1.06-5.89)] were associated with HIV. (Table 6.6) 
 
Table 6.6 Multivariate analysis of cytokines associated with HIV status 
 
OR Adj. OR 95% CI Adj. 95% CI p-value Adj. p-value 
IL-2 2.77 2.59 0.20-57.80 0.97-7.69 0.48 0.07 
IL-4 0.13 3.13 0002-8.13 0.57-20.11 0.34 0.21 
IL-17A 1.13 2.37 0.07-18.09 0.89-6.51 0.93 0.09 
IL-13 0.24 0.7 0.09-0.57 0.32-1.47 0.08 0.34 
IL-7 0.90 0.84 0.50-1.62 0.48-1.46 0.73 0.29 
IL-9 0.35 1.76 0.02-6.59 0.33-12.84 0.46 0.54 
FGF-basic 0.56 4.44 0.13-2.90 0.1-25.99 0.46 0.07 
PDGF-BB 0.99 0.79 0.47-2.17 0.46-1.42 0.02 0.38 
VEGF 0.45 0.48 0.17-1.14 0.2-1.09 0.09 0.09 
GM-CSF 3.99 3.08 0.70-24 0.87-15.48 0.12 0.12 
IL-8 1.58 1.4 0.71-3.51 0.89-2.18 0.26 0.14 
Eotaxin 1.41 1.01 0.08-26.81 0.22-5.51 0.82 0.98 
IP-10 0.80 0.94 0.41-1.54 0.55-1.6 0.50 0.81 
MCP-1 0.32 0.7 0.06-1.54 0.23-1.97 0.18 0.51 
MIP-1α 56.7 1.38 5.92-628.09 0.67-2.84 0.20 0.38 
MIP-1β 0.08 1.26 0.01-0.73 0.57-2.76 0.70 0.57 
RANTES 3.72 2.22 0.83-16.69 0.88-5.4 0.08 0.08 
IL-1β 0.45 1.39 0.19-1.18 0.91-2.17 0.07 0.13 
IL-6 0.12 1.14 0.02-0.6 0.46-2.71 0.90 0.77 
TNF-α 4.13 2.48 0.80-21.46 1.06-5.89 0.09 0.04* 
*significant after adjusting for community state type (CST), partner smoker status, maternal age, para, vaginal douching 
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A heatmap was constructed to visualize the relationship between the vaginal microbiota 
and cytokines (Figure 6.6). Included in the heatmap were inflammatory scores assigned 
by grouping women as having high inflammation if their inflammatory factor score was 
in the upper quartile (≥ 75th percentile), medium inflammation if their score was in the 
interquartile range (<75th - >25th percentile) and low inflammation if their score was in 
the lower quartile (≤25th percentile).  
 
Figure 6. 6 Heatmap showing cytokine distribution by HIV status, community state type and 
inflammation using supervised hierarchical clustering (Bray Curtis distances) of log2 
transformed standardized counts of cytokines. Each column represents a woman and rows 
represent individual cytokines. Red colour represents higher concentrations while blue 
presents lower concentrations of cytokines. 
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6.2 Discussion  
While many previous studies have evaluated the role of vaginal microbiota in 
transmission of HIV infection in women  [9, 167, 168], few have analysed both vaginal 
microbiota and cytokines in pregnant HIV-infected women. Here, we describe vaginal 
microbial communities and concentrations of cytokines in HIV-infected versus HIV-
uninfected pregnant women.   
 
As expected it was observed in our study that BV and Nugent score were high in 
pregnant women who are HIV-infected as is expected, Consistently, our study results 
demonstrated significantly higher alpha and beta diversity in women who were HIV-
infected as compared to HIV-uninfected women, consistent with the findings of studies 
conducted by Buve et al., (2014) and Chehoud et al., (2017). It follows that significant 
differences in CSTs by HIV status were also observed, with more HIV-infected women 
having CST3 vaginal microbiota. In contrast, Chehoud and colleagues (2017), in a 
longitudinal study of non-pregnant women from Chicago, did not find any significant 
differences in community structure associated with HIV status (p=0.4) among 
Chicagoan women, and the lack of significant differences was attributed to effective 
antiretroviral therapy  [152]. 
 
Our results demonstrated that the relative abundance of particular bacteria also differed 
by HIV status. L. crispatus species were dominant in HIV-uninfected women while 
there was a reduction in HIV-infected women. Additionally, as expected, a notably high 
number of BV-associated organisms were significantly more abundant in HIV-infected 
compared to uninfected women according to metagenomSeq analysis (G. vaginalis, 
Megasphaera, P. timonensis, BVAB1, A. vaginae, Sneathia, Mycoplasma, Gemella, P. 
pallens, Aerococcus, Dialister). This concurs with previous studies that have reported 
that dysbiotic vaginal microbiota and BV+ status were associated with HIV acquisition 
in non-pregnant African women  [131, 152, 169, 171, 442]. However, relatively little 
has been published on HIV and the microbiota in pregnancy in African women. 
 
There is lack of conclusive reproducibility in individual taxa associated with HIV 
infection in different studies that have been conducted. In some studies performed in 
non-pregnant women, Propionibacterineae, Anaerococcus, Citrobacter [172], G. 
vaginalis, M. hominis [171], Prevotella bivia and A. vaginae [145] were associated with 
HIV status. A study done in pregnant women found that Mycoplasma species (M. 
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genitalium, U. urealyticum, M. hominis) were highly associated with HIV infected 
status [278]. Similar to these previous studies, in our study we found that Mycoplasma, 
G. vaginalis, Prevotella species and A. vaginae were associated with HIV infection. 
The inverse relationship between L. crispatus and HIV positivity that was demonstrated 
in our study was also reported by Schellenberg et al., (2011) in a study of non-pregnant 
sex workers living in Nairobi, Kenya, though their results were statistically 
insignificant  [443]. The variation in findings of various cohort studies may be due to 
the fact that not all populations have the same dominant microbiota in their vaginal 
canal as the microbiota is influenced by different physiological and environmental 
factors 
 
In non-pregnant women, vaginal microbiota modulates genital inflammation; 
organisms such as L. crispatus are associated with reduced inflammation and HIV 
transmission risk, while vaginal anaerobes such as Prevotella and Sneathia are 
associated with increased vaginal inflammation [134, 167]. The presence of high 
inflammation leads to functional imbalances that affect mucosal surface permeability 
leading to detrimental health effects [444]. This disruption of mucosal surface 
permeability during dysbiosis could lead to increased viral shedding, which may 
impose a higher risk of HIV transmission from pregnant mothers to their partners or 
infants. In support, it has been shown previously that higher levels of vaginal 
inflammation were associated with increased risk of HIV shedding  [164]. It has also 
been found that inflammatory cytokines (IL-6, IL-8, IL-1β) were upregulated in 
cervico-vaginal fluid of acutely HIV infected women with low CD4+ count [445], 
suggesting an association between mucosal inflammation and degree of 
immunocompromise [445, 446]. This may partially explain the observation in this study 
where HIV infected women were more likely to have preterm deliveries as compared 
to HIV uninfected women since more HIV infected women had high and medium level 
of inflammation. 
 
However, although in our study, we found high microbial diversity in these HIV-
infected pregnant women, few differences in inflammation were observed between 
HIV-infected and uninfected women were observed. Similarly, in non-pregnant 
women, another study found that cervicovaginal inflammatory cytokine profiles did not 
differ when comparing the same women pre- and post- HIV infection [164]. It is 
possible that the lack of inflammation in our HIV-infected women was due to the fact 
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that most women were on ART. Maharaj and colleagues (2017) found that HIV-
infected pregnant women on HAART had low levels of serum proinflammatory 
cytokines [437]. This was true in non-pregnant HIV infected women found concurring 
results in plasma levels of circulating inflammatory biomarkers [439]. This led to the 
conclusion that the use of HAART suppresses the proinflammatory response, thereby 
leading to consistently lower cytokine concentrations, although immune activation does 
not necessarily return to baseline but remains elevated [437, 439, 447]. Given that 95% 
of HIV-infected women in our cohort were already on HAART treatment long before 
they became pregnant, with a mean CD4+ count of 532 cell/mm3 and high degree of 
viral suppression, this may explain the low levels of inflammation in the genital tracts 
of HIV-infected compared to uninfected women. Another potential explanation for the 
lack of inflammation associated with HIV infection in our cohort is that these women 
were pregnant. Pregnancy is a state of relative immunosuppression characterised by 
anti-inflammatory responses which are important for embryonic implantation and 
pregnancy maintenance [448]. 
 
In our study, low levels of the Th2 cytokine IL-13, which is important in pregnancy 
tolerance, was associated with being HIV infected. Previous studies have highlighted 
the importance of Th2 cytokines in pregnancy, suggesting that imbalances may cause 
poor pregnancy outcomes [334, 405, 407]. However, in our study there were no 
significant differences in poor outcomes between HIV-infected and HIV-uninfected 
women, although there was a notable trend of HIV-infected women being more likely 
to deliver preterm as compared to HIV-uninfected women. High levels of vaginal TNF-
α were independently associated with HIV infection in our study in agreement with a 
previous study that have reported increased levels of placental TNF-α in HIV-infected 
women during pregnancy [435] and in vaginal fluid of HIV-infected non-pregnant 
women compared to HIV-uninfected women [449]. Plasma TNF-α is usually increased 
in early pregnancy as it is critical for processes of gamete, follicle, placental 
differentiation and development and parturition among others [321]. However, 
elevation of TNF-α in the third trimester may be associated with poor pregnancy 
outcomes such as PTB, LBW or PROM [450, 451]. In HIV infection among other 
possible reasons, TNF-α is associated with viral control as it engages in selective 
destruction of virally infected cell [452], thus it is known for increasing TNF- α 
expression [436], this may explain the high level observed in HIV positive as compared 
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to HIV uninfected women and a trend of higher preterm delivery in HIV-infected 
women.  
 
 
In summary, we affirm previous findings of a positive association of microbial diversity 
and HIV status, where HIV-infected women had highly diverse vaginal communities 
as compared to HIV-uninfected women during pregnancy. Despite having highly 
diverse microbial community, it is interesting to note that HIV-infected women did not 
have significantly higher levels of genital inflammation overall. The key pro-
inflammatory cytokine TNF-α was increased in HIV-infected women, although without 
any observed association with poor outcomes. Other physiological and chemical factors 
not considered in this study may need to be studied to expand knowledge on the 
relationship between HIV, cytokines and microbiota in pregnancy. 
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Chapter 7 Discussion 
The main aim of this thesis was to explore the relationship between vaginal microbiota, 
BV, HIV and pregnancy outcome in Zimbabwean women. In order to address our main 
research question, we first characterized the vaginal microbiota of these Zimbabwean 
pregnant women. We noted that as opposed to studies conducted in North America [51, 
58],pregnant Zimbabwean women had a high prevalence of dysbiosis and L. iners was 
the most common organism identified. The vaginas of these pregnant women were 
predominantly colonised by a milieu of diverse anaerobic bacteria similar to that found 
in non-pregnant sub Saharan African women and women of African descent  [51, 58, 
135, 145]. The widely expressed view that an optimal vaginal environment is 
Lactobacillus spp dominant [57] may not be true for all populations, as  it is consistently 
evident that the optimal vaginal microbiota for black women is dysbiotic  [85, 145]. 
There has been an appreciation of the differences of the vaginal microbiota according 
to ethnic and geographical background from recent studies [51, 57, 58]. Our study adds 
more data that sub Saharan African pregnant women also have a tendency toward 
dysbiosis. We also confirmed the prevalence of L. iners in the vaginas of women in this 
cohort and its ubiquitous nature of surviving even in dysbiotic environment unlike other 
Lactobacillus spp [57, 67, 453].  
 
Next, we looked at vaginal microbiota and pregnancy outcomes.  Although there were 
weak associations between preterm birth and vaginal microbiota, there was an 
association between vaginal microbiota and low birth weight and SGA. Surprisingly, 
women with BV were less likely to deliver LBW infants and there was a significantly 
lower alpha diversity in the vaginas of women who delivered LBW infants. On further 
probing, the relative abundance of L. iners was most abundant in women who delivered 
LBW infants therefore explaining the association with lack of BV and low diversity. 
Since L. iners was the most prevalent lactobacillus in this cohort and in other African 
women, this may partly explain why the rates of LBW are so high in this setting.  
 
G. vaginalis and A. vaginae were seemingly lower in pregnancies that resulted in LBW 
neonates in this particular cohort using various methods. This differs from the existing 
dogma that an unhealthy vaginal microbiota is a cause of adverse birth outcomes. 
However, it may be that their relative abundance was lower as a result of the increased 
relative abundance of L. iners. This speculation could be validated using quantitative 
PCR. None-the-less, our findings suggest that a low abundance of G. vaginalis and A. 
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vaginae seem to correlate adverse birth outcomes. This is possibly due to their 
inflammatory nature and the fact that lack of inflammation in the vagina was associated 
with good pregnancy outcomes.  
 
The prevalence of bacterial vaginosis in these pregnant women was high (32%) similar 
to data from previously published Zimbabwean cohorts [28]. While we did not observe 
any association between BV and PTB or SGA, lack of BV was associated with LBW. 
This however contrast the existing dogma that a dysbiotic vaginal environment is 
associated with poor birth outcomes. This baseline information is important in this 
particular population, however, there is need to validate these results in a longitudinal 
cohort in pregnant women. Furthermore, it is imperative to also establish the vaginal 
microbiota of women in this population in non-pregnant women and adolescents. This 
is important as these findings would be linked with possible research on interventions 
whenever needed for this population.  
 
We hypothesized that there would be differences in the vaginal microbiota in pregnant 
HIV infected and HIV uninfected women.  We were able to confirm our hypothesis, as 
we found that HIV-infected women had significantly higher alpha diversity and their 
microbial communities clustered significantly differently to that of HIV negative 
women, despite the fact that most, if not all, of the cohort were on combination ART. 
We were able to establish the strong relationship between HIV and CST3. Some 
individual taxa (Megaspahaera and Mycoplasma) were highly associated with HIV 
infection, similar to that in other pregnant  [278, 454] and non-pregnant cohorts [219]. 
Knowledge of organisms associated with HIV status is of paramount importance for 
health management since our population has a high prevalence and incidence of HIV.  
 
We analysed the immunological biomarkers and possible predictors of bacterial 
vaginosis and adverse pregnancy outcomes by measuring vaginal cytokine 
concentrations. We observed that L. iners (CST1) and G. vaginalis (CST3) dominated 
CSTs were highly inflammatory with high levels of IL-1β, TNFα, IL-8 and IL-6 as 
compared to CST2 (L. crispatus dominant).  Similarly, individual taxa such as G. 
vaginalis, Dialister, A. vaginae, Aerococcus, Prevotella, L. iners, Megasphaera 
andBVAB1 were associated with high inflammation while L. crispatus was associated 
with low inflammation in line with many previous studies [46, 411, 412]. And as 
expected inflammation was higher in BV+ women as compared to BV-.  
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Low levels of Th2 cytokine (IL-13) were highly associated with LBW, PTB, SGA. 
Additionally, low levels of growth factor PDGF-BB were associated with PTB and 
LBW while the associations were not upheld in SGA delivery after multiple 
comparisons. Growth factors act as placental growth regulators and play an important 
role in fetal development [455]. Th2 cytokines are thought to be important for 
pregnancy tolerance [340]. Therefore, low levels of theses cytokines this might explain 
the reason for the association with poor birth outcomes. However, due to the nature of 
our study design, results are inconclusive since our study was cross sectional. However, 
longitudinal studies would provide substantiated evidence when many time points are 
evaluated throughout pregnancy.  
 
As expected, pregnancy induced hypertension was a risk factors associated with PTB, 
LBW and SGA in line with a previous study done in Zimbabwe [401]. We think this is 
unlikely to be solely due to induction of labour, since this is uncommon practice in 
Zimbabwe unless in case of severe complications. HIV infection was a risk factor 
associated with PTB and LBW, while GBS carriage was a risk factor for SGA 
deliveries. Furthermore, a history of previous poor outcomes was associated with LBW 
delivery. There were more HIV infected women who experienced poor birth outcomes 
as compared to HIV uninfected women in this high-risk cohort in line with findings 
from previous studies [192, 401]. The reason for this finding is difficult to ascertain as 
poor birth outcome causes are multifactorial. Although some have reported poor birth 
outcomes associated with ART use [22, 188], others have reported the contrary [194-
196] HIV infection was associated with and low levels of IL-13, and IL-7 cytokines 
which are important for angiogenesis, implantation and development of the foetus. 
While on the other hand HIV was associated with high levels of TNF-α which has been 
reported to be detrimental in third trimester as compared to first trimester, However, 
we did not we did not find any associations between HIV and poor birth outcomes. 
 
Finally, its satisfying to know that this study has added to the base of the scientific 
knowledge on vaginal microbiota of sub Saharan African women during pregnancy and 
created a basis for further studies and research in this area. Specifically, this thesis has 
provided valuable insight on relationship between BV, vaginal microbiota and 
pregnancy outcomes an area that had not been explored in the Zimbabwean population. 
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7.1 Limitations 
Ø We should stress that our study was limited by the kind of study design 
employed. Cross sectional microbiome studies tend to be variable and difficult 
to reproduce. Therefore, due to the fact that samples were collected at a single 
time-point in this study, future longitudinal studies would be important to 
confirm these findings. This will give more reliable results which may show 
possible variation at different stages of pregnancy.  
Ø 16S rRNA amplicon sequencing does not provide information about non-
bacterial microbial taxa that also constitute the vaginal microbiome and some 
bacteria are only classified to genus and not species level therefore using our 
data for inferences should be treated with caution. 
Ø Microbiota and cytokines were assessed in samples collected from women at 
different stages in their pregnancies and this could have introduced 
heterogeneity that may mask certain gestational age-associated relationships.  	
Ø The study was underpowered to truly assess differences by PTB status and HIV status 
as there were relatively low numbers of both.  
Ø Our study was limited in determining accurate gestational age of the 
pregnancies. Very few women had access to ultrasound scans, therefore manual 
methods such as last menstrual period and fundal height were used which might 
lead to inaccurate PTB classification.  
Ø The fact that our cohort was composed of a mostly high-risk referral cases might 
limit the generalizability our findings. 
Ø The failure to pass QC by other cytokines such as IL-12p70, IL-15, IL-10, IL-
5, GCSF and IFN-γ has greatly affected our analysis. We were not able to make 
reliable analysis since some important Th1 and Th2 cytokines we were 
interested in during our protocol design plan. 
Ø Data on recent sexual activity, which can impact the vaginal microbiota and 
may differ in pregnancy, was not collected at enrollment.  
 
7.2 Future studies 
Longitudinal studies should be pursued to give a comprehensive conclusion to the 
relationships between vaginal microbiota at all trimesters in relation to pregnancy 
outcomes in a non- risky cohort. Furthermore, there is need to employ whole genome 
sequencing technique which would give information as to the function of the microbiota 
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and would help to characterise some organisms to species level which we were not able 
to characterised fully using the V4 hypervariable region. Future studies can also be 
conducted in pregnant women from both urban and rural areas and also include non-
pregnant women of reproductive age and adolescents to understand the population 
vaginal microbiota. 
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Appendix A: Cytokine analysis Interplate controls 
 
Plate 1 vs 
Plate 2 
Plate 1 vs 
Plate 3 
Plate 1 vs 
Plate 4 
Plate 1 vs 
Plate 5 
Plate 2 vs 
Plate 3 
Plate 2 vs 
Plate 4 
Plate 2 vs 
Plate 5 
Plate 3 vs 
Plate 4 
Plate 3 vs 
Plate 5 
Plate 4 vs 
Plate 5 
IL-1b 1.00 0.90 1.00 0.90 0.90 1.00 0.90 0.90 1.00 0.90 
IL-1ra 0.71 1.00 0.71 0.35 0.71 0.70 0.60 0.70 0.35 0.90 
IL-2 0.45 0.92 0.50 0.91 0.62 0.89 0.67 0.69 0.92 0.57 
IL-4 0.70 0.89 0.56 0.60 0.89 0.87 0.90 0.86 0.89 0.97 
IL-5 0.24 0.53 0.24 0.29 0.79 -0.05 -0.11 0.53 0.50 0.95 
IL-6 0.29 0.82 0.50 0.76 0.67 0.92 0.76 0.87 0.97 0.89 
IL-7 0.97 0.80 0.97 0.67 0.72 0.92 0.76 0.87 0.56 0.68 
IL-8 0.90 1.00 1.00 0.90 0.90 0.90 1.00 1.00 0.90 0.90 
IL-9 0.87 0.97 0.97 0.97 0.90 0.90 0.80 1.00 0.90 0.90 
IL-10 0.49 -0.65 -0.16 0.32 -0.13 -0.03 0.62 0.29 -0.36 0.56 
IL-12(p70) 0.76 0.82 0.29 0.00 0.97 0.29 0.00 0.36 0.00 0.00 
IL-13 0.95 0.87 0.53 0.89 0.82 0.55 0.97 0.67 0.74 0.65 
IL-15 0.87 0.50 -0.21 -0.05 0.67 0.11 0.16 0.74 0.05 0.16 
IL-17 0.90 0.90 0.70 0.70 1.00 0.90 0.90 0.90 0.90 1.00 
Eotaxin 0.60 0.90 0.70 0.60 0.80 0.90 1.00 0.90 0.80 0.90 
FGF basic 0.53 0.50 0.34 0.50 0.92  0.92 0.92 0.76 1.00 0.76 
G-CSF 0.67 0.15 0.87 0.87 0.00 0.60 0.50 0.60 0.50 0.90 
GM-CSF 0.90 0.80 0.30 0.70 0.90 0.60 0.90 0.70 0.70 0.70 
IFN-g -0.10 0.50 0.10 0.30 0.70 0.80 0.90 0.80 0.90 0.90 
IP-10 1.00 0.90 0.90 0.90 0.90 0.90 0.90 1.00 1.00 1.00 
MCP-1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
MIP-1a 0.70 1.00 0.97 1.00 0.70 0.82 0.70 0.97 1.00 0.97 
PDGF-bb 0.29 0.29 0.76 0.97 0.76 0.71 0.41 0.68 0.36 0.87 
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MIP-1b 0.90 0.90 1.00 1.00 1.00 0.90 0.90 0.90 0.90 1.00 
RANTES 1.00 0.90 0.90 0.90 0.90 0.90 0.90 1.00 1.00 1.00 
TNF-a 0.82 0.97 0.97 1.00 0.90 0.90 0.82 1.00 0.97 0.97 
VEGF 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
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Appendix B1 Cytokine interplate control 
  
The cytokines highlighted in red boxes failed the interplate quality control and were excluded from the analysis 
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Appendix B2 Cytokine interplate controls 
 
 The cytokines highlighted in red boxes failed the interplate quality control and were excluded from the analysis 
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Appendix B3 Cytokine interplate controls 
  
The cytokines highlighted in red boxes failed the interplate quality control and were excluded from the analysis 
0 10 20 30 40
0
10
20
30
40
inter MCP-1
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 2 4 6 8
0
2
4
6
8
10
inter MIP-1b
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 500 1000 1500 2000
0
500
1000
1500
2000
inter VEGF
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 2 4 6
0
2
4
6
inter MIP1a
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 5 10 15
0
2
4
6
8
10
inter RANTES
P1 v P2
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 2 4 6 8
0
2
4
6
8
10
inter il-5
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 10 20 30 40
0
10
20
30
40
50
inter PDGF-bb
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 10 20 30 40
0
10
20
30
40
interTNF-a
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
0 2 4 6 8
0
2
4
6
8
inter IL-9
P1
P1 v P2
P1 v P3
P1 v P4
P1 v P5
 
 
159 
Appendix C: NCBI Blasting Annotations 
 
Lactobacillus_OUT_9 (Lactobacillus Crispatus) 
 
 
Lactobacillus OUT_745 (Lactobacillus jensenii) 
 
 
Prevotella OUT_8 (Prevotella timonensis) 
 
Gardnerella _OTU_11 (Gardnerella vaginalis) 
 
 
Neisseria _OTU_40 (Neisseria gonorrhoeae) 
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Appendix D: Methodology summary  
 
 
 
 
 
 
  
 
2 vaginal swabs per woman 
 
 
Cytokines 
(luminex) 
 
 
Microbiome analysis: 
PCR and 16S rRNA  gene 
sequencing, V4 region 
using Illumina Miseq 
 
 
 
Microscopy,Ph measurent, and 
GBS culture: 
Columbia CNA agar + 5% SB, 
CHROMagar,  CAMP test. 
Confirmation=MALDI-TOF 
 
 
Data analysis 
QIIME, UPARSE, custom R scripts, 
good quality reads (>/=5000) 
 
420  pregnant women 
(15 -35 weeks gestational age) 
Chitungwiza and Harare 
Referral hospitals 
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